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Summary  
 
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, 
currently affecting 6.3 million people worldwide. Although it is associated, in the long 
term, with severe complications (dyskinesias), L-DOPA remains the gold standard 
treatment. An alternative approach to the treatment of PD is the replacement of the lost 
striatal dopaminergic innervation by transplantation of foetal ventral mesencephalon 
(VM) dopaminergic precursor cells. Opened trials have provided the proof of concept 
that intrastriatal VM transplant can survive, integrate and in some cases, restore motor 
functions. Nevertheless, later double blind studies reported inconsistent benefit of the 
therapy and the development of dyskinesias remaining after withdrawal of L-DOPA 
medication.  
 
The failure of the animal models in predicting these problems raises concern about their 
reliability. Therefore, the global aim of this PhD work was to identify some of the 
critical factors that can influence the functional outcome of cell therapy for PD, and on 
the basis of this, to develop an improved 6-OHDA unilaterally lesioned rat model for 
transplantation. The first step was to determine the most reliable method to assess 
dyskinesias in rats. The second part of this thesis was set out to determine the effect that 
chronic L-DOPA treatment, administered at different time could had on the survival and 
function of immunologically incompatible foetal VM transplant. The results 
demonstrated that L-DOPA administered chronically post-grafting increases the host 
immune response around the xenogeneic transplant. Therefore, the last set of 
experiments were designed to create a model of mixed donors graft to better reproduce 
the patient situation, where each transplant required up to 8 donors from unknown 
immunological background. All of these experiments come together to help to develop a 
rat model that more accurately represents all aspects of patients undergoing 
transplantation for PD. 
 
 
 
  
	   III	  
ACKNOWLEDGEMENTS 
 
I would like to start by thanking my two supervisors, Dr Emma Lane and Prof 
Stephen Dunnett, for their scientific guidance throughout my PhD. It was a privilege 
and a pleasure to work with such admirable scientists. I wish to thank Dr Lane in 
particular for the time she dedicated to me and for her invaluable support and 
encouragement, which were very much appreciated. I am also very grateful to her for 
giving me an opportunity to teach.  
From the School of Pharmacy, I would like to thank: Emma Kidd for her helpful 
critique during my first year viva and group meetings, Mat Smith for his assistance 
with the HEA application, Leanne Roberts and Rhian Thomas for their help with 
teaching, as well as Dawn Turner, Zakky Cholisoh, Ed (Jin) Zhang and Dwaine 
Burley for their support. 
I wish to thank all the members (current and past) of the Brain Repair Group (BRG), 
especially (and not in any particular order): Jane Heath, for her help in histology, 
Eduardo Torres for his support with anything related to microscopy, Ngoc-Na Vinh 
for helping me with the virus related paper work, Kate Shires for helping me with 
animals related paper work and Anne-Marie McGorrian for her help with all the other 
types of paper work, as well as Prof Anne Rosser, Claire Kelly, Becky Trueman, 
Zubeyde Bayram-Weston, Susannah Williams, Rike Zietlow, Alex Klein, Simon 
Brooks for their interesting suggestions at the lab meetings. 
I would like to express my deep gratitude to Mariah Lelos for her useful critiques and 
(very) enthusiastic encouragement. I am very grateful for her help (in particular with 
writing and stats). 
Many thanks to Damla Khan for helping me getting my head around the immune 
system. I also would like to thank Claris Diaz, Marija Fjodorova and Yateen Patel 
for they moral support during the dark days. 
I would like to thank Ellen Murphy for her help and support during the long testing 
hours and with the creation of the postgraduates PD network. 
	   IV	  
Many thanks to Gaynor Smith for her help at the beginning of my PhD, especially with 
surgery. Thanks also to Hanna Lindgren and Andy Heuer for the interesting scientific 
conversations and for their hospitality (looking forward to working with you again).  
My best encouragements to all the PhD students in the BRG: Amy Evans, Claris Diaz, 
Damla Khan, Emma Yhnell, Marija Fjodorova, Nan Choompoo, Vicky Roberton, 
Harri Harrison and in the School of Pharmacy: Zakky Cholisoh and Zana 
Abdulkareem. 
Many thanks to Alun Morgan, and all the patients I have met so far for making me 
believe in the importance of the research.  
I wish to thank my family, in particular my sister and my parents for their unconditional 
support - Je remercie ma famille, en particulier ma soeur et mes parents pour leur 
soutien inconditionnel.  
I would like to thank my other half, Aymeric, for accepting my constraining career 
choices and for believing in me more than I do. 
I would like to express my deep gratitude to Joanna Chen for being (one of) my 
proofreaders, as well as my surrogate family.  
The PhD was a great adventure and during these years, I have met many amazing and 
inspiring people, who all contributed to the person and the scientist I became. To all of 
the people who somehow influenced my path, thank you! 
 
 
 
 
 
 
  
	   V	  
ABBREVIATIONS 
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5-HT: 5-hydroxytryptamine or serotonin  
6-OHDA: 6-hydroxydopamine 
α-syn : alpha-synuclein 
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PTEN: phosphatase and tensin homolog 
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S.C.: subcutaneous 
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1.1 Parkinson’s disease 
Parkinson’s disease (PD) is the most common neurodegenerative movement disorder. It 
affects 1% of the population at 65 years of age, and reaches 5% for those over 85 years 
(Lang and Lozano, 1998). It is a progressive disease that typically appears in the 6th 
decade of life, although up to 20% of people affected are classified as “young-onset” 
and develop the disease before they are 50. PD has a higher incidence in men than in 
women, with a risk 1.5 times higher in men (Wooten et al., 2004). Currently, 6.3 million 
people suffer from PD worldwide. In “The pledge for Parkinson’s disease”, the 
European Parkinson’s disease association stated that the annual cost of the disease in 
Europe reached 13.9 billion Euros in 2012 for approximately 1 200 000 patients 
affected (EPDA, 2012). 
 
The following section traces the main scientific discoveries on PD and cell therapy, 
providing a global view of the timeline in context (Figure 1). It is succeeded by a more 
in-depth discussion of the literature.  
 
1.1.1 A brief overview of the history of Parkinson’s disease 
Although evidence of PD has been found in the remains of ancient civilisations, it was 
first formally described in 1817, by the English physician James Parkinson (Manyam 
and Sanchez-Ramos, 1999, Raudino, 2012). In his publication entitled Paralysis 
Agitans (Shaking Palsy), James Parkinson described 6 cases of individuals presenting 
similar symptoms: “Involuntary tremulous motion, with lessened muscular power, in 
parts not in action and even when supported; with a propensity to bend forwards, and 
to pass from a walking to a running pace” (Parkinson, 1817). The disease was named 
after him, 60 years later, now referred to as “Parkinson’s disease”. The second man to 
have his name associated with this disorder is the German neurologist Fritz Heinrich 
Lewy, who performed the autopsy of a patient affected with PD in 1912 and reported 
the presence of neuronal inclusions, which later bore his name (Lewy, 1912). These 
aggregates were the first pathological hallmark of the disease to be described. 
 
In 1926, Bell and Clark reported that PD inheritance in these families follows a 
Mendelian distribution, therefore confirming the familial aggregation of the disease 
described by some of the clinicians in the early 1880s (Bell and Clark, 1926). It is worth 
highlighting that the only information available for Bell and Clark regarding DNA was 
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that it is a string of nucleotides residing in the nucleus of cells (Levene, 1919). The 
concept of DNA as a hereditary molecule emerged the following year, thanks to the 
work of Nikolai Koltsov (Koltsov, 1927). 
 
More than 25 years after the discovery of Lewy bodies in the brain of PD patients, the 
second main pathological feature of the disease was unveiled by German pathologist 
Rolf Hassler. In 1938, he described a dramatic loss of the pigmented neurones of the 
substantia nigra pars compacta (SNpc) in the brains of patients presenting with PD 
(Hassler, 1938). Nowadays, the confirmation of diagnosis is still based on these two 
hallmarks: presence of Lewy bodies and degeneration of the SN. In the mid-50s, 
dopamine (DA) was recognised as having an effect on the central nervous system, the 
basal ganglia nuclei in particular, which led Herbert Ehringer and Oleh Hornykiewicz to 
believe that it might be a key player in PD (Bertler and Rosengren, 1959, Holzer and 
Hornykiewicz, 1959, Sano et al., 1959). Their post mortem analysis of the brain of 
patients, who were diagnosed with basal ganglia symptomatology, demonstrated that all 
and only PD patients showed a severe loss of DA in the striatum (Ehringer and 
Hornykiewicz, 1960). This discovery marks a giant step forward in the understanding of 
the disease, but fundamentally, it led to the development of the first pharmacological 
treatment.  
 
The amino acid 3,4-dihydroxyphenylalanine was firstly synthetized as an L, D racemate 
50 years before the role of DA in PD was discovered (Funk, 1911). The purified DA 
precursor L-3,4-dihydroxyphenylalanine (L-DOPA) was originally extracted from fava 
beans (Vicia Faba) but is now synthetically manufactured. Soon after the publication 
evidencing the lack of striatal DA in PD patients, clinical trials using intravenous 
injections of L-DOPA (Birkmayer and Hornykiewicz, 1961, Birkmayer and 
Hornykiewicz, 1962) or oral administration (Barbeau et al., 1962) were initiated. 
Although some improvement was observed with the motor symptoms, particularly 
akinesia, the results were controversial (Barbeau, 1969). At the end of the 60s, the 
administration of a peripheral aromatic L-amino-acid decarboxylase (AADC) inhibitor, 
reducing the peripheral side effects and increasing the amount of DA precursor reaching 
the brain, established L-DOPA as an effective treatment for PD (Cotzias et al., 1969). 
The same paper published by Cotzias and colleagues, however, also highlights the 
appearance of severe abnormal motor movements, called dyskinesias, which rapidly 
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limited the effect of the treatment. 
 
Around the same period, Urban Ungesrtsedt performed studies in rats, using 
intracerebral injection of the neurotoxin 6-hydroxydopamine (6-OHDA) and induced 
depletion of the dopaminergic and noradrenergic neurons (Ungerstedt, 1968). The use 
of the neurotoxin 6-OHDA became very popular among researchers working on PD as 
it was the only way to produce permanent lesions in the dopaminergic system, until the 
discovery of 1-methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) in the 80s. In 
1982, young drug addicts developed severe parkinsonian symptoms after injecting 
themselves with desmethylprodine (1-methyl-4-phenyl-4-propionoxypiperidine, 
MPPP), a potent opioid analgesic. Unfortunately, the home-made drug was not purified 
and contained a fair proportion of MPTP, which was later proven to be responsible for 
the accelerated degeneration of their SN, leaving them unable to move, completely 
“frozen” (Langston et al., 1983). MPTP was rapidly seen as a new way to create better 
animal models of PD and is still currently widely used in a variety of non-human 
primates (Chiueh et al., 1984, Langston et al., 1984, Bezard and Przedborski, 2011, 
Blandini and Armentero, 2012). 
 
In the 80s, it was well established that, although L-DOPA was the best treatment 
available to relive akinesia in PD patients, it could not stop disease progression. 
Scientists strived to develop new strategies to “heal the brain” and restore motor 
functions, using the newly developed MPTP-lesioned animal models. The 20th century 
was marked by the advent of organ transplants, beginning with the first successful 
corneal graft performed by Eduard Zirm in, what was at the time the Austro-Hungarian 
Empire (Zirm, 1906). It was followed (2 World Wars later) by pancreas, kidney and 
liver transplants and the first heart transplant in South-Africa (Lawler et al., 1950, Starzl 
et al., 1963, Kelly et al., 1967, Barnard, 1967). Continuing along that path, the interest 
in cell therapy grew quickly among the scientific community. The introduction of 
stereotaxic surgery in 1945, allowing the precise targeting of specific brain regions 
(Spiegel et al., 1947), followed by the development of the powerful immunosuppressive 
drug cyclosporine (cycloA) in the 70s allowed the start of clinical trials for 
transplantation (Borel et al., 1976a, Borel et al., 1976b). The first clinical study 
performed in 1982 in Stockholm by Erik-Olof Backlund and co-workers reported 
transient and limited alleviation of symptoms in the 2 patients who received the first 
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striatal implantation of autologous adrenal medulla (Backlund et al., 1985). Ignacio 
Madrazo and colleagues claimed rapid and drastic improvement of the motor 
symptoms, using the same approach, although these results could have never been 
reproduced by any other scientific teams (Madrazo et al., 1987). Indeed, systematic 
comparisons of the outcome of adrenal medulla transplantation for PD performed in the 
US demonstrated that improvements, if any, were limited and transient and that the 
procedure was associated to serious risk of mortality (Quinn, 1990, Goetz et al., 1990b, 
Goetz et al., 1990a). In parallel, in 1988, another Swedish group initiated clinical trials 
for the transplantation of dopaminergic precursors obtained from foetal tissue (Lindvall 
et al., 1989, Lindvall et al., 1990). Transplanted patients exhibited significant clinical 
benefit, marking the first milestone in the history of foetal transplant. 10 years later, the 
American double-blind randomized studies reported sever dyskinesias in some of the 
patients, who received intrastriatal foetal graft (Freed et al., 2001, Olanow et al., 2003). 
It then took over a decade before the next trial was initiated (TransEUro).  
 
The end of the 20th century also saw the advent of genetics. In 1997, Mihael 
Polymeropoulos and co-workers identified a mutation associated with autosomal 
dominant inheritance of PD in the alpha-synuclein gene (α-syn). α-syn has been shown 
to be the main component of the Lewy bodies discovered 85 years earlier 
(Polymeropoulos et al., 1997, Spillantini et al., 1997). The number of genetic studies 
frenetically increased following the mapping of the human genome at the beginning of 
the 21st century. To date, 25 genes have been identified as involved in PD (Puschmann, 
2013). 
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Figure 1: Key discovery timeline of PD research. 
 
1.1.2  Symptoms & diagnosis 
Currently, PD diagnosis is based on the observation of the motor symptoms that were 
described by James Parkinson, nearly 200 years ago, and autopsy remains the only 
definitive proof of the disease. PD is clinically recognised by 4 cardinal motor 
dysfunctions: bradykinesia or akinesia, tremor, rigidity and postural instability. 
Bradykinesia manifests as slowness followed by complete loss of spontaneous 
movements (akinesia), including facial expressions, gesturing, impaired swallowing and 
blinking, and one of the most easily recognised signs of PD, reduced or absent of arm 
swing while walking (Jankovic, 2008). Although bradykinesia represents the first step 
	   10	  
of the diagnosis, it is not a definite proof of PD as it can be associated with other 
diseases (Chang et al., 1992, Kim, 2001, Staekenborg et al., 2008). PD is also 
characterised by unilateral tremors disappearing with activity or during sleep. Often the 
hands are affected with supination–pronation (or ‘‘pill-rolling’’) movements but it can 
also involve the lower limbs; characteristically in young-onset patients. Facial tremors 
involving the jaw, tongue, chin etc. tend to be observed in older patients; over 70 (Lees 
et al., 2009). Rigidity, defined as involuntary muscle stiffness, is one of the most 
frequent initial symptoms of PD but is often misdiagnosed as arthritis. Finally, postural 
instability is a late stage manifestation, which commonly appears after the onset of other 
features. It is, with “freezing periods”, one of the main causes of falls. Other 
characteristic motor disturbances or abnormalities can help to diagnose PD, including 
micrographia (Rao et al., 2003) or anosmia (Doty et al., 1995). It is important to note 
that separately, these symptoms can be the manifestation of other diseases. It is usually 
the association of unequivocal bradykinesia and at least one of the other 3 cardinal 
symptoms, combined with the effectiveness of L-DOPA treatment that defines the 
disease (Rao et al., 2003, Jankovic, 2008).  
 
When James Parkinson depicted PD, he described it as a motor disorder, affecting the 
motor functions: “ the senses and intellects being uninjured” (Parkinson, 1817). One of 
the most significant deviations from this original description is the growing body of 
evidence that PD patients suffer from a diverse range of other symptoms, all grouped 
under the designation: “non-motor symptoms”. These symptoms include: 
neuropsychiatric problems (such as depression, anxiety and/or cognitive impairment), 
sleep disorders (insomnia, restless-leg syndrome, REM sleep disturbance), autonomic 
dysfunctions (bladder and sexual dysfunctions) and have been recently reviewed by 
others in more details (Simuni and Sethi, 2008, Chaudhuri et al., 2011, Lima et al., 
2012). Some of these symptoms appear at a very early stage, before the first motor 
manifestation of the disease (Goldstein et al., 2011). Although most of the research 
performed during the past century focused on treating the motor symptoms of PD, the 
past 10 years have witnessed a growing interest in the other aspects of the disease as 
demonstrated by the increasing number of scientific publications on the non-motor 
symptoms of PD (Figure 2). 
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Figure 2: Number of scientific publications on “non-motor symptoms of Parkinson’s disease 
from 2000 to present (Corlan, 2004). 
 
1.1.3 Pathology 
1.1.3.1 Cell loss and basal ganglia dysfunction 
A major pathological hallmark of PD is the extensive degeneration of the melanised 
dopaminergic A9 neurons in the SNpc, which project and release DA in the caudate 
nucleus and the putamen, the two basal ganglia nuclei that form the striatum in primates 
(Figure 3) (German and Manaye, 1993). The putamen is implicated in planning and 
modulation of movements through the stimulation of the motor cortex while the caudate 
nucleus plays an important role in other cognitive processes (Haber, 2003). A general 
deregulation of the basal ganglia has been observed in PD patients. The basal ganglia 
are a group of subcortical nuclei composed of the caudate nucleus and the putamen, the 
SN, the subthalamic nucleus (STN) and the globus pallidus (internal (entopeduncular 
nucleus in rodents) and external: GPi and GPe respectively).  
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Figure 3: The nigrostriatal pathway, affected in PD (left) (Bethesda, 2001) and the basal ganglia 
nuclei (right, modified from www.servier.co.uk/medical-art-gallery). 
 
An oversimplification of the interactions occurring in the basal ganglia had been 
described in the 80s (Chevalier et al., 1985, Deniau and Chevalier, 1985). The post-
commissural putamen receives glutamatergic cortical input for all the basal ganglia, in a 
topographic manner. Under normal conditions, (Figure 4a) the striatum also receives 
dopaminergic input from the SNpc, leading to the activation of the striatal γ-amino 
butyric acid (GABA)-ergic medium spiny neurons. DA binding on D1-family G-protein 
coupled receptors activates the excitatory pathway, also called the direct pathway. 
Direct pathway neurons, expressing substance P and dynorphin, send inhibitory 
GABAergic efferents to the ventrolateral internal part of the globus pallidus (GPi) 
(Gerfen et al., 1990). This inhibition of the GPi causes a decrease in its GABAergic 
output to the thalamus, disinhibiting the latter. Conversely, the thalamus also receives 
an increased GABAergic signal from the SN  pars reticulata (SNr) through the indirect 
pathway. Indeed, the DA binding on D2-family DA receptors inhibits the indirect 
pathway neurons, which contain enkephalin, leading to a decrease in the GABAergic 
signal reaching the GPe (Gerfen et al., 1990). This lack of inhibition of the GPe leads to 
a reduction of the STN’s activity, decreasing the glutamatergic signal reaching the 
caudolateral part of the GPi and the SNr (Kita et al., 1983). The dual and opposing 
effects of DA stimulation on the striatal GABAergic neurons, through activation of both 
the direct and indirect pathway, is necessary to ensure an appropriate balance of 
stimulation of the motor cortex and the execution of normal motor function. The 
reduced dopaminergic drive occurring in PD affects both the direct and indirect 
pathways leading to hyperactivity of the output nuclei (GPi and SNr) and resulting in a 
strong inhibition of the thalamus and the output from the cortex, and thus an overall 
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decrease in motor drive (Figure 4b) (Albin et al., 1989). Since the first description of the 
basal ganglia communication model, other reciprocal pathways have been identified and 
are believed to play a role in the regulation of motor functions (Gerfen et al., 1990). 
 
 
Figure 4: Simplified schematic of the basal ganglia communication pathways in normal brain 
(a), PD brain before (b) or after (c) the development of L-Dopa-Induced dyskinesia modified 
from Jenner et al. (2008). Representation of the dopaminergic (purple), glutamatergic 
(excitatory, in green) and GABAergic (inhibitory, in red) pathways between the cortex, the 
substantia nigra (SN), the striatum, the globus pallidus internal (GPi) and external (GPe), the 
subthalamic nucleus (STN) and the thalamus. Arrows represent activating signals while flat 
lines are for inhibition, the line weight represent the modifications occurring: increase (thick 
line) or decrease (dotted lines) of the signal. 
 
Although degeneration mainly occurs in the SN, cell loss has also been observed in 
other structures of the brainstem, namely in the: raphé nucleus, locus coeruleus, dorsal 
nuclei of the vagus and nucleus basalis of Meynert (Mann and Yates, 1983). PD is also 
associated with a significant depletion of serotonin (5HT) levels in the striatum (mainly 
in the caudate nucleus), hypothalamus and the frontal cortex, due to serotonergic cell 
loss in the raphé nucleus. The noradrenergic and cholinergic pathways are also affected. 
The degeneration of the locus coeruleus leads to a decrease of noradrenaline in the 
hypothalamus, the cortex and the hippocampus (Fahn et al., 1971). Degeneration of 
cholinergic neurons occurs in the pedunculopontine nucleus and is believed to play a 
role in gait and posture disorder (Hirsch et al., 1987).  
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1.1.3.2 Lewy bodies 
Lewy bodies are associated with various diseases, such as depression, multiple system 
atrophy, Alzheimer’s disease etc. (Kahle, 2008). However, they are one of the 
characteristic features of PD and the confirmation of the diagnostic, post mortem, is 
established based on extensive cell loss in the SNpc combined with the presence of 
these cytoplasmic inclusions. These insoluble phosphorylated protein aggregates are 
mainly composed of phosphorylated α-syn, a small protein abundant in the brain, but 
also contain other proteins, such as ubiquitin (Lowe et al., 1988, Maroteaux et al., 1988, 
Spillantini et al., 1997). Several studies reported the presence of α-syn at the 
presynaptic membrane, in smaller aggregates than Lewy bodies, which suggests that α-
syn could also play a role in the modulation of neurotransmitter release at the synapse 
(Sidhu et al., 2004, Lundblad et al., 2012). Interestingly, α-syn inclusions are usually 
found at the location of major cell loss, in particular in the SNpc and locus coeruleus but 
also in the cortex as the disease progresses and could explain some of the non-motor 
symptoms. Post-mortem studies performed on patients at various stages of the disease 
revealed that Lewy bodies first appear in the dorsal motor nucleus of the vagus nerve 
and anterior olfactory bundle. They then spread to the raphé nucleus and the locus 
coeruleus before reaching the amygdala, the basal forebrain (pedunculopontine nucleus 
and magnocellular nucleus) and the SN, which corroborates with the appearance of 
motor symptoms. Finally, Lewy bodies affect the cortex, starting in the antero-medial-
temporal mesecortex and gradually extending to the neocortex (Braak et al., 2006). It 
has been proposed that the presence of Lewy bodies in the vagus at the early stage of 
the disease may contribute to autonomic symptoms such as constipation, which precede 
the motor disorder. Following the same train of thought, the spread of Lewy bodies to 
the locus coeruleus and raphé is believed to contribute to depression while their 
presence in the frontal cortex, during late stages of the disease, could explain dementia. 
Nonetheless, attempts established a correlation between Lewy body pathology and 
extent of cell death or severity of clinical symptoms has failed (Schulz-Schaeffer, 
2010).  
 
1.1.4 Aetiology of Parkinson’s disease 
The exact causes of PD remain unknown, however, different risk factors have been 
identified such as age and family history. Nevertheless, less than 20% of PD patients 
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come from a family where other members are affected and where a genetic link could 
have been established (Nuytemans et al., 2010). PD is believed to be due to a 
combination of genetic and/or environmental factors, especially for the 80% of sporadic 
cases. 
 
1.1.4.1 Genetic factors 
Familial forms of PD are generally associated with young onset of the disease 
(Latourelle et al., 2009). During the last 2 decades, several molecular genetic analyses 
in PD families have been carried out to identify genes responsible for the disease. 
Mutations in seven genes have been shown to be implicated in the autosomal dominant 
forms of PD (Table 1): α-syn (Polymeropoulos et al., 1997), leucine-rich repeat kinase 
2 (LRRK2, dardarin) (Paisan-Ruiz et al., 2004, Zimprich et al., 2004), Vacuolar protein 
sorting-associated protein 35 (VPS35) (Wider et al., 2008, Vilarino-Guell et al., 2011), 
eukaryotic translation initiation factor 4 gamma 1 (EIF4G1) (Chartier-Harlin et al., 
2011), parkin (Kitada et al., 1998), phosphatase and tensin homolog (PTEN)-induced 
putative kinase 1 (PINK1) (Valente et al., 2004) and DJ-1 (Bonifati et al., 2003) (Table 
1). Gain-of-function mutations in LRRK2 have been identified as the most common 
cause of familial PD (Horowitz and Greenamyre, 2010). However, the link between 
these genetic factors and the cell death observed in the SN of PD patients remain to be 
unveiled. However, there is a growing body of evidence that impaired lysosomal 
function could be involved in Lewy body formation and nigral degeneration as the α-
syn, LRRK2 and PINK1 have been associated with these alterations (Dehay et al., 
2013). 
 
Gene Role Transmission Lewy bodies 
α-syn Presynaptic protein Dominant Always 
LRRK2 Kinase Dominant Usual 
VPS35 
Involved in the transport of proteins from endosomes 
to the Golgi 
Dominant Unknown 
EIF4G1 Involved in the recruitment of mRNA to the ribosome Dominant Usual 
Parkin Subunit of the E3 ubiquitin ligase Recessive Usual 
PINK1 Mitochondrial kinase Recessive 
1 case 
reported 
DJ1 Ubiquitin ligase Recessive Unusual 
Table 1: Main genes implicated in Parkinson’s disease (Puschmann, 2013) . 	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Although PD has been shown to follow a Mendelian distribution in family cases, most 
forms are sporadic. Some of the genes implicated in the familial forms of PD also play a 
role in idiopathic PD such as α-syn (Kruger et al., 1999, Kay et al., 2008), PINK1 
(Valente et al., 2004) and DJ-1 (Choi et al., 2006) and mostly LRRK2 (Pirkevi et al., 
2009, Horowitz and Greenamyre, 2010). Mutation or over-expression of α-syn leads to 
the formation of Lewy bodies resulting in the death of the dopaminergic cells, mainly in 
the SNpc (see 1.1.3.2. Lewy bodies). PINK1 and DJ-1 are implicated in oxidative stress 
regulation mediated by the mitochondria. Mutations in these genes can also lead to cell 
death. Finally, mutations in the LRRK2 gene are the most frequently known cause of 
both familial and sporadic PD, and are usually associated with a late-onset slow 
progression form of PD. LRKK2 is a 2527-amino acid cytoplasmic protein thought to 
be implicated in aggregate formation, oxidative stress and increased level of reactive 
oxygen species, resulting in neuronal autophagy and apoptosis (Pirkevi et al., 2009, 
Horowitz and Greenamyre, 2010). The cause of idiopathic PD still awaits elucidation 
but probably involves a mix of genetic predispositions and environmental components. 
It has been suggested that idiopathic PD may be more a spectrum of conditions 
characterised by parkinsonism resulting from the degeneration of the SNpc, rather than 
a single entity. This hypothesis is supported by the heterogeneity of the disease 
(Ramsden et al., 2001). 
 
1.1.4.2 Environmental factors 
PD cannot be explained only by genetic factors, exposures to certain environmental 
agents have been consistently associated with this disorder. Repeated exposure to 
MPTP induced rapid and extensive degeneration of the SN. MPTP, crosses the blood-
brain barrier and is converted in MPP+, a potent inhibitor of complex I of the 
mitochondrial respiratory chain. MPP+ exposure results in selective death of the 
dopaminergic neurons and the development of PD (Langston et al., 1983, Langston et 
al., 1984, Barbeau et al., 1985). Although MPTP exposure is highly unlikely in the 
general populations, it illustrates how a toxin of this nature could manifest as neuronal 
degeneration. Several epidemiological studies have shown that some agro-chemicals, 
such as Paraquat, a widely used herbicide with a similar chemical structure to MPP+, is 
associated with an increase risk of developing PD, also its ability to cross the blood-
brain barrier remains highly debated (Naylor et al., 1995, Corasaniti et al., 1998, 
Shimizu et al., 2001, Widdowson et al., 1996). Other agents, such as Maneb, a common 
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fungicide (Ferraz et al., 1988, Hertzman et al., 1990) or rotenone, a mitochondrial 
complex I inhibitor commonly used as insecticide (Betarbet et al., 2000) have also been 
incriminated in as potential causes of PD. Similar compounds can be found in solvents 
such as paints, varnishes and glues, or even simply in household products, might 
increase the risk of developing PD (Goldman et al., 2012). 
 
1.1.5 Animal models of Parkinson’s disease 
In recent decades, animal models have used different methods to mimic the specific loss 
of dopaminergic neurones in the SN observed in PD. The first animal models of PD 
used pharmacological agents, such as the alkaloid reserpine, to induce reversible loss of 
DA. Reserpine blocks the vesicular monoamine transporter which prevents the reuptake 
of neurotransmitters, including DA, thus inducing akinesia in rabbits and rats (Carlsson 
et al., 1957). The models moved on to use neurotoxins, due to the improvement of our 
understanding of the aetiology of PD and now includes genetically modified models of 
PD.  
 
The use of toxins to induce cell loss comparable to the depletion observed in PD 
patients is the most commonly used. Many different toxins are used but the majority 
produce degeneration of dopaminergic neurones by inhibition of the Complex I of the 
mitochondrial respiratory chain and enhancing the production of reactive oxygen 
species (Meredith et al., 2008). First described in 1968 (Ungerstedt, 1968), the 6-OHDA 
rat model is currently one of the most extensively used. The neurotoxin 6-OHDA has a 
structure similar to DA and noradrenaline and is able to penetrate dopaminergic neurons 
through their catecholamine reuptake transporters (Breese and Traylor, 1971). Once 
inside neurons, 6-OHDA inhibits mitochondrial complexes I and IV and produces two 
highly toxic components: hydrogen peroxide and paraquinone (Glinka et al., 1997). 6-
OHDA is not able to cross the blood-brain barrier but can be injected directly in the SN, 
in the terminal fields of the striatum or in the nigro-striatal dopaminergic tracts of the 
medial forebrain bundle (MFB). Bilateral 6-OHDA lesions produce severe akinesia 
compromising animal health (Ungerstedt, 1971). Consequently, the unilateral 
dopaminergic depletion model is commonly preferred, as it does not alter feeding and 
drinking ability of the animals. Moreover, the ipsilateral side of the animal can be used 
as a control for behaviour testing and the intact side of the brain as a control for brain 
analyses. For example, the extent of the dopaminergic depletion can be assessed by 
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various motor and sensory tests (e.g. cylinder test, vibrissae-elicited limb placing) 
comparing the rat’s performances between the side of the body contralateral to the 
lesion and the other side (Torres and Dunnett, 2012). Despite the absence of Lewy 
bodies and the fact that the model creates severe lesions without progression, it has been 
extensively used in the development of new therapies for PD (e.g. cell transplant or 
gene therapy) (Dunnett et al., 1981, Choi-Lundberg et al., 1997, Neto et al., 2012, Back 
et al., 2013). 
 
MPTP can induce severe parkinsonism in human by causing rapid nigral cell death (as 
previously described in section 1.1.4.2. Environmental Factors). Following that 
discovery, MPTP has been widely used in animals, mainly in mice (Sonsalla and 
Heikkila, 1986) and non-human primates (Burns et al., 1983) to mimic the human 
condition. For reasons that are not yet clear, rats are not sensitive to this toxin. It has 
been hypothesised that they cannot convert MPTP to MPP+ in adequate quantities due to 
a lower expression of monoamine oxidase B. However, intraventricular delivery of 
MPP+ produces dopaminergic cell loss, comparable to what has been observed in mice 
and monkeys (Yazdani et al., 2006). Similarly to the 6-OHDA toxicant models, MPTP-
induced parkinsonism is not associated with Lewy bodies although it is associated with 
an increased in α-syn immunoreactivity (Chiueh et al., 1984, Kowall et al., 2000, 
Purisai et al., 2005, Halliday et al., 2009). Nevertheless, exposure to MPTP is still 
currently the best way to create a non-human primate model of PD, characterized by all 
of the cardinal symptoms and responsive to anti-parkinsonian drugs (Blandini and 
Armentero, 2012).  
 
Environment toxins, as they were suspected to play a role in the development of PD, 
could be used to generate chronic PD models (Betarbet et al., 2000, Sherer et al., 2003). 
Others models based on the inflammation observed in PD patients are also used but they 
are inconsistent and could be associated with high death rates in animals. In those 
models an endotoxin: lipopolysaccharide is used to induce inflammation in the SN 
which again produces the death of dopaminergic neurons (Meredith et al., 2008). Lastly, 
recent human genetic linkage studies led to the development of various genetically 
modified animal models for PD (drosophila, nematode, mouse etc.) (Feany and Bender, 
2000, Tabrizi et al., 2000, Vartiainen et al., 2006). Unfortunately, none of the current 
PD models completely recreates the key clinical and neuropathologic features of PD. 
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They usually present with α-syn pathology but either: do not express the motor 
phenotype, or do not present dopaminergic cell loss. Furthermore, the models that have 
motor symptoms appear to do so because the spinal cord is more vulnerable. I will not 
develop this topic here but genetic animal models of PD have been recently reviewed 
(Dehay and Bezard, 2011, Lee et al., 2012) 
 
1.2 Current treatments for Parkinson’s disease 
Despite centuries of research, there is currently no cure for Parkinson’s disease and L-
DOPA remains the most effective treatment available. Nonetheless, because of its long-
term adverse effects, every effort is made to postpone its usage. Pharmacological 
alternatives, such as DA agonists, monoamine oxidase B (MAO-B) inhibitors or 
amantadine, can be used at the early stages of the disease. However, as the disease 
progresses, these treatments will become ineffective and all patients will eventually 
receive L-DOPA treatment (Antonini and Barone, 2008).  
 
1.2.1 Early pharmacological treatments 
In the early stage of the disease, as long as there are enough dopaminergic terminals 
remaining, the level of DA available at the synaptic cleft can be stabilised by blocking 
the metabolization of DA. The enzyme MAO-B, responsible for DA deamination, is 
found at the outer mitochondrial membrane of the serotonergic neurons of the basal 
ganglia (Youdim et al., 1972). Lazabemide had very limited effect on PD motor 
symptoms and has therefore been dropped as a treatment (Riederer et al., 2004). 
Contrarily, selegiline and rasagiline are commonly used as mono-therapy in the 
treatment of motor symptoms in early PD (Figure 5). Selegiline generates amphetamine 
or methamphetamine metabolites, while rasagiline does not. MAO-B inhibitors are also 
used in later stages of PD, as an adjunct to L-DOPA therapy for ‘end-of-dose’ 
fluctuations. Indeed, by limiting the conversion of DA, they prolong the anti-akinetic 
effect of L-DOPA, therefore reducing sudden “wearing off”. Finally, MAO-B inhibitors 
might have a protective effect and slow down the progression of the disease (Zhu et al., 
2008, Maruyama et al., 2002).  
 
DA receptor agonists were developed during the 1970s. Initially, they were used as an 
adjunctive therapy to L-DOPA in the treatment of advanced PD patients exhibiting 
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fluctuating motor responses or dyskinesias (Braham et al., 1970, Calne et al., 1974). 
Although apomorphine is still exclusively used to help even out the L-DOPA response 
(discussed later in section1.2.2.1 Motor fluctuations), most DA agonists are now used as 
mono-therapy in the early stage of the disease, to delay L-DOPA treatment. Indeed, 
they can cross the blood-brain barrier easily and stimulate directly post-synaptic DA 
receptors in a selective manner (Perachon et al., 1999). Various DA agonists are 
currently available and fall into two major classes, the ergolines: bromocriptine, 
pergolide, lisuride, alphadihydroergocryptine, cabergoline, and the non-ergolines: 
ropinirole, piribedil, pramipexole, rotigotine and apomorphine. DA agonists are 
associated with side effects such as dizziness, hallucination, psychosis, nausea (Thomas 
et al., 2006). Ergot-derived DA agonists are also associated with a risk of pulmonary 
and cardiac fibrotic reactions, although it is limited (Lledo, 2000). Despite having 
different physical and chemical properties, they all present the advantage of acting 
directly on DA receptors and most of them have longer half-lives than L-DOPA, 
providing a more physiological and continuous stimulation of the receptors, with the 
exception of apomorphine (Brooks, 2000, Bonuccelli et al., 2009, Martinez-Martin and 
Kurtis, 2009).  
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Figure 5: Pharmacotherapy for PD and mechanisms of action. Current pharmacological 
treatments are written in black, enzymes in light blue. As the disease progresses, dopaminergic 
neurons degenerate and L-DOPA is taken into 5-HT neurons and converted into dopamine (see 
section 1.2.2.2 L-DOPA-induced dyskinesia). 3-OMG: 3-O-methyl dopa, 5-HT: serotonin, 
AADC: aromatic L-amino acid decarboxylase, DA: Dopamine, COMT: Catechol-O-
methyltransferase, HVA: Homovanilic acid MAO: Monoamine oxydase  (inspired by Youdim 
et al. 2006). 	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1.2.2 L-DOPA 
Currently, no curative treatment for PD exists. The administration of the DA precursor 
L-3,4-dihydroxyphenylalanine (L-DOPA), introduced in the 1960s (Barbeau et al., 
1962, Birkmayer and Hornykiewicz, 1962), is highly effective at replacing the missing 
dopaminergic drive and therefore alleviate motor symptoms, in particular bradykinesia, 
in the early stages of the disease. It is widely used and still represents the “gold 
standard” treatment for PD (Worth, 2013). L-DOPA, in contrast to dopamine, is able to 
cross the blood-brain barrier. Once transported to the brain through the large amino acid 
transporters, L-DOPA is converted into DA by the aromatic AADC present in the few 
dopaminergic neurones still intact and in the serotonergic terminals, before being 
released at the synapse (Wade and Katzman, 1975b). Indeed, serotonin (5-HT) neurons 
contain the enzymatic machinery required for the conversion of L-DOPA to DA and can 
store the neurotransmitter in synaptic vesicles (Carta et al., 2007). Serotonergic neurons 
are very efficient at releasing this dopamine, but lack the auto-receptors allowing 
feedback mechanisms. This uncontrolled delivery leads to the over stimulation of the 
postsynaptic DA receptor, which plays a role in the development of L-DOPA-induced 
long term side effects, discussed in the following paragraph. L-DOPA is available as 
oral tablets containing a combination of L-DOPA and the AADC inhibitor: carbidopa 
(Sinemet, Parcopa, Atamet) or benserazide (Madopar, Prolopa), in order to prevent the 
conversion of L-DOPA into DA in the periphery. The co-administration of L-DOPA 
with AADC inhibitors, unable to cross the blood-brain barrier, prevents peripheral side 
effects such as oedema, nausea or vomiting, and increases the quantity of L-DOPA 
reaching the brain, making the treatment more effective at lower doses (Greenacre et al., 
1993). Although L-DOPA remains the best medication currently available, long-term 
treatment is associated with severe and disabling motor complications (Curzon, 1967, 
Cotzias et al., 1969).  
 
1.2.2.1 Motor fluctuations 
After a few years of chronic treatment and as the neurodegeneration progresses, patients 
are subject to “motor fluctuations” and they oscillate between 2 phases: 1)“on”-phase: 
when L-DOPA provides therapeutic benefit, reducing the PD motor symptoms and 2) 
“off”-phase: associated with poor drug response and increase of PD-related disability 
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(Quinn, 1998). These fluctuations can become progressively more severe leading to 
“freezing” behaviours, when patients suddenly switch into the “off” state. This 
narrowing of the therapeutic window can be improved with the use of control-release 
(CR) formulation to ensure constant release of L-DOPA over 4 to 6 hours (e.g. Sinemet 
CR, Madopar CR). Continuous L-DOPA delivery can be accomplished by surgical 
implantation of a duodenal probe releasing constant dose of L-DOPA gel (Duodopa) 
and has been proven effective in reducing “off-state” (Nyholm, 2006, Antonini et al., 
2007, Honig et al., 2009, Antonini et al., 2010a). However, this strategy presents some 
major drawbacks, as it requires invasive surgery and constant carrying of a portable 
duodenal infusion system (Antonini et al., 2010b). 
 
Alternatively, catechol-O-methyl transferase (COMT) inhibitors can be prescribed in 
order to prevent peripheral conversion of L-DOPA into 3-methoxy-4-hydroxy-L-
phenylalanine (3-OMD), either as an additional treatment (e.g. Tolcapone and 
Entacapone), or combine with L-DOPA and carbidopa (Stalevo). The COMT inhibition 
also limits peripheral production of 3-OMD, which competes with L-DOPA for 
transport through the blood-brain barrier (Wade and Katzman, 1975a). Prolongation of 
the “on-phase” can be obtained by administration of DA agonists and apomorphine, 
pergolide, pramipexole, ropinirole and rotigotine have demonstrated some efficacy in 
clinical trials (Olanow et al., 1994, Lieberman et al., 1998, Dewey et al., 2001, 
Holloway et al., 2004, LeWitt et al., 2007). Apomorphine delivered as continuous 
infusion reduces “off-time” by 50% in most patients and could also have anti-dyskinetic 
properties (Dewey et al., 2001, Katzenschlager et al., 2005). Moreover, it is now 
available in prefilled syringes, pen or ampoules, allowing patients to self-administered a 
“rescue injection” when L-DOPA starts to wear out. Patches of rotigotine, a non-
ergoline DA agonist, had proven efficacy in smoothing out motor fluctuations (LeWitt 
et al., 2007, Poewe et al., 2007).  
 
1.2.2.2 L-DOPA-induced dyskinesia 
The most striking and disabling side effect of L-DOPA is the development of abnormal 
movements; named L-DOPA-induced dyskinesias (LIDs) appearing after prolonged 
treatment. A significant proportion of patients, estimated 40%, develop dyskinesias after 
4-6 years of repeated pulsatile treatment and this risk increases by 10 % with every 
additional year on medication (Ahlskog and Muenter, 2001). The risk of developing 
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dyskinesias is highly increased with young-onset of the disease. Indeed, more than 90% 
of the patients who were diagnosed before the age of 40 develop dyskinesia within 5 
years of L-DOPA treatment (Golbe, 1991, Kostic et al., 1991). Other parameters, such 
as genetic factors might play a role in LID development, such as mutations in LRRK2 
gene (Lesage et al., 2008). Genes coding for DA transporters (Kaiser et al., 2003) or 
receptors (Oliveri et al., 1999) and more recently identified, brain-derived neurotrophic 
factor (BDNF) (Foltynie et al., 2009) might also play a role in the development of LIDs. 
 
LIDs are described as hyperkinetic and dystonic abnormal movements and postures, 
which are irregular, purposeless and uncontrollable. Although the manifestation of LIDs 
is heterogeneous and varies between patients, they most commonly arise in facial 
muscles before rapidly spreading to the head and neck, eventually affecting the limbs. 
LIDs are mainly characterised by hyperkinetic movements, included chorea and 
dystonic movements, presented as sustained muscle contraction (Goetz et al., 2008, 
Armand et al., 2009). Dyskinesias fluctuate with L-DOPA dosing, usually associated 
with high plasma and brain concentrations of the drug, so called “peak-dose” or “on 
phase” dyskinesias, they are predominantly choreiform and choreo-dystrophic 
movements. LIDs can also be related to changes in L-DOPA concentration, during the 
increasing or decreasing phases (diphasic dyskinesia) or to very low levels of L-DOPA 
(“off state”) and are, in both cases, mostly characterized by dystonic, sometime painful, 
movements. These three patterns of dyskinesias can be exhibited in the same patient 
(Thanvi et al., 2007). In clinical practice, dyskinesias are assessed using subjective 
rating scales based on clinical examination, patient historical self-evaluation or a 
combination of both. The variability in evaluation techniques made clinical studies 
impossible to compare and at the end of the 2000s, the Movement Disorders Society 
commissioned a task force to compare the different clinical rating scales (Goetz et al., 
2007, Colosimo et al., 2010). Moreover, recent clinical trials aiming at evaluating the 
effect of potential anti-dyskinetic drugs, such as fipamezol or levetiracetam, showed 
contradictory results, depending on the scale used and despite significant effect on the 
time spent “on” without dyskinesia (Zesiewicz et al., 2005, Wolz et al., 2010, Lewitt et 
al., 2012). This observation raises important questions concerning the relevance of these 
scales and their sensitivity for the detection of an improvement in the patients’ 
condition. Validating LID scales, in term of their sensitivity regarding anti-dyskinetic 
drug properties is not an easy task since the only medication available for the treatment 
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of dyskinesia is the anti-viral amantadine, a weak glutamate N-Methyl-D-aspartic acid 
(NMDA) antagonist. Indeed, amantadine has very limited effects and only works for a 
few years in some patients (Godwin-Austen et al., 1970, Elahi et al., 2012).  
 
If the causes of abnormal movements remain elusive, 3 main factors have been 
identified as risk factors in the development of LIDs: disease progression, duration of L-
DOPA treatment and medication dosage. These 3 parameters are closely linked and the 
relative contribution of each toward LIDs development is hard to establish. Indeed, as 
the disease progresses, more DA neurons are lost; therefore, a higher dose of L-DOPA 
will be required to alleviate motor symptoms. Not to mention that, over the years, the 
duration of medication will increase in parallel of disease progression. The only 
exception is the MPTP-intoxicated drug addicts who developed the disease over few 
days and within months, presented motor complications (motor fluctuations and 
dyskinesia) similar to the one normally encountered in patients following years of L-
DOPA chronic treatment (Langston and Ballard, 1984, Ballard et al., 1985). Moreover, 
some case studies have sporadically reported dyskinesia appearance after the first 
exposure to dopaminergic drugs (Onofrj et al., 1998). From these reports, it is apparent 
that the extensive loss of dopaminergic neurons is sufficient to induce motor 
complication when the patients are exposed to L-DOPA. Although many animal studies 
have showed that lesions in the dopaminergic pathway are required to observe 
dyskinesia, some studies performed in non-primates have reported contradictory results 
(Boyce et al., 1990b, Pearce et al., 2001, Togasaki et al., 2001, Paille et al., 2007). In 
both cases, with or without lesions, dyskinesias appear in a dose dependent manner but 
occur earlier, more consistently and with lower doses of L-DOPA in severely lesioned 
animals (Schneider, 1989, Di Monte et al., 2000, Pearce et al., 2001).  
 
Pulsatile discharge of DA in the striatum is thought to be the main actor in LID 
development (Carta et al., 2008, Lindgren et al., 2010). Animal studies have 
demonstrated that intrastriatal infusion of DA is sufficient to induce dyskinesia in 6-
OHDA lesioned rats (Carta et al., 2006). While given systematically, L-DOPA crosses 
the blood-brain barrier and enters dopaminergic and serotonergic neurons. As the 
disease progresses, less dopaminergic neurons remain. In the absence of dopaminergic 
cells, L-DOPA is converted into DA by the 5-HT neurons and released in an 
uncontrolled manner (Hollister et al., 1979). The striatum is therefore flooded with DA, 
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which leads to an over stimulation of postsynaptic DA receptors. Lesions of the 
serotonergic pathway or administration of a combination of 5-HT1A/1B auto-receptor 
specific agonists (8-OH-DPAT and CP94253) have been proven effective at abolishing 
established dyskinesias in the rat and non-human primate models (Carta et al., 2007, 
Munoz et al., 2008). Similar results have been reported recently with the mixed 5-
HT1A/1B receptor agonist eltoprazine in the same 2 animal models (Bezard et al., 2013). 
Finally, there is evidence that chronic L-DOPA treatment elicits sprouting of 5-HT 
terminals in the striatum of dyskinetic animals, which correlates with AIM’s severity, a 
phenomenon that is believed to exacerbate aberrant DA release even more (Rylander et 
al., 2010, Lindgren et al., 2010). In dyskinetic patients, positron emission tomography 
(PET) scans revealed a correlation between the severity of LID and the amplitude of 
changes observed in striatal DA level (Pavese et al., 2006).  
 
As the disease progresses, compensation mechanisms occurring in the striatum lead to 
maladaptive plasticity of the medium spiny neurons. The density of D2-like DA 
receptors increases, while D1 DA receptors are over-expressed and become hyper-
sensitive (Creese et al., 1977, Lee et al., 1978, Aubert et al., 2005, Guigoni et al., 2007, 
Berthet et al., 2009). Thus, the rapid increase in striatal DA levels following L-DOPA 
administration leads to hyper-activation of the thalamus through the over-activation of 
the direct pathways and inhibition of the indirect pathway. This unbalanced striatal 
response drives abnormal stimulation of the basal ganglia, resulting in hyperactivity of 
the motor cortex and therefore, development of involuntary and uncontrolled 
movements (Figure 4c). To elaborate, the activation of D1 DA receptors by DA 
converted from L-DOPA, leads to inhibition of the GPi through the direct pathway. In 
parallel, D2 DA receptors stimulation decreases glutamatergic striatal output to the GPe, 
which releases more GABA, thus inhibiting the STN. The STN inhibition results in a 
lack of activation of the GPi and SNr, lifting the inhibition on the thalamus. The over 
activation of the thalamus results in the development of abnormal and involuntary 
movements (AIMs) (Albin et al., 1989, Jenner, 2008).  
 
After years of chronic treatment with L-DOPA important post-synaptic modifications 
occur that correlate with the severity of LIDs. In greater details, the aberrant stimulation 
of sensitized D1 DA receptors leads to hyper-activation of the cAMP-signalling 
cascade. The increased activity of the cAMP-dependent protein kinase (PKA) and of the 
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dopamine- and cAMP-dependent phosphoprotein of 32 kDa (DARPP-32), has been 
shown to correlate with LID in animal models (Picconi et al., 2003, Santini et al., 2007, 
Santini et al., 2010). Moreover, genetic depletion of DARPP-32 reduces AIMs in mice, 
whether the protein was knock out in striatonigral neurons or in striatopallidal neurons 
(Santini et al., 2007, Bateup et al., 2010). Furthermore, stimulation of the PKA and 
DARPP-32 pathway is accompanied by an increased phosphorylation of the 
extracellular signal-regulated kinases (ERK) correlating with LID in animal studies 
(Bezard et al., 2005, Pavon et al., 2006, Santini et al., 2007). Finally, ERK signalling is 
involved in the regulation of the mammalian target of rapamycin complex 1 (mTORC1) 
and FosB-like proteins, which have also been reported, to be increased in dyskinetic 
rodent and primate models (Andersson et al., 1999, Francardo et al., 2011). FosB has 
been shown to be up-regulated in dyskinetic patients (Lindgren et al., 2011). Moreover, 
animal studies have demonstrated that striatal over-expression of Δ-FosB gene is 
sufficient to induce AIMs in lesioned rats, highlighting the causative role played by the 
Fos-B family genes in the development of LIDs (Andersson et al., 1999, Cao et al., 
2010). 
 
1.2.3 Animal models of L-DOPA-induced dyskinesia 
The first animal models of LIDs used non-human primates treated with L-DOPA after 
MPTP lesion (Crossman et al., 1987). MPTP-lesioned monkeys exhibit choreiform and 
dystonic movements very similar to the adverse effects observed in patients after 
chronic treatment with L-DOPA, which can be assessed using subjective rating scales 
adapted from the clinic, as recently reviewed by Fox and colleagues (e.g. the Abnormal 
Involuntary Movements Scale (AIMS), similar to the patient’s scale bearing the same 
name, or the Dyskinesia Disability Scale resembling the Unified Dyskinesia Rating 
Scale (UDysRS)) (Fox et al., 2012). Non-human primates represent a reliable model for 
the study of LID as they exhibit phenomenological similarities to peak-dose dyskinesias 
experienced by PD patients but also display other features associated with long-term 
treatment with L-DOPA such as fluctuations in the response to the treatment inducing 
“wearing off” phases or diphasic dyskinesia (Boyce et al., 1990a, Petzinger et al., 2001, 
Jenner, 2003). For these reasons, non-human primates have been used to study the 
mechanisms underlying the development of LID, as well as test new potential anti-
dyskinetic drugs (Grondin et al., 1999, Guigoni et al., 2007, Berton et al., 2009, Porras 
et al., 2012, Berthet et al., 2012, Bezard et al., 2013).  
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As a result of its resemblance to the human manifestation of LID, the MPTP-lesioned 
non-primate model was rapidly and widely accepted. In contrast, the adaptation of the 
LID primate scale to the assessment of AIMs in the 6-OHDA-lesioned rats was at first 
highly debated as it was believed that rodents could not express the full panel of LIDs 
movements observed in humans and monkeys (Cenci et al., 1998, Cenci et al., 2002). 
Furthermore, it has been argued that motor effects induced by L-DOPA in dopamine-
denervated rats were simply repetitive behaviour, resembling stereotypies observed with 
other psychostimulants such as apomorphine, amphetamine or cocaine (Randrup et al., 
1963, Fog, 1969, Ervin et al., 1977). The first dyskinesia rodent scale used a 0-4 scoring 
methods (similar to the human Abnormal Involuntary Movement Scale) based on the 
duration of the 3 different subtypes of dyskinesias and the evaluation of the rotational 
behaviour. Due to its ethical, practical and financial advantages over the primate model, 
the 6-OHDA-lesioned rat, and more recently mouse, became rapidly widely used in the 
study of LIDs and new scales were developed (Winkler et al., 2002, Steece-Collier et 
al., 2003, Lundblad et al., 2005, Lane et al., 2006, Maries et al., 2006). Among these 
new scoring methods, very few have been validated and their sensitivity toward the 
detection of new potential anti-dyskinetic agents has never been assessed. Moreover, 
one of these scales included the scoring of facial stereotypic behaviour where the 
boundary between dyskinesias and stereotypy induced by L-DOPA remains blurry. The 
first part of this thesis is therefore dedicated to the comparison of the most common 
rodent rating scales as well as defining the difference between LID, stereotypic and 
rotational behaviour. 
 
1.3 Alternative therapeutic approaches  
1.3.1 Ablative therapy and deep brain stimulation 
In 1952, an accidental ligation of the anterior choroidal artery was performed on a PD 
patient and showed beneficial effect on motor symptoms (Cooper, 1953). Earlier studies 
had already demonstrated some improvement following lesion in the pallidal or sub-
pallidal structures (Meyers, 1942, Fenelon, 1950, Guiot and Brion, 1953). Later, 
neurosurgeons refined the technique and demonstrated a more consistent benefit by 
specifically destroying the medial part of the pallidus or the ventral part of the thalamus 
(Svennilson et al., 1960, Krayenbuhl and Yasargil, 1960). More rigorous study has 
	   29	  
found that pallidotomy alleviates tremor, rigidity, bradykinesia, and dyskinesias in PD 
patients, whilst thalamotomy does not improve bradykinesia or akinesia but has a 
beneficial effect on rigidity and tremor (Krayenbuhl et al., 1961, Paine, 1962, Scott et 
al., 1970, Kelly et al., 1987, Vitek et al., 2003). However, electrolytic lesions were not 
well tolerated when performed bilaterally and were associated with high morbidity. In 
the 1960s, surgeons performing ablative surgeries on PD patients reported rhythmic 
cellular discharges synchronous with the patients’ tremors. The observation later led to 
the development of deep brain stimulation (DBS), which was introduced in the 1980s 
and slowly replaced ablative procedures (Albe Fessard et al., 1963, Benabid et al., 1987, 
Vitek et al., 1998, Benabid and Torres, 2012). This surgical technique uses electrical 
electrodes attached to an impulse generator of 2-5 V, placed under chest skin, offering a 
finer control and the possibility of being turned off, while there is no way back with 
ablative surgeries. DBS typically uses high frequency stimulations around 130 Hz, with 
pulse of 60 to 120 µsec (Benabid et al., 1987, Siegfried and Lippitz, 1994, Schuurman 
et al., 2000, Wooten et al., 2004). The loss of the nigro-striatal dopaminergic pathway 
occurring in PD is associated with an over activity of the GPi and the STN, making 
these 2 nuclei the most commonly targeted (see section 1.1.3.1. Cell loss and basal 
ganglia deregulation) (Benabid and Torres, 2012). PD motor symptoms respond well to 
both targets, while dyskinesia is most commonly alleviated with GPi stimulation. A 
reduction in LID can be observed following STN DBS, however it is more the result of 
a decrease in L-DOPA medication enabled by the alleviation of PD symptoms than 
direct effect of DBS (Mentzel et al., 2012). Although the exact changes induced by DBS 
remain unclear, it is believed to modify the firing rate of individual neurons and act at 
the synapses, inducing the release of neurotransmitters, such as adenosine and glutamate 
(Lee et al., 2004, Tawfik et al., 2010). 
 
1.3.2 Gene therapy 
The idea of using genetic material as a therapy emerged in the 1960s following the 
developing understanding of the viral cycle and the transduction mechanism (Tatum, 
1966). PD mainly affects a well-defined area of the basal ganglia, which can be 
effectively targeted since the development of stereotaxic surgery. However, because PD 
is not a monogenic disorder, there is no obvious gene candidate for this therapeutic 
approach. Different strategies have been investigated, among them: the restoration of 
DA synthesis, or the production of neurotrophic or neuroprotective factors. They will be 
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examined in further detail below. (Other approaches have been used and have been 
reviewed elsewhere (Porras and Bezard, 2008, Coune et al., 2012)). 
 
L-DOPA is synthetized from tyrosine by the tyrosine hydroxylase (TH) enzyme. It is 
then converted in DA by the AADC. The activity of TH, and therefore the efficiency of 
the production of L-DOPA, requires the co-factor tetrahydrobiopterine (BH4) 
synthetized by the enzyme GTP-cyclohydrolase-1 (GCH-1). The “enzymes 
replacement” gene therapy strategy aims to restore the level of striatal DA by inducing 
ectopic synthesis of DA in the GABAergic medium spiny neurons. One possible 
approach is to deliver the genes encoding for TH, AADC, and GCH1 in the striatum, 
using a viral vector. The transfer of these 3 genes produces a significant increase in 
striatal DA level, accompanied by some improvement of motor functions in the 6-
OHDA-lesioned rat and the MPTP-lesioned non-human primate models (Azzouz et al., 
2002, Shen et al., 2000, Muramatsu et al., 2002, Sun et al., 2003, Jarraya et al., 2009). 
This approach is currently undergoing a clinical trial (Wirth and Yla-Herttuala, 2013).  
 
The glial cell line-derived neurotrophic factor (GDNF) is believed to have a protective 
effect on dopaminergic neurons. The delivery of the GDNF gene in 6-OHDA-lesioned 
rat and the MPTP-lesioned non-human primate models of PD showed a significant 
improvement in dopaminergic neurons survival and motor functions (Engele et al., 
1996, Bilang-Bleuel et al., 1997, Choi-Lundberg et al., 1998, Kordower et al., 2000, 
Rosenblad et al., 2000). Although open label trials provided encouraging results, double 
blind studies failed to demonstrate significant improvement following GDNF 
intraputamenal infusion (Gill et al., 2003, Patel et al., 2005, Lang et al., 2006, Slevin et 
al., 2007, Marks et al., 2010). It difficult to draw any conclusions on the benefit that 
patients could derive from GDNF treatment as the inconsistences of the results between 
double blind trials and positive open-label studies may be due to technical differences. 
 
1.3.3 Cell therapy 
One of the major challenges in the research for new treatments lies in the impossibility 
of diagnosing PD before the occurrence of widespread degeneration and establishment 
of long-term changes in the basal ganglia circuitry. At the beginning of the 20th century, 
scientists were seeking ways to regenerate the tissue or replace it with transplanted 
neurons, in order to reverse the damage and restore normal function. Using cell therapy 
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to repair brain tissue is a very old idea, which presents its fair share of significant 
challenges. First, reaching a discrete area of the brain without affecting the surrounding 
nuclei is not an easy task and could not be achieved without the development of 
stereotaxic apparatus. Secondly, mature neuronal tissue does not survive transplantation 
well, possibly due in part to the severing of the axonal projections (Dunn, 1917). 
Nevertheless two schools of thought emerged, using an autograft of the patient’s own 
catecholamine producing adrenal gland cells, or using an allograft of embryonic 
dopaminergic neurons precursors collected from surgical terminations of pregnancy. 
The refinement of transplantation techniques for the use of embryonic neurons allowed 
an excellent rate of survival of the grafted cells in animals models (Le Gros Clark, 1940, 
Stenevi et al., 1976). Based on this data, and the poor results emanating from clinical 
trials of adrenal graft in PD patients, scientists started to consider foetal ventral 
mesencephalon (VM) tissue as a promising source of dopaminergic cells (Backlund et 
al., 1985, Brundin et al., 1986). The use of human foetal cells, obtained from elective 
abortions, as the “donor” raised important ethical questions and was, and still is, subject 
to active debate (Boer, 1994). Furthermore, 5-8 embryos of 6-10 weeks old are required 
in order transplant a patient unilaterally, a timeline that can cause practical issues, as the 
tissue cannot be kept for more than few days, added to the changing protocols for 
terminations of pregnancy from surgical to medical in some countries. Notwithstanding 
the ethical and practical hurdles, the first open clinical trial for foetal VM transplant for 
PD went on in Sweden in 1989 with 2 of the drug abusers left “frozen” by MPTP 
consumption. The patients transplanted exhibited clinical benefit, which correlated with 
increased of 18fluorodopa binding in PET scans. For the following 2 decades several 
open-label trials were performed and provided the proof of concept that foetal VM cells 
survive and innervate the striatum of PD patients, providing, an alleviation of PD motor 
symptoms and allowing a decrease in L-DOPA medication (Lindvall et al., 1990, 
Kordower et al., 1995, Hauser et al., 1999, Hagell and Brundin, 2001). Between 1980 
and 2002, over 100 patients received intrastriatal VM transplants but the outcomes have 
been extremely variable. Although the European trials demonstrated a clear clinical 
benefit in most of the grafted patients, the two double-blind studies funded by the 
American National Institute of Health (NIH) in the mid-1990s failed to show a 
significant improvement in the transplanted group when compared to the placebo group 
(Freed et al., 2001, Olanow et al., 2003). However, further detailed analysis revealed a 
significant clinical benefit in younger patients (less than 60) reaching a maximum 4 
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years post transplantation. This highlights the importance of the choice of study end-
point, as the graft needs time to mature (Ma et al., 2010). If one can argue that the 
design of the trials were inappropriate, the development of severe abnormal and 
uncontrollable movements, which persisted after the withdrawal of L-DOPA 
medication, raised significant concerns. Indeed, 9 out of the 70 patients transplanted in 
the NIH trials had to undergo subsequent DBS to alleviate these so called graft-induced 
dyskinesias (GID) (Greene et al., 1999).  
 
1.3.3.1 Graft-induced dyskinesia 
The first report of these severe motor side effects following intrastriatal transplantation 
of foetal dopaminergic neurons emanated from the first US NIH sponsored double-blind 
control trial performed by Freed and co-worker in the early 2000s. These abnormal 
movements were described as stereotypic and dystonic, mainly affecting the lower parts 
of the body, similar to diphasic LID (Olanow et al., 2003). In total, 30 PD patients 
received human embryonic VM tissue grafts and 15% of them developed severe 
dyskinesias during the second and third year post grafting. These dyskinesias were 
directly linked to transplantation and persisted after reduction or complete withdrawal 
of dopaminergic drug therapy (Greene et al., 1999). Similar adverse effects of the 
transplantation were described after the second US NIH sponsored double blind study 
involving 23 patients. More than half (13, 56%) of these patients developed mild off-
medication dyskinesias between the 6-12 months following transplantation (Olanow et 
al., 2003). Lastly, a retrospective analysis of the video-based evaluation of GIDs 
performed on 14 grafted patients during the Swedish trials 11 years ago, underlined 8 
cases of mild GIDs, which reached their peak severity after 3 years (Hagell et al., 2002). 
Interestingly, patients in all of these studies continued to derive benefit from the grafts, 
which gradually improved for up to 13-16 years post transplantation, based on the 
reduction of their Unified Parkinson’s Disease Rating Scale (UPDRS) scores (Hagell et 
al., 2002). This was a feature, which echoed through all of the studies. 
 
1.3.3.2 Animal models of graft-induced dyskinesia 
After the development of transplantation side effects in patients and the variable lack of 
efficacy, scientists went back to the bench. Transplantation studies in non-human 
primates and rodents were performed and carefully monitored for dyskinesia in the 
absence of anti-parkinsonian drugs. Only infrequent, spontaneous GIDs were reported 
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in the MPTP-treated primates (Redmond et al., 2008). Similarly, in the 6-OHDA-
lesioned rat model, very few spontaneous dyskinesias were observed in the absence of 
medication and were considered too inconsistent and unreliable to constitute a good 
model of GID (Lane et al., 2006, Vinuela et al., 2008). Although, it has been established 
that VM dopaminergic grafts are capable of reducing AIMs induced by L-DOPA in the 
6-OHDA-lesioned rat, a few studies have described the appearance of a novel 
stereotypic behaviour limited to the forelimb and facial region described as a specific 
GID-type behaviour. It is however important to note that this forelimb-facial stereotypy 
appears under L-DOPA treatment and are associated with single site ‘hot-spot’ VM 
transplants (Steece-Collier et al., 2003, Maries et al., 2006, Steece-Collier et al., 2009). 
These facial-forelimb and forelimb stereotypies were not observed in rats receiving 
multiple sites deposition of the same number of foetal cells producing a more evenly 
innervating graft. This observation was consistent with the proposal from the Denver-
Columbia clinical trial, which identified ‘hot spots’ of DA in their GID patients (Ma et 
al., 2002, Maries et al., 2006). However, this movement is hard to evaluate as it can be 
easily masked by mild LIDs.  
 
An alternative approach, which still relies on drug stimulation, is that of amphetamine-
induced abnormal movements. The amphetamine-induced rotation test is commonly 
used to assess the severity of DA depletion following 6-OHDA lesions and as a crude 
estimate of foetal VM transplantation success. Closer observation, following description 
of GIDs in the American trials, demonstrated that dyskinetic movements, generally 
resembling mild to moderate LIDs, were evoked by amphetamine administration in 6-
OHDA lesioned rats, transplanted with VM tissue (Carlsson et al., 2006, Lane et al., 
2006). Typically, the amphetamine-induced dyskinesias are hyperkinetic limb and/or 
orofacial dyskinetic movements, reaching their peak severity at 12-16 weeks post 
transplantation and disappearing if the graft is completely rejected by the host brain 
(Carlsson et al., 2006, Lane et al., 2006, Lane et al., 2008). Although this model is now 
commonly used to study the parameters influencing the development of GIDs (Carlsson 
et al., 2006) it is not fully representative of the clinical situation. Indeed, transplanted 
patients receiving amphetamine for 11C raclopride PET imaging scans did not show the 
appearance or worsening of GIDs (Piccini et al., 1999, Carlsson et al., 2006, Smith et 
al., 2012). Despite the efforts made to reproduce some important clinical conditions (i.e. 
extremely severe DA depletion mimicking late stage patients, and long-term, high dose 
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of L-DOPA to induce severe LID prior to grafting), in neither the rodent, nor the 
primate, are we able to establish true spontaneous GIDs. One hypothesis that will be 
addressed in this thesis is that these models have still failed to recreate a situation close 
enough to the clinical experience, omitting specific critical factors. For instance, the 
impact of L-DOPA treatment post-graft and non- fully immunologically compatible 
transplants have never been rigorously assessed in the context of GIDs (Steece-Collier 
et al., 1990, Steece-Collier et al., 1995, Maries et al., 2006, Lane et al., 2008, 
Soderstrom et al., 2008, Steece-Collier et al., 2009, Garcia et al., 2011). 
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1.4 Aims of the thesis 
Although neuronal transplantation represents a promising way to treat PD, previous 
clinical trials have reported very inconsistent results in terms of clinical efficacy. 
Furthermore, the appearance of unpredicted dyskinesias following transplantation raised 
numerous questions about the safety and the efficacy of this therapeutic approach. The 
global aim of this thesis was to identify some of the critical factors that can influence 
the functional outcome of neurotransplantation for PD. 
 
The fact that, neither the heterogeneity of the results of the clinical trials, nor the 
development of GIDs, was predicted pre-clinically raised concern about the reliability 
of the animal models currently used in transplantation studies. This thesis focuses on the 
6-OHDA unilaterally lesioned rat model of PD and first addresses the question of the 
accuracy of the most commonly used rat dyskinesia rating scales in a systematic 
manner. Once this was established, the model itself required adapting to consider 
clinically relevant factors. To this end, I assed the effect that chronic L-DOPA 
treatment, administered either pre and/or post-transplantation, had on the survival and 
function of foetal transplantation. Furthermore this was considered in transplants of 
different level of immune compatibility. A final clinically applicable condition to be 
considered was the use of multi-donor grafts and preliminary work to define this model 
was undertaken. 
 
The main aims of this PhD work were:  
 
1. To compare the different methods of AIM scoring in the 6-OHDA unilaterally 
lesioned rat model and identifying the most reliable (Chapter 3) 
 
2. To determine the effect of chronic L-DOPA treatment can have on the survival 
and function of foetal transplant of different level of immune compatibility 
(Chapter 4) 
 
3. To create a model of multi-donor transplantation with mixed level of 
compatibility (Chapter 5) 
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Chapter 2: General Methods  
 
Declaration 
Details of the compounds used for the experiments can be found in the table provided in 
Appendix I.	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2.1  Animal husbandry 
Adult female Sprague Dawley rats (200-250 g body weight at the start of the 
experiments) were housed 2-4 per cage (L: 54 cm, W: 37 cm, D: 21 cm) containing 
hygienic animal bedding (Lignocel), a cardboard tube and wood stick. The animals had 
ad libitum access to food (14% protein, Harlan) and water, and were maintained under 
14 hours light-10 hours dark cycle with an environment of 45-65% humidity and 
temperature of 20-22° C. Time-mated pregnant female Wistar rats and CD1 mice were 
also kept in this environment (mice and rats were housed in separated rooms), until 
embryo collection for transplantation. Animals were purchased from Charles River UK 
(Chapter 3) and Harland UK (Chapter 4 and 5). All of the experiments were carried out 
in accordance with the Animals (Scientific Procedures) Act 1996 Home Office 
regulations (Project Licence 30/2498, Personal Licence 30/9044).  
 
2.2  Surgical procedures  
For all surgeries anaesthesia was induced in an induction chamber with 3-4% 
Isofluorane in oxygen and then maintained on 2–3% Isofluorane, in a 2:1 mixture of 
oxygen and nitrous oxide. Surgery was performed on a Kopf stereotaxic frame and the 
rat mounted with blunt ear bars. After the intervention, the wound was cleaned and 
sutured using Vicryl 4-0 sutures. The animals received subcutaneous (s.c.) injection of 5 
ml of 0.18% sodium chloride, 4% glucose for hydration and 10 µl of analgesic 
(Metacam) before being placed in a recovery chamber at 30° C until they were fully 
righting themselves. Health and weight checks were carried out for the 3 days following 
the surgical procedures and twice weekly intervals thereafter. 
 
2.2.1 Unilateral 6-hydroxydopamine lesion 
For the unilateral DA denervation, the rats received 6-OHDA injection into the 
ascending DA fibres of the MFB in the right hemisphere (MFB, Figure 6) according to 
a previously established protocol, first developed by Ungerstedt and then refined by 
Torres and colleagues (Ungerstedt, 1968, Torres et al., 2011). 6-OHDA (hydrobromide 
salt, premixed with ascorbic acid) was dissolved in 0.9% saline to obtain a 30 mM 
solution containing 0.03% of ascorbic acid. 3 µl of this solution were infused 
stereotactically using a 30-gauge stainless steel cannula connected via polyethylene 
tubing to a 10 µl glass syringe mounted on a Harvard micro-drive infusion pump. 6-
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OHDA was a delivered at a rate of 1 µl/min. Injection into the MFB was performed at 
the following coordinates: -4.0 mm on the anterior-posterior axis from bregma (AP); 
+1.3 mm laterally from the midline (ML); -7.0 mm deep from dura (DV) with the 
incisor bar set at -4.4 mm below the intra-aural line. The cannula was left in place for a 
further 3 min before being withdrawn to allow better diffusion of the toxin.  
 
 
Figure 6: 6-OHDA unilateral lesion. The neurotoxin was injected in the right MFB leading to 
retrograde death of the dopaminergic cell bodies in the substantia nigra and loss of their 
projections in the striatum. a: representation of the SN, MFB and striatum (modified from Kirik 
et al. (2004)). b and c: TH+ labelling showing a typical absence of dopaminergic projection and 
cells bodies in the right striatum and substantia nigra respectively. 
 
2.2.2 Ventral mesencephalon transplantation 
Time-mated pregnant female (Sprague Dawley or Wistar rats, CD1 mice) were obtained 
commercially (Harlan, UK) and terminally anesthetized by intra-peritoneal (i.p.) 
injection of 500 mg/kg sodium pentabarbitone (Euthatal). According to a previous 
study, the optimal embryonic stage for mouse VM transplantation is 12 days post-
copulatory (E12) (Torres et al., 2007). The mouse embryos correspond to carnegie stage 
16, which in rats is achieved 14 days post-copulation (E14) rats (Butler and Juurlink, 
1987). Mouse and rat embryos were collected at 12 days and 14 days post-copulation 
respectively in order to maintain comparable developmental stages (Table 2). The 
crown rump length (CRL) of the embryos was measured before decapitation and the 
brains were removed and dissected in Hanks’ balanced salt solution (HBSS) (Figure 7, 
8). Each VM was cut as indicated in figure 7 and the meningeal layer was removed. The 
dissected pieces were pooled in trypsin solution (0.1% trypsin and 0.05% DNAse in 
Dulbecco’s minimum Eagle medium (DMEM) at 37° C. When using a common 
dissociation protocol typically used in rats (Bjorklund et al., 1983, Torres et al., 2007), 
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mouse tissue became rather sticky, preventing proper dissociation and consequently, 
transplantation. The protocol was therefore adapted with a reduced duration of trypsin 
incubation from 30-20 min to 10 min and the addition of trypsin inhibitors to stop the 
enzymatic reaction (37° C for 10 min). These small procedural changes significantly 
improved the usability of the tissue. After one wash in DNAse (0.1% in DMEM 
medium), VM were broken into small cells clusters by mechanic dissociation using 
gentle triturations using a 1,000 µl and 200 µl Gilson pipette. The solution was 
centrifuged at 2,000 rpm/min for 3 min and the number of cells was counted using a 
haemocytometer slide. After centrifugation, the pellet was suspended in adequate 
volume of DNAse to obtain the desired concentration (between 100 000 and 400 000 
cell/µl,	  as specified in each chapter) and loaded into a 10 µl Hamilton syringe. 2 µl of 
the cell suspension were injected over 2 min in the depleted striatum of anaesthetized 
animals, at the following coordinates: AP: +0.5 mm; ML: -2.5 mm; DV: -5.0 mm and -
4.0 mm (1 µl at each depth) with the nose-bar set at -4.5 mm allowing a flat head. In the 
last experiment of chapter 5, two deposits were performed at AP: +1.2 mm and -0.3 
mm; ML: -3 mm; DV: -5.0 mm (note: after realising that the graft were too medial in 
chapter 4, the ML coordinates were changed to -3 mm). The syringe was left in place 
for an additional 3 min for diffusion before being retracted. Animals transplanted with 
xenogeneic tissue received cyclosporine A i.p. injections (50 mg/kg) daily from the day 
preceding surgery as an immunosuppressant treatment. The health and weight of rats 
receiving cycloA was monitored weekly, and particular attention was paid to tumour 
development and the growth of teeth and claws.  
 
 
Figure 7: Ventral mesencephalon (VM) dissection (E14 rat embryo). For all VM dissections, the crown 
rump length (CRL) of the mouse and rat embryos was measured, the skin and skull were pulled out and 
VMs were cut (a). A representative drawing of the embryonic brain and the cutting lines is shown in b 
(modified from Bjorklund et al. (1983)). 
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 Species & Strain  Bred Days post-copulatory 
Syngeneic graft  Rat - Sprague Dawley  Outbred 14 
Allogeneic graft Rat -Wistar 
Outbred 
14 
Xenogeneic graft  Mouse - CD1 
Outbred 
12 
Table 2: Animals used in transplantation studies 
 
Embryos were used if measuring: 10.5-12.5 mm for the E14 rats and 8.5-10.5 mm for 
E12 mice (Torres et al., 2008). Wistar rat embryos were bigger than the Sprague 
Dawley (t(97)=4.529, p<0.0001), however no significant difference was observed in the 
number of cell per VM (data not shown). As expected, E14 rat embryos were 
significantly bigger than mouse E12 and had more cells (Mann Whitney test, p<0.001) 
(Figure 8). 
	  
Figure 8: Average number of cells per VM dissected and size of the embryo of  
E14 rats (n=100) and E12 mouse (n=39) 
 
2.3 Spleen cells injections 
The peripheral injection of spleen cells obtained from the same strain as the VM donor 
has been shown to trigger an immune response against the allograft that would 
otherwise be well-tolerated by the host immune system (Soderstrom et al., 2008). To 
this end, male Wistar rats were terminally anesthetised with i.p. injection of 0.5 ml 
sodium pentobarbital (Euthatal) and the spleen was removed and placed in HBSS 
medium. The tissue was forced through a 100 µm sterile cell strainer. The cell 
suspension obtained was then centrifuged (1500 rpm for 3 min) and the pellet was 
suspended in fresh HBSS. Sprague Dawley female rats, which have been transplanted 
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with Wistar VM (allogeneic transplant), recipients were then injected s.c. with 
50,000,000 cells.  
 
2.4 Behavioural assessments  
2.4.1 Amphetamine-induced rotations 
The extent of the 6-OHDA lesions was evaluated 2 and 4weeks post-surgery, based on 
the ipsilateral (toward the lesioned side) rotational behaviour induced by the i.p. 
administration of D-Amphetamine (2.5 mg/kg in 0.9% saline). The animals were placed 
in perspex bowls and harnessed to automated rotometers (Figure 9) based on the design 
of Ungerstedt and Arbuthnott (Ungerstedt and Arbuthnott, 1970) and the net rotations 
were recorded over 90 min. Rats were deemed adequately lesioned and used for further 
study if they performed at least the equivalent of an average of 6 full turns per minute. 
This is reported to correspond to more than 90% depletion of the dopaminergic 
terminals (Torres et al., 2011). The same process was used post-transplantation in order 
to monitor the functional efficacy of the graft (typically successful transplantation will 
lead to reduced amphetamine rotations or reversal). During these sessions the rats were 
rated for amphetamine-induced dyskinesia using Scale B (adapted from Winkler et al 
(2002) as detailed later in section 2.3.3.2.1 Scale B and later discussed in chapter 3). 
    
Figure 9: Rotometer apparatus  
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2.4.2 Motor tests 
All behavioural assessments were carried out during daytime hours, between 8am-7pm. 
Rats were not deprived of food and water except for the duration of the test. 
 
2.4.2.1 Stepping test    
This task evaluates the ability of the rat to adjust a weight bearing forepaw in response 
to movement along a flat surface. The rats were held above a flat bench allowing only 
one forelimb to touch the surface of the table bearing weight (the body weight was 
largely supported by the experimenter but some weight it given to the paw). The rat was 
moved across 1 meter of bench over a period of 10 s and the number of steps made by 
the paw was counted for each forelimb when moved in the forehand and backhand 
directions (Figure 10). This test was repeated 3 times at each time points (before lesion, 
after lesion, after grafting). A practice session was performed at the beginning of the 
experiment to ensure that the rats were comfortable handled this way. 
 
 
Figure 10: Stepping test: the animals are able to perform adjusting steps when the paw on the 
ipsilateral side of the lesion is dragged along the bench surface (a,b), but they are unable to 
move the contralateral forelimb (c, d).  
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2.4.2.2 Vibrissae-elicited limb placing - Whisker test  
The rats were held in a way that allowed the forelimbs to move freely when the torso 
and hind limbs were supported (Figure 11). The rats were moved upward from under 
the bench, allowing the whisker on the tested side to gently brush the edge of the table. 
This induced an automatic limb placing response ipsilaterally to the side of the whiskers 
that had been stimulated (Fleming and Schallert, 2011). This test was performed 10 
times on each side in order to obtain an accurate percentage of response on each side. At 
each time point (before lesion, after lesion and after grafting) the test was repeated 3 
times for each animals and the mean number of accurate placements calculated. 
 
 
Figure 11: Whisker test: Animal whiskers are brushed against the edge of the bench, inducing 
automatic response of limb placement. 
 
2.4.2.3 Cylinder test 
The rats were put in a perspex cylinder (height: 33.5 cm, diameter: 19 cm) and video 
recorded. The cylinder was placed between 2 mirrors, creating a 45° angle to allow 
scoring when the rats were back to the camera (Figure 12). The number of each 
forelimb touches made by each paws, out of the first 20 touches performed on the 
cylinder wall was counted. Results are given in percentage of right or left touches out of 
the total.  
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Figure 12: Cylinder test.  
 
2.4.3 L-DOPA-induced motor dysfunctions 
2.4.3.1 Drugs 
The dose of L-DOPA used is specified in each chapter but always between a range 
considered therapeutically relevant (6-12 mg/kg). L-DOPA solutions were prepared in 
0.9% saline by mixing the appropriate amount of L-3,4-Dihydroxyphenylalanine methyl 
ester hydrochloride and 15 mg/ml of benserazide hydrochloride. Benserazide is a 
peripheral AADC inhibitor, unable to cross the blood brain barrier, which blocks the 
conversion of L-DOPA into DA in the periphery. This permits a higher concentration of 
L-DOPA to reach the brain and limiting peripheral side effects. It has been shown that a 
dose of 12-15 mg/kg of beserazide a day gives an optimal effect, blocking most of the 
peripheral AADC without affecting the enzyme activity in the brain. L-DOPA solution 
was injected s.c. (1 ml/kg) as this route of administration gives a more homogeneous 
response than i.p. (Lindgren et al., 2007). For the dyskinesia rating sessions, L-DOPA 
injections were performed such that a constant interval of 1 min between each animal so 
that they were all rated precisely at the same time following L-DOPA administration. 
 
D1 and D2 DA receptor antagonists, R(+)-SCH-23390 hydrochloride (0.2 mg/kg) and 
R(-)-Raclopride(+)-tartrate (2 mg/kg), and amantadine (40 mg/kg) were all prepared in 
0.9% sodium chloride and injected i.p. 20 min before L-DOPA administration (Smith et 
al., 2012). 
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Bromocriptine was mixed with 2.5% acetic acid and 3 drops of 95% ethanol. Sonication 
was used to dissolve the powder and distilled water was added to allow a final 
concentration of 2 mg/ml (animals were injected i.p. with 2 mg/kg of bromocriptine). 
 
2.4.3.2 AIMs rating scales 
This section describes the different rating scales used to assess L-DOPA-induced motor 
dysfunction in unilateral 6-OHDA lesioned rats. These methods have been compared 
for reproducibility, variance and time dependent changes in chapter 3. Based on these 
results, the subsequent experiments (Chapter 4 and 5) were performed using Scale B to 
assess AIMs and stereotypies were evaluated separately, according to the scale 
developed by Creese and Iversen (Creese et al., 1977).  
 
2.4.3.2.1 Scale A 
Animals were individually observed and rated for 1min every 20 min for a total 
duration of 180min following L-DOPA injection. This method, based on the scale 
developed by Cenci et al. (Cenci et al., 1998), assesses 4 subtypes of AIMs for duration 
(Table 3). The duration scores are summed together to obtain the total AIMs score. 
Hind limb dystonia has been added as a 5th subtypes and the results with or without this 
extra parameter are discussed in chapter 3. 
 
AIMs subtype Definition Duration score 
Locomotive 
Increased locomotion toward 
the contralateral side of the 
lesion 
 
0 = absent 
 
1 = occasional 
 
2 = frequent 
 
3 = continuous but 
interrupted by sensory 
distraction 
 
4 = continuous, severe, not 
interrupted by sensory 
distraction 
Axial dystonia 
Axial dystonia, i.e. 
contralateral twisted posturing 
of the neck and upper body 
Orolingual 
dyskinesia 
Stereotyped jaw movements 
and contralateral tongue 
protrusion 
Forelimb 
dyskinesia 
Repetitive rhythmic jerks or 
dystonic posturing of the 
contralateral forelimb, and/or 
grabbing movement of the 
contralateral paw 
Hind limb 
dystonia 
Abnormal extension of the hind 
limb 
Table 3: Scale A  
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2.4.3.2.2 Scale B 
Scale B is based on the method described by Winkler and co-workers (2002) and 
evaluates 4 different AIMs subtypes and allocates a duration score (identical to the one 
described in the Cenci method) but also an amplitude score to each subtype (Table 4). 
The AIMs severity score is obtained by multiplying the duration score to the associated 
amplitude score. The total AIMs score of each rating session is obtained by summing all 
the severity scores. 
AIM subtype Amplitude Score Duration score 
Locomotive None 
0 = absent 
 
1 = 
occasional 
 
2 = frequent 
 
3 = 
continuous 
but 
interrupted 
by sensory 
distraction 
 
4 = 
continuous, 
severe, not 
interrupted 
by sensory 
distraction 
 
Axial 
dystonia 
1 = lateral deviation of head and neck (<30°) 
 
2 = lateral deviation of head and neck (30°- 60°) 
 
3 = lateral deviation or torsion of head, neck and 
upper trunk (60°- 90°) 
 
4 = torsion of neck and trunk at (>90°), causing the 
rat to lose balance 
 
Orolingual 
dyskinesia 
1 = jaw movements, facial grimacing 
2 = tongue protrusion. 
Forelimb 
dyskinesia 
1 = tiny oscillatory movements of the paw and the 
distal forelimb around a fixed position 
 
2 = movements of low amplitude but causing visible 
translocation of both distal and proximal limb 
 
3 = translocation of the whole limb with visible 
contraction of shoulder muscles 
 
4 = vigorous limb and shoulder movements of 
maximal amplitude.  
 
Hind limb 
dyskinesia 
1 = abnormal posturing of limb 
2 = sustained posturing of limb, mildly extended in 
abnormal posture 
3 = severely hyperextended in abnormal position 
4 = hind limb fully extended, causing the rat to lose 
balance 
Table 4: Scale B 
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2.4.3.2.3  Scale C 
The scale is based on the methods used by the US group led by Dr Steece-Collier. Due 
to the extensive number of AIMs subtypes assessed, the animals had to be recorded for 
1min, every 30 min of 180 min. The AIMs were then scored, based on recording. The 
forelimb dystonia subtypes had to be excluded because wrist and digits movements 
cannot be assessed accurately on a video, especially in the animals that rotate a lot. 
Similarly to Scale B, the severity score of each AIM was obtained by multiplying the 
duration and the amplitude score (Table 5). This scale traditionally considers only 1 
time point at 30 min (Steece-Collier et al., 2003, Maries et al., 2006). In order to study 
the importance of multiple time points, the score at 30 min (Scale C30) were compared 
with the total severity score (Scale C) obtained by summing all severity scores obtained 
at each time point.  
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AIM 
subtype Amplitude score Duration score 
N
ec
k 
dy
st
on
ia
 
0.5 = mild tilt of head 
1 = mild displacement of head posture but returns to neutral position  
1.5 = mix of mild and moderate posture 
2 = more notable displacement (>45°) no return to normal position  
2.5 = mix of moderate and severe posture 
3 = severe torsion of neck musculature 
 
0 = absent 
 
1 = intermittent, 
<50% of 
observation 
period 
 
 
2 = intermittent, 
50% of 
observation 
period 
 
 
3 = persistent 
throughout 
entire 
observation 
period without 
stopping 
 
T
ru
nk
 d
ys
to
ni
a 1 = mild dystonia; <45° between upper and lower torso; 
1.5 = mix of mild and moderate dystonia 
2 = moderate dystonia; (>45°) some loss of balance when ambulating 
2.5 = mix of moderate and severe dystonia 
3 = severe dystonia, twisted (‘‘corkscrew’’) or unable to ambulate 
Fo
re
lim
b 
dy
sk
in
es
ia
 1 = abnormal posturing of limb with returns to neutral position 
2 = mix of mild and severe extension of hind limb 
3 = sustained posturing of limb; severely hyperextended in abnormal 
H
in
d 
lim
b 
dy
st
on
ia
 1 = small amplitude side to side, up & down wiping/tapping cage wall  
2 = same as 1 + downward hyperextension (<50%)  
3 = severe downward hyperextension, pulls opposite of neck 
O
ro
lin
gu
al
 
dy
sk
in
es
ia
 
1 = chewing 
2 = chewing + tongue protrusion and/or open mouth chewing 
H
ea
d 
bo
bb
in
g 1 = small amplitude 
2 = large amplitude 
Fo
re
lim
b-
fa
ci
al
 
st
er
eo
ty
py
 
1 = present None 
Table 5: Scale C 
 
2.4.3.3 Stereotypy rating scale 
This scale assesses stereotypic movements. Animals were rated for 1min every 10 min, 
from 10 min post-injection to 180 min. The scores were given as follows: 0= asleep or 
stationary, 1= active, 2= predominantly active but with bursts of stereotyped sniffing or 
rearing, 3= stereotyped activity such as sniffing along a fixed path, 4= stereotyped 
sniffing or rearing maintained in one location, 5= stereotyped behaviour in one location 
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with bursts of gnawing or licking, 6= continual gnawing or licking of the bowl or cage. 
The total score is obtained by summing of all the scores over the 180min (Creese and 
Iversen, 1973). 
 
2.4.3.4 L-DOPA-induced contralateral rotations 
In all experiments, involving AIMs and stereotypy scoring, rotations were recorded 
simultaneously using automated rotometers (Figure 9) (Ungerstedt and Arbuthnott, 
1970). The system records the number of quarter of turns performed in each direction 
every min. The relative number of full contra-lateral turns, toward the side opposite to 
the lesion, was calculated as follow: (c-i)/4, where c = number of quarter turns 
performed contralaterally and i = number of quarter of turns performed ipsilaterally.  
 
2.5 Perfusion 
At the end of each experiment the animals were terminally anaesthetized with intra-
hepatic injection of 200 mg/kg of Euthatal before being perfused transcardially with 50 
ml of 0.1M TRIS buffer saline (TBS) pH 7.4 in order to remove all the blood. They 
were then perfused with a solution of 1.5% paraformaldehyde (PFA, in TBS): 100 ml 
over 4 min. The brains were removed and placed into 1.5% PFA over night before being 
immersed in a TBS solution containing 25% sucrose until they sank. They were then cut 
on a freezing microtome into 40 µm thick coronal sections and kept at -20º C in a 
cryoprotective solution (0.1 M TBS, 25% sucrose, 0.1% sodium azide) for further 
analysis.  
 
2.6 Immunohistology 
All immunohistochemistry straining was performed on fixed sections following the 
same protocol at room temperature on an automated shaker. A 1 in 12 series was used 
for each staining. After 3 washes of 10min in TBS, the sections were placed in 10% 
hydrogen peroxide and 10% Methanol in 80% distilled water for 15 min in order to 
quench endogenous peroxidise enzyme activity. 3 washes were then performed before 
putting the sections into a block solution of 0.2% triton in TBS (Tx-TBS) containing 
3% normal goat serum for 1 hour. The sections were then placed in the primary 
antibody solution over night (Table 6). After 3 washes of 10 min in TBS, the brain 
slices were transferred in the secondary biotinylated antibody solution for 1-2 hours. 
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After 3 wash of 10 min, the sections were incubated in the Vectastain Elite ABC 
solution (an biotin/avidin system linked to the horse radish peroxidase). Tissue sections 
were washed in TRIS non-saline buffer (TNS) 4 times for 10 min each and incubated in 
TNS 0.03% H2O2, 0.8% 3,3′-Diaminobenzidine tetrahydrochloride hydrate, substrate of 
the peroxidase, in order to obtain a specific dark brown labelling of the tissue. Finally, 
the sections were rinsed 4-5 times in TBS before mounting on gelatine coated 
microscope slides. The slides were allowed to dry at room temperature over night or for 
2 hours at 37º C before dehydration in successive alcohol baths (75%, 95% and 100%, 5 
min each). The slides were then transferred into xylene for delipidisation before 
coverslipping with distyrene plasticizer and xylene (DPX).   	  
Labelling Serum Primary antibody against Secondary antibody against  
Dopaminergic 
neurons Goat 
Tyrosine Hydroxylase 
1/2 000 (Rabbit, Millipore) 
Rabbit IgG  
1/200 (Goat,Vector) 
Blood vessels 
Horse 
 
Reca-1 
1/2 000 (Mouse, AbD Serotec) 
Mouse IgG  
(Rat IgG absorbed) 
1/200 (Horse, Vector) 
Leukocytes CD45 1/500 (Mouse, AbD Serotec) 
T-lymphocytes 
(CD4) 
CD4  
1/500 (Mouse, AbD Serotec) 
T-lymphocytes 
(CD8) 
CD8 
1/500 (Mouse, AbD Serotec) 
Microglia Ox42 (CD11b) 1/2 000 (Mouse, AbD Serotec) 
Table 6: List of the antibodies used for immunohistochemical analysis of the tissue. Prepared in 
TBS, 1% serum. 	  
2.7 Quantification and microscopy 
All quantifications were carried out by keeping the experimenter blind to the animal 
grouping. TH + cell bodies were counted on a Leica light microscope (20x). SN TH+ 
counts were performed at the level of the medial terminal accessory nucleus of the optic 
tract (separating the SN from the ventral tegmental area (Figure 13) and the results are 
expressed as a percentage of the intact SN (left side).  
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Figure 13: Schematic representation of the accessory optic tract (red), substantia nigra (SN, 
green) and ventral tegmental area (VTA, blue) in the rat brain (Paxinos and Watson, 1998) 
 
In the transplantation experiments, TH+ cell bodies were counted for all sections from a 
1 in 12 series through the rat striatum and the total number of dopaminergic cells was 
estimated using the Abercrombie method: N= Σ { n x F x T / (T+H) } where n=number 
of cells counted, F=frequency of the sections (12), T=thickness of the sections (40µm) 
and H=mean diameter of the cells (Hedreen, 1998). CD45+ quantification was carried 
out using an automated stereology microscope (Olympus BX50) and a PC-based image 
analysis software (Olympus C.A.S.T grid system version 1.6). The whole striatum was 
outlined (4x) and the enclosed area was measured by the software. Sections within the 
selected striatal area were sampled randomly and cells were counted within a 3862µm2 
window (40x). The total number of cells was estimated using the following formula: N= 
Σ { n x (A/a) } x F x T / (T+H) where n=number of cells counted, A= inclusion area 
(striatum), a= total sampling area, F= frequency of the sections (12), T=thickness of the 
sections (40 µm) and H=mean diameter of the cells. 
 
The surface area of the blood vessel was estimated by taking pictures of the sections, 
stained for Reca-1 (x10), on a Leica DMRBE microscope and analysing them with 
ImageJ software (version 1.45, National Institutes of Health, USA). The pictures were 
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converted in 8-bit black and white pictures and the threshold was adjusted to avoid 
background noise, before the stained area was measured by the software and used as a 
measure of blood vessel area. 
 
2.8 Analysis 
Statistical analyses were performed using Prism5 in chapter 3 and then SPSS20 in the 
subsequent chapters (Chapter 4 and 5) as Prism5 does not allow the consideration of so 
many factors. The nature of dyskinesia rating data is ordinal rather than interval, 
therefore strictly a non-parametric analysis should be considered. However, non-
parametric analyses do not permit combining scores between different limbs or analysis 
interaction between the different parameters studied (times, type of treatment, 
transplantation…) as is required for the factorial design used in all experiments. 
Therefore, I have used throughout parametric ANOVA analysis as the only practical 
option for analysis of this type of data, taking into account that: 1) the categories of 
dyskinesia rating are strictly interval and monotonic 2) inspection of the data indicated 
that the scores were well distributed between the different categories and 3) analysis of 
variance is recognised to be extremely robust to derivation of the data from the 
normality of distribution, that is the basis of the underlying mathematics (Box, 1953). 
Details of the test used are given in each chapter, briefly, Univariate analysis of the 
variance (One-way ANOVA) or Multivariate analysis of the variance (Two-way 
ANOVA) were used to analyse immunohistochemistry staining data and the repeated 
measure ANOVA analysis was used for the behaviour tests. T-tests were also used 
when appropriate. Post-hoc tests were implemented to specific significance to 95% 
(*p<0.05), 99%(*p<0.01), 99.9% (*p<0.001). 	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Chapter 3: Reliability of different approaches 
used in assessing L-DOPA-induced motor 
dysfunctions 
 
Summary 
Establishing a sensitive and robust method to evaluate L-DOPA-induced motor 
impairment in rodents is crucial for the study of the mechanisms underlying LID as well 
as for the development of potential treatments. In this chapter, 3 different AIMs rating 
scales, 1 stereotypy scale and automated recording of L-DOPA-induced contralateral 
rotations are compared. The reliability of these different methods in the evaluation of 
the development of motor dysfunction induced by L-DOPA over time and their 
sensitivity in revealing anti-dyskinetic effects have been assessed in the 6-OHDA-
lesioned rat model in this chapter. The results showed a good correlation between the 3 
AIMs scales but clearly demonstrated that AIMs and stereotypies are two different 
components of the motor dysfunctions induced by L-DOPA, which do not follow the 
same pattern of development. Neither do the two behaviours respond to drugs with anti-
dyskinestic properties in the same manner. Interestingly, the number of amphetamine-
induced rotations performed by the animals after unilateral 6-OHDA-lesion was proven 
non-predictive of the development of AIMs, stereotypy and rotational behaviour 
induced by L-DOPA. Finally, the specific test environment was found to have no 
impact on the results obtained with the different methods.  
 
Declaration 
Most of the data presented in this chapter have been published in Neurobiology of 
Disease (Breger et al., 2013).  
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3.1 Introduction 
In PD patients, L-DOPA-induced dyskinesias are assessed using subjective rating scales 
based on clinical examination, patient historical self-evaluation, or a combination of 
both. Over 8 different methods have been used since the 1970s and significant effort is 
currently being put in the establishment of a unified, reliable and widely accepted 
dyskinesia rating scale (Colosimo et al., 2010). This is particularly important to measure 
the effectiveness of potential anti-dyskinetic treatments in clinical trials (Colosimo et 
al., 2010, Wong et al., 2011). Preclinical studies are currently facing the same 
challenge. Indeed, the scales vary not only from one laboratory to another, but the shape 
of the testing environment in which the animals are tested (circular bowls or rectangular 
cages), as well as the method applied (single versus multiple time points assessment, 
video based rating or direct scoring) can also differ. For practical reason, rodents are 
usually tested in hemispherical bowls while rotations are recorded in rectangular 
activity cages. Pinna and colleagues have performed the only comparisons of 
environment but different techniques were applied to the two groups, making this 
inconclusive (Pinna et al., 2006). 
 
The first animal model of LID was the MPTP treated non-human primate (Burns et al., 
1983, Bedard et al., 1986, Schneider, 1989). When chronically exposed to L-DOPA, 
MPTP-lesioned primates develop LID that can be evaluated using a rating scale adapted 
from the human yardstick (Petzinger et al., 2001, Jenner, 2003). Since its introduction in 
the 1980s, the MPTP model has been used extensively to determine the value of 
potential anti-dyskinetic therapies. However, the results obtained with this model have 
been sometime over interpreted and led to less successful clinical outcome than 
expected. Indeed agents, such as the adenosine A2a antagonist KW-6002 or the ∝-2 
noradrenergic antagonist idazoxan, that had a promising effect in rodent and primates 
failed to show significant and consistent improvements in patients (Manson et al., 2000, 
Rascol et al., 2001, Hauser et al., 2003, Linazasoro, 2004, Hauser et al., 2008, Knebel et 
al., 2012). As with patient studies, primate experiments have used a variety of scales to 
evaluate motor improvements and LID, and this lack of consensus on the LID scoring 
method to be used in preclinical studies is believed to play a critical role in the 
reliability of the animal models and how well preclinical results transfer to the clinic 
(Fox et al., 2012). Whilst in primates studies work has been undertaken to compare and 
develop new reliable scales for non-human primates, rodents have been left out of this 
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debate with different laboratories adapting scales as they wish without the validation 
undertaken by the Cenci group during the original scales development (Imbert et al., 
2000, Petzinger et al., 2001). 
 
The major complications associated with the use of primates in research, raised interest 
in cheaper and less ethically challenging models of PD, the most common being the 
unilaterally 6-OHDA-lesioned rat. However, for many years since its introduction, 
lesioned rats were thought to be unable to show the full repertoire of the L-DOPA-
induced side effects observed in human and non-human primates (Cenci et al., 2002). 
Much earlier studies had focused on stereotypic behaviours, showing a causal link 
between over-stimulation of dopaminergic system and stereotypy in rodents. Indeed, 
stimulation of DA receptors with the mixed DA agonist apomorphine, exacerbation of 
endogenous DA release with amphetamine or inhibition of monoamine reuptake with 
cocaine, all lead to the development of normal but purposeless and repetitive 
movements which exemplify stereotypy (Randrup et al., 1963, Fog, 1969, Hall et al., 
1984). Because of the association between dopaminergic pathway stimulation and 
appearance of these stereotypic movements, motor side effects induced by L-DOPA in 
DA depleted rats were first simply described as stereotypies (Ervin et al., 1977, Blunt et 
al., 1991) and were not recognised and scored as abnormal movement until the late 90s 
when Cenci and colleagues published the first dyskinesia rating scale for rats (1998).  
 
In 1998 Cenci and colleagues demonstrated that lesioned rats also exhibit abnormal 
dystonic and choreic movements when repeatedly exposed to L-DOPA, which are 
considered comparable to the dyskinesia observed in patients or non-human primates. 
Moreover, these movements are alleviated by drugs that have known anti-dyskinetic 
effects in humans and non-human primates, establishing the clinical relevance of the 
hemi-parkinsonian rat model for the study of LID (Lundblad et al., 2002). In the 
original method described by Cenci and co-workers, forelimb movements, orolingual 
and jaw movements, axial contortion and rotational locomotion were rated depending 
on the duration of time that each subtypes was present during the observation phases 
(Cenci et al., 1998). In 2002, an adapted version was published, which included an 
amplitude score as a second parameter to each movement subtype. This new parameter 
considered the extent of the movement, differentiating, for example, between small but 
clearly present movements of the forelimb and wrist and larger, more dystonic-like 
	   56 
movements involving the whole shoulder (Winkler et al., 2002). Not long after that, 
Steece-Collier and colleagues developed a new scoring method, which considered fewer 
time points but more behavioural characteristics (Steece-Collier et al., 2003, Maries et 
al., 2006). Thus far, these three different scoring methods have been used to follow the 
development of AIMs and test new agents aiming to reduce LIDs (Lundblad et al., 
2002, Monville et al., 2005, Taylor et al., 2005, Rylander et al., 2010). Nevertheless, 
arbitrarily modified versions of these rating scales are also commonly used, without 
prior validation, which has heightened the need for well-defined and validated rating 
scales (Steece-Collier et al., 2003, Carta et al., 2006, Maries et al., 2006, Monville et al., 
2009, Bido et al., 2011).  
 
There have been no controlled studies, which systematically compare the different 
scoring approaches. Moreover, for practical reason, scientists often assess animals in 
different environments, when it has been suggested that the shape of the testing 
environment can influence the expression of L-DOPA-induced motor side effects 
(Pinna et al., 2006). This chapter, therefore, critically discusses the reliability of 4 
behavioural rating scales (3 AIM scales and 1 stereotypic scale) used to assess motor 
dysfunction induced by chronic L-DOPA treatment in the 6-OHDA-unilaterally-lesined 
rats (Creese and Iversen, 1973, Cenci et al., 1998, Winkler et al., 2002, Maries et al., 
2006). In order to compare these methods in a systematic manner, all scales were used 
to follow the development of L-DOPA-induced motor dysfunctions and assess the effect 
of amantadine and DA receptor antagonists in the all animals. The animals were also 
tested in 2 different environments, oblong cages or perplex bowls, to study the effect 
that the shape of the environment can have on the AIM and stereotypic scores.  	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3.1.1 Aims of the chapter 
The aims of this study were to evaluate the validity of the 3 published AIMs rating 
scales alongside a stereotypy rating scale:  
1) Throughout the development of LID and at different doses of L-DOPA 
2) In different testing environments 
3) In the presence of agents known to reduce LIDs in the primate model or clinical 
setting 
All of which will define the protocols to be used in further experiments in this thesis. 
 
3.2 Experimental design 
28 female Sprague Dawley rats received 6-OHDA infusions into the right median 
forebrain bundle. The extent of the lesion was assessed using the amphetamine-induced 
rotations test and later confirmed by immunohistochemistry (TH+ cell depletion greater 
that 90% in the right SNpc). The rats received daily s.c. injections of L-DOPA 6mg/kg 
for 5 weeks then the dose was increased to 12 mg/kg for a further 5 weeks, always co-
administered with 15 mg/kg benserazide (Figure 14). All animals were assessed for 
motor dysfunction induced by L-DOPA twice a week. On the first session, half of the 
animals were rated using Scale A and B, the other half using Scale C and the stereotypic 
scale. The groups were then interchanged for the second weekly session. The 4 scales 
are described in details in chapter 2 and the main characteristics have been summarised 
in table 7. Rotation was automatically recorder in each of the test environments at the 
same time as the rats were rated for dyskinesia and stereotypy. 
 
In order to assess the reliability of these methods in detecting anti-dyskinetic effects, D1 
and D2 DA receptor antagonists and the weak NMDA receptor antagonist amantadine 
were administered i.p. 20 min prior to L-DOPA injection (12 mg/kg + 15 mg/kg 
benserazide). These agents are known to decrease LID in MPTP-treated primates and 
humans. All drugs were dissolved in 0.9% sterile saline at the following concentration 
D1 DA receptor antagonist: R(+)-SCH-23390 hydrochloride (0.2 mg/kg), D2 DA 
receptor antagonist: R(-)-Raclopride(+)-tartrate (2 mg/kg) and amantadine (40 mg/kg). 
After 10 weeks of chronic L-DOPA treatment, the 3 “anti-dyskinetic” drugs and saline 
were administered to the animals following a 4x4 Latin square randomisation. 3 days 
washout intervals were allowed between each session. At that stage 2 animals had to be 
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excluded because of tumour development. Therefore, for this part of the study: n=26.  
 
Figure 14: Time line of the experiments 
 
Scales Observation Time course  Subtypes rated (Amplitude scores) Duration score Total score 
Scale A 
Direct 
For 1 min 
Every 20 min 
From 20 to 180 min 
Trunk (none) 
Forelimb (none) 
Orolingual (none) 
0: Never 
 
1: <50% 
 
2: >50% 
 
3: Stop with 
sensory stimuli 
 
4: Never stop 
Min: 0 
Max: 144 
Scale B 
Trunk (0-4) 
Forelimb (0-4) 
Hind limb (0-4) 
Orolingual (0-2) 
Min: 0 
Max: 478 
Scale C 
Video 
Recording 
 
For 2 min 
At 30 min 
Or 
Every 30 min 
From 30 to 180 min 
Neck (0-3) 
Trunk (0-3) 
Hind limb (0-3) 
Forelimb(0-3) 
Orolingual (0-2) 
Head bobbing (0-2) 
FFS (0-1) 
0: Never 
1: <50% 
2: >50% 
3: continuous 
 
Min: 0 
Max: 306 
Stereotypy Direct For 1 min 
Every 10 min 
From 10 to 180 
Stereotypic behaviour 
(0-6) None 
Min: 0-18* 
Max: 108 
Table 7: Summary of the main characteristics of the 3 different AIMs scales and stereotypic 
scale. (*18 can correspond to an animal active during the entire session) 
 
On completion of the scale comparison, half of the animals were retested in bowls 
(height: 14.5cm; width: 33.5cm (top), 15.5cm (bottom)), the other half in rectangular 
cages (height: 18.5cm; length: 36cm; width: 25.5cm). The following day, the testing 
was repeated in the other environment. The rotational behaviour was assessed using an 
automated rotometer to measure the number of contralateral rotations for a total of 180 
min in both the round and rectangular environments.  
 
Statistical analyses of the performance on each scale over time were undertaken by 
repeated measures ANOVA with significant changes over time evaluated by 
comparison against the scores recorded on the first week of the treatment as the baseline 
value (Dunnett post-hoc test). Correlational analyses were performed using linear 
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regression. For the study on the impact of the environment shape, the statistical analysis 
was performed using a two-tailed Student’s t-test. Results were considered to be 
significant if p<0.05. 
  
3.3 Results 
3.3.1 Development of L-DOPA-induced motor impairments  
The 3 dyskinesia rating scales (AIMs scales) showed an increase in the total AIMs 
scores as a function of time (F9,243=62.38, 42.45, 54.00 and 31.29 for Scales A, B, C, 
C30 respectively, all p<0.0001). AIMs scores gradually increased and reached 
significance after 4-5weeks of 6mg/kg chronic L-DOPA treatment (p<0.05, relative to 
the first day of treatment) (Figure 15). A dose dependent increase was observed with 
scales A and B when the treatment was enhanced from 6mg/kg to 12mg/kg (p<0.001). 
However, scale C did not change significantly when the L-DOPA dose was doubled, 
regardless of the use of single or multiple time points (C and C30). Although the 
stereotypic scores displayed an increasing trend, this scale did not show any significant 
difference over time during the first phase of the treatment. Moreover, the mean score 
remained below 18, which can correspond to a normal but constantly active animal (i.e. 
18 scoring sessions each scoring 1 for an active animal would give a score of 18). 
Animals were generally active but displayed none or very few stereotypies when treated 
with 6mg/kg L-DOPA. To the contrary, when the dose was increased to 12 mg/kg L-
DOPA the animals exhibited severe stereotypic behaviour (F9,243=6.919, p<0.0001). 
With all scales, a ceiling effect was observed after the first injection of the higher dose 
of L-DOPA (12mg/kg) and no significant change was observed within the second phase 
of treatment (Figure 15, a-e). Finally, no difference was observed in the total 
contralateral rotations during the first phase of treatment (6 mg/kg) but the increased 
dose led to a significant worsening of the rotational behaviour (F9,243=40.52, p<0.0001). 
Contrary to the AIMs and stereotypy scores, the total of rotations did not reach a plateau 
until the 3rd week following the increase in L-DOPA dosage (Figure 15, f).  
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Figure 15: Development of motor side effects induced by chronic treatment with L-DOPA. 
AIMs scores obtained with scale A, B, C30 and C (respectively a, b, c and d) and stereotypy 
scores (e) following injection of L-DOPA 6 mg/kg (left) and 12 mg/kg (right) are presented as 
mean score of all the animals ± SEM. The vertical dotted line at 18 corresponds to the 
maximum score animal will obtain while being just active (e). The total of contralateral turns 
performed by the animals over 180 min is presented as the mean of all animals ± SEM (f). 
n=28, One-way ANOVA and Dunnett post-hoc test*p<0.01, **p<0.001 compared to week 1.  
 
3.3.2 Time course of L-DOPA-induced motor impairments 
To better characterise the evolution of L-DOPA induced motor dysfunction, the time 
course of motor responses within the sessions were compared for each method, for the 
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first and final weeks of each dose (week 1 and 5 at 6 mg/kg and weeks 6 and 10 at 
12 mg/kg) (Figure 16). The maximum AIMs score increased between the first and last 
scoring sessions with 6 mg/kg L-DOPA when measured by Scales A and B (46.9% and 
76.7% increase respectively) but not with Scale C. With all AIMs scales, the time for 
the response to peak varied depending on the scale used. In week 1 (6 mg/kg), the AIMs 
response as measured by Scales A and B peaked at 80 min, while with Scale C this was 
recorded at 60 min. Chronic treatment with L-DOPA for 5 weeks shifted the peak 
response from 80 min down to 60 min as identified with Scale A and B and from 60 to 
30 min with Scale C (Figure 16, a-c). 
 
None of the scales showed a significant difference in the maximum AIMs score 
obtained after the original increase of the L-DOPA dose from 6 mg/kg to 12 mg/kg, 
between week 5 and week 6. The increase observed in the total score is therefore not 
due to an augmentation of the severity but was only produced by an extension in the 
duration over which the animals exhibited these movements (Scale A: 120–180 min, 
p < 0.001; Scale B: 120–140 min, p < 0.05, Scale C: 100–160 min, p < 0.001). 
Prolonging treatment with L-DOPA 12 mg/kg, however, did not affect AIMs scores and 
no significant difference was observed between week 6 and week 10, with the exception 
of changes in time-to-peak which were delayed back to 60 min with Scales A and B, 
and 80 min with Scale C (Figure 16, a-c). 
 
The recording of rotational behaviour over time showed that the animals rotate toward 
the side ipsilateral to the lesion for approximately 20 min, until the L-DOPA takes 
effect, inducing contralateral rotations (Figure 16, e). Both speed and duration of the 
rotational behaviour increased in a dose dependant manner (week 5 to week 6). 
Interestingly, the speed continued increasing after chronic treatment with L-DOPA 12 
mg/kg (between week 6 and week 10).  
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Figure 16: Evolution of L-DOPA induced motor side effects over the 180 min following drug 
administration. AIMs scores obtained with scale A, B and C (respectively a, b and c) and 
stereotypy score (d) following injection of L-DOPA 6 mg/kg (week 1 and 5) and 12 mg/kg 
(week 6 and 10) are presented as mean score of all the animals ± SEM. The vertical dotted line 
on the stereotypy graph (e) corresponds to the score of a normal active animal. The total of 
contralateral turns performed by the animals is presented as the mean of all animals ± SEM. 
n=28.  
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3.3.3 Pharmacological validation of the scales 
In order to validate the sensitivity of the different rating scales in assessing the potential 
of new anti-dyskinetic therapies, we co-administered L-DOPA with agent known to 
reduce dyskinesia in humans or non-human primates: D1 receptor antagonist SCH-
23390, or D2 receptor antagonist raclopride, or the NMDA antagonist amantadine. 
Interestingly, the 3 different components of L-DOPA-induced motor dysfunctions 
studied in this experiment: AIMs, stereotypies and rotational behaviour, did not respond 
the same way to the drugs. All three multiple time points dyskinesia scales (Scale A, B 
and C) and the stereotypic scale illustrated a significant reduction of AIMs scores 
following administration of SCH-23390 and raclopride (Figure 17); F3,75 = 20.71; 
19.70; 11.16 and 23.57 for scales A, B, C, and stereotypies respectively, all p<0.01 ). 
Importantly, when considering a single time point, the Scale C30 failed to show an effect 
of D2 receptor antagonism (Figure 17, c; F3,75 = 5.39; p>0.05). On closer inspection it 
was noted that the reduction induced by raclopride was found mainly during the last 
hour of observation (Table 8). Finally, rotational behaviour was only significantly 
reduced by D1 antagonists only (F3,75 = 8.67, p<0.05).  
 
Amantadine had no significant effect on the AIMs scores rated with scale A (Figure 17 
& Table 8). In contrast, Scale B, C and C30 showed a significant decrease of AIMs 
scores when L-DOPA was co-administered with amantadine (F3,75 = 8.67, p<0.01). 
Interestingly, amantadine significantly increased the total score of stereotypy (p<0.01). 
Indeed, if it decreased AIMs scores significantly around peak time, it prolonged the 
temporal course of stereotypy and rotations (Table 8).  
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Figure 17: L-DOPA induced motor side effects following administration of drugs known to 
reduce dyskinesia. The AIM scores obtained with a) Scale A, b) Scale B, c) Scale C30, d) Scale 
C, e) stereotypy scores and f) total number of contralateral rotation over 180 min following co-
administration of L-DOPA (12 mg/kg) and: saline (white), SCH-23390 (light grey), raclopride 
(dark grey) (D1 and D2 receptor antagonists) or amantadine (black) are presented as mean score 
of all the animals ± SEM. n=26, One-way ANOVA and Dunnett post-hoc test: *p<0.05, 
**p<0.01 (compared to L-DOPA co-administer with saline score).  
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 Saline SCH-23390 Raclopride Amantadine 
 AIM - Scale A 
1h 13.8 (±1.1) 10.0 (±1.1)** 12.6 (±1.2) 10.9 (±1.1) 
2h 14.7 (±1.2) 8.9 (±1.1)*** 12.8 (±1.2) 13.2 (±1.1) 
3h 8.2 (±1.4) 1.5 (±0.5)*** 4.4 (±0.8)** 10.3 (±1.2) 
 AIM - Scale B 
1h 28.0 (±3.4) 18.7 (±3.3)** 24.5 (±2.8) 22.1 (±3.3) 
2h 31.7 (±3.7) 17.6(±3.7)*** 24.4 (±3.1)* 24.8 (±3.3)* 
3h 17.0 (±3.1) 5.0 (±2.1)*** 6.0 (±1.2)*** 15.8 (±2.6) 
 AIM - Scale C 
1h 23.7 (±2.3) 15.8 (±3.0)*** 18.1 (±2.6)* 12.6 (±1.9)*** 
2h 22.1 (±2.3) 12.7 (±2.3)*** 16.9 (±2.0)* 16.7 (±2.0)* 
3h 11.2 (±2.2) 2.9 (±1.3)*** 13.5 (±1.8)*** 13.5 (±1.8) 
 Stereotypy  
1h 9.5 (±0.5) 6.5 (±0.8)** 8.3 (±0.8) 11.5 (±1.0) 
2h 9.5 (±0.6) 6.7 (±0.7)* 8.2 (±0.7) 12.2 (±1.0)** 
3h 8.5 (±0.7) 2.5 (±0.6)*** 4.8 (±0.6)*** 11.4 (±0.9)** 
 Rotation 
1h 445.9 (76.5) 269.7 (42.8) 568.9 (68.8) 276.5 (74.6) 
2h 699.1 (113.3) 398.8 (73.2) ** 860.5 (112.2) 718.7 (132.6) 
3h 360.2 (85.5) 132.1(45.0) * 230.9 (46.0) 665.8 (135.0)** 
 
Table 8: Evolution of L-DOPA induced motor side effects over the 3 hours following 
administration L-DOPA (12 mg/kg) and either saline, or SCH-23390 or Raclopride, or 
Amantadine. Data are presented as mean score or rotations ± SEM of all animals (n=26). 
*p<0.05, **p<0.01, ***p<0.001 compared to saline. Significant increases from saline are 
presented in bold.  
 
3.3.4 Correlation between the different methods  
When considering the scores of each rat individually after 10 week of chronic treatment 
with L-DOPA, there was a good correlation between the 3 AIMs scales (Figure 18). 
Understandably, given that they share similar roots, the strongest correlation was found 
between Scale A and B (Linear regression, p<0.0001). The inclusion of the hind-limb 
variable did not alter this correlation (Figure 19). There was a good correlation between 
the single time point scoring method and the other AIMs scales. However, the 
stereotypy score did not correlate with any of the dyskinetic scales (Figure 20), or with 
the severity of rotational behaviour induced by L-DOPA (Table 9). Finally, 
amphetamine-induced rotations performed after the 6-OHDA lesions did not relate to 
any of the L-DOPA-induced motor dysfunction components assessed in this experiment 
(Table 9).  
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Figure 18: Correlation between the different AIMs scales (L-DOPA 12 mg/kg). **p<0.01, 
***p<0.0001, n=28. 
 
 
 
Figure 19: Impact of adding hind limb subtype to the AIMs scale A and B. n=28, ***p<0.0001  
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Figure 20: Correlation between stereotypic score (y) and the different AIMs scores (x). n=28, 
p>0.05. 
 
 
r2 Scale A Scale B Scale C30 Scale C Stereotypy 
L-DOPA 
rotations 
Amphetamine 
rotations 0.0112 0.0261 0.0432 0.0214 0.0234 0.0476 
L-DOPA 
rotations 0.2710** 0.2998** 0.2778** 0.3157** 0.0072 - 
 
Table 9: Correlation between the number of amphetamine-induced ipsilateral rotations 
performed post-lesion, the number of L-DOPA-induced contralateral rotations and AIMs and 
stereotypic scores after chronic treatment with L-DOPA 12 mg/kg. The table presents r2 value, 
n=28, **p<0.01. 
 
3.3.5 Impact of the shape of the environment 
No difference in AIMs score was found, regardless of the testing method used, when the 
animals were tested in rectangular cages or bowls (Figure 21) (Scale A: t(27)=1.844, p= 
0.0763; Scale B: t(27)=0.4840, p= 0.6323, Scale C30: t(27)=1.147, p= 0.2615; Scale C: 
t(27)=0.3974, p= 0.6942; Stereotypy: t(27)=1.058, p= 2995; Rotations: t(27)=0.4912, 
p= 0.6272)). 
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Figure 21: Impact of the shape of the environment on the AIM score obtained with Scale A, B, 
C30 and C (a-d), on stereotypic (e) and on rotational behaviour (f) induced by L-DOPA. Data 
presented as mean ±S.E.M. No significant difference has been found between the two testing 
environments p>0.05. n=28. 
 
 
3.4 Discussion 
The unilaterally 6-OHDA-lesioned rat is an affordable and easily constructed model that 
is broadly used for the study of LID. However, the lack of well-validated and systematic 
way of assessing the severity and development of dyskinesia could hinder its reliability 
and translatability. The work performed in this chapter is an important step toward 
establishing a more standardised approach to study of L-DOPA-induced motor 
dysfunction in the hemi-parkinsonian rat model.  
 
3.4.1 Stereotypic and rotational behaviour 
One of the main findings emanating from this work is that LID, stereotypies and 
rotational behaviour are three distinct motor complications induced by L-DOPA in this 
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model, with different profiles of development. The fact that dyskinetic, stereotypic and 
rotational behaviours do not respond to agents known to have anti-dyskinetic properties 
similarly indicates that these 3 types of motor dysfunctions might be driven by different 
mechanisms. It has been shown previously that rotational behaviour does not respond as 
well to anti-dyskinetic compounds but it is the first time that stereotypic behaviour has 
been assessed in parallel (Lundblad et al., 2005, Monville et al., 2005). Interestingly, 
amantadine worsened stereotypy. Since no correlation was found between stereotypy 
and AIMs scores, this effect cannot be attributed to the reduction of AIMs, which could 
have masked these repetitive movements. It is reasonable to think that the distinction 
between AIM and stereotypy will become even more crucial in the study of graft-
induced side effects. Indeed, patients transplanted with foetal dopaminergic cells who 
developed “off drug” adverse effect have been described as more stereotypic than actual 
dyskinesia (Olanow et al., 2003). Similarly, post-grafting dyskinesia in rodents, induced 
by L-DOPA or amphetamine, are also more stereotypic in nature (Maries et al., 2006). 
 
3.4.2 Dyskinesia rating scales 
Out of the 3 main rodent AIMs methods commonly in used, Scale A, which was the 
original scale described by Cenci and co-workers, is the only one that has been 
validated pharmacologically and pathologically (Lundblad et al., 2002, Lundblad et al., 
2005, Dekundy et al., 2007). Studies have indeed shown a good correlation between 
striatal FosB protein, prodynorphin expression and the AIMs score (Andersson et al., 
1999, Lindgren et al., 2011). Moreover, Scale A has been proven effective in showing a 
reduction in AIMs score with compounds such as amantadine, clozapine or buspirone, 
which have a known anti-dyskinetic efficacy in human and non-human primates 
(Lundblad et al., 2002, Lundblad et al., 2005, Dekundy et al., 2007). On the contrary, 
Scale B and C have never been validated with known anti-dyskinetic agents, let alone 
compared with the original Scale A.  
 
As expected, all AIMs scales were effective at following the development of AIMs over 
time. However, Scale A and B better reflected the increase in L-DOPA dose. All the 
scales showed a reduction in dyskinesia scores when animals were treated with DA 
receptor antagonists or amantadine. Nevertheless, none of the 2 DA receptor antagonists 
tested here were able to completely abolish AIMs in the rats. These results corroborate 
previous findings showing that dyskinesias and the rotational behaviour are not 
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mediated by a single DA receptor subtype (Lane et al., 2005, Taylor et al., 2005). While 
Scale A failed to show an effect of amantadine on AIMs in this study, it has been shown 
to be effective by others. This discrepancy may be due to a lower dose of L-DOPA 
being used in these studies (Lundblad et al., 2002, Lundblad et al., 2005, Dekundy et al., 
2007). This then introduces the importance of dose in the assessment of anti-dyskinetic 
agents, even within the therapeutic range used in this study and by others. Finally, 
although Scale A and B showed a good correlation between scores with or without the 
addition of the hind limb subtype, adding this parameter increased the significance of 
the amantadine effect with Scale B. Therefore, although it is not a mandatory element, 
adding hind limb rating is recommended as it improves the sensitivity of the scale.  
 
The description of the rating criteria for intensity in Scale C is very subjective and open 
to interpretation and, although the authors provided video clips in the supplementary 
data, they did not associate with the corresponding score. Generally speaking, it would 
be advisable that rating scales are published along with video material providing the 
corresponding final intensity score as well as the break down for each subtype of 
dyskinesia. Moreover, Scale C presents important drawbacks from a practical point of 
view. Indeed, the number of different AIMs rated and the complexity of the scale 
necessitates video recording of the animals. Indeed, the original scale considers 8 
different subtypes of AIMs and uses different scoring scales (e.g. neck dystonia is 
ranked from 0.5 to 3 with steps of 0.5 when hind limb dystonia is scored from 1 to 3 
with steps of 1, other are simply scored from 1 to 2). Moreover, it is difficult to score 
wrist dystonia accurately and to separate it from the forelimb dyskinesia due to the 
small size of the rats. This scale would be almost impossible to apply to mice in such 
detail. Finally, whereas video recording provides an easy way to ensure blind 
assessment, it disproportionately increases the amount of work (i.e. time to record the 
rats and time to score the video tape at low speed to allow accurate rating) without 
contributing significantly to a greater sensitivity. This is a major limitation of this 
method, especially when considering multiple time points of recording, which is likely 
to be why single or limited time points are considered by users of this scale. Moreover, 
scoring small movements on video recording can be challenging, in particular for 
animals displaying a strong rotational behaviour or facing away from the video camera.  
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3.4.3 Single versus multiple time points 
The AIMs scale described by Steece-Collier (Scale C) is generally used to rate the 
animals at a single time-point, 30 min, considered as the time-of-peak response to L-
DOPA (Steece-Collier et al., 2003, Steece-Collier et al., 2009). Nevertheless, 
considering a single time point could be detrimental, as it does not faithfully reflect the 
worsening of the AIMs severity. Moreover, prolonged L-DOPA treatment induces a 
shift of the time-of-peak severity and increases the duration during which the animals 
exhibit severe dyskinesia. Therefore, animals should be assessed at multiple time points 
to ensure that the effect observed translates to a global reduction of dyskinesia instead 
of a shift in time-to peak response. Furthermore, the single time point method, Scale 
C30, failed to show an effect of D2 DA receptors antagonism when the multiple time 
points version, Scale C, highlighted a significant reduction of AIMs scores with 
raclopride. The use of a single time point method to test the potential of anti-dyskinetic 
therapies can be misleading and it is likely to be important to consider the global effect 
of new treatments on the full duration of LID expression. Indeed, a short acting drug 
providing a significant effect at the time-of-peak response might not confer any real 
benefit for the patients. In contrast, the effect of an agent which could reduce the overall 
duration of LID, would not be sufficiently detected using this type of methodology and 
could fail in pre-clinically studies, despite having real potential. 
 
3.4.4 Impact of the testing environment  
In this study, the shape of the environment has been found to have no effect on AIMs 
and stereotypy scores or on rotational behaviour. By contrast, previous study reported 
an increase in the duration of some AIMs subtypes, as well as an increase in the 
amplitude score of limb dyskinesia and axial bias, when the animals were tested in 
cages comparing to the assessment in bowls (Pinna et al., 2006). In parallel, these 
authors showed an enhanced number of contralateral rotations when the animals were 
placed in a hemispherical environment. In this chapter, 26 female rats were tested 
successively in the 2 environments, whereas Pinna and colleagues used 8 males. It has 
been found, in our lab, that contrary to what is observed in patients, gender has little 
influence on the development of LID in rats (Lane EL, unpublished data) so the 
difference in the results is unlikely to be due to the animal gender. Moreover, another 
study performed in males did not report any difference in AIMs score between the two 
environments (Papathanou, 2010). Finally, the effect described by Pinna et al. on 
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rotational behaviour is highly questionable as the method used to count the number of 
contralateral rotations varies between the 2 environments (recorded by an automated 
rotometer in hemispherical bowls but evaluated visually in the cage). The experiment 
described in this chapter measured the number of rotations using the same automated 
rotometer, in the same testing room, for both environments, which allows a more 
accurate comparison. It is important to note that the size and probably more importantly 
the steepness of the bowl itself may have an impact and could explain the divergence in 
results. 
 
3.4.5 Validating dyskinesia rating scales 
This chapter highlighted the fact that small modifications, such as adding time points or 
a new subtype of abnormal movement, can change the sensitivity of the scale. 
Consequently, any modifications from the original scales should be tested and fully 
validated before using the modified method to assess potential new anti-dyskinetic 
drugs. Furthermore, given that the use of multiple time points significantly improves the 
sensitivity of the scale in detecting anti-dyskinetic effects of amantadine or DA 
agonists, one could suggest that patients diary based evaluation dyskinesia might 
provide a more accurate measurement of potential anti-dyskinetic drugs efficacy 
(Hauser et al., 2000, Hauser et al., 2004). Most of the scales currently available only 
assess patients for few minutes (2-15 min) and might not reflect the full effect of the 
treatments (Colosimo et al., 2010). This idea is supported by the one of the 
levetiracetam (Keppra) clinical trials, where a significant reduction of “on-time” with 
troublesome dyskinesias was reported using a patients diary based method, yet there 
was no improvement on the AIMS, the Unified Parkinson's Disease Rating Scale IV 
(UPDRS) or the UDysRS scores (Zesiewicz et al., 2005, Wolz et al., 2010). Of course, 
patients based evaluation has serious drawback as it could be easily affected by mood 
swings and depression, which are common in PD. The results obtained in this chapter 
highlighted the importance of pharmacologically validating the dyskinesia rating scales. 
This is mirrored by the effort beginning in 2010, when the Michael J. Fox Foundation 
for Parkinson's Research founded a multi-centres trial aiming at evaluating the 
responsiveness of the different clinical LID rating scales to amantadine treatment in 
order to validate them pharmacologically (Colosimo et al., 2010, Goetz, 2010).  
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3.5 Conclusion 
In this chapter, I have demonstrated the importance of using well-characterised methods 
to study L-DOPA-induced motor dysfunction. To be complete, a study of the motor 
effects induced by L-DOPA in rodent should assess in parallel: AIMs, stereotypic 
behaviour as well as the measuring of the contralateral rotations, which is the approach 
that will be used throughout the remainder of this thesis. Scale B was proven to be a 
reliable and practical scale and was therefore chosen to rate AIMs in the subsequent 
studies (Table 10). 
 
 
Cost 
effectiveness 
Objectivity Practicality 
Sensitivity to 
L-DOPA dose 
increase 
Sensitivity to 
“anti-dyskinetic” 
agents 
Scale A +++ - ++ +++ ++ 
Scale B +++ - ++ +++ +++ 
Scale C ++ - + + +++ 
Scale C30 ++ - + - ++ 
Stereotypies +++ - ++ +++ - 
Rotations + +++ +++ ++ + 
Table 10: Summary of the main advantages of each method. 
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Chapter 4: Effect of L-DOPA treatment on the 
efficacy of cell therapy 
 
Summary	  
There are discordant views on the potential toxic effect of long term L-DOPA treatment 
on dopaminergic neurons, particularly in the context of transplantation. The aim of this 
chapter was therefore to determine the effect of chronic L-DOPA administered during 
different phases of the transplantation process on the survival and function of non-
compatible grafts. To that end, 6-OHDA unilaterally lesioned rats received sham 
surgery, allogeneic transplant or xenogeneic transplant, while being treated with L-
DOPA before and/or after transplantation. The results showed that both types of graft 
survived and alleviated amphetamine-induced rotations. L-DOPA was found to have no 
detrimental effect on the graft, despite significantly promoting immune response around 
the xenograft (as demonstrated by the infiltration of peripheral immune cells). However, 
a critical finding was the differing immune response between the groups. Indeed, 
chronic L-DOPA administered post-transplantation increases the number of microglia 
and infiltrated peripheral immune cells around the graft. 
 
Declaration 
Part of the leukocytes immunostaining was performed by Korbinian Kienle during his 
Master’s degree training.  	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4.1 Introduction 
Transplantation of foetal dopaminergic precursor neurons into the striatum of PD 
patients showed encouraging results in restoring dopamine production at a level 
enabling improvement of motor symptoms in PD patients (reviewed by Barker and 
Kuan (2010)). However, a number of patients failed to receive benefit from the graft, 
and many that did improve also developed the motor side effects of GID (Hagell et al., 
2002, Olanow et al., 2003) (see 1.3.3 Cell therapy). Typically, patients selected for 
these transplantation trials were at an advanced stage of disease progression. They had 
therefore been treated with L-DOPA for several years and in most cases had already 
developed LID. The dopaminergic neurons take time to mature post transplantation and 
most patients needed to remain under the dopaminergic medication regimes. Some 
patients were then able to reduce or even cease their anti-parkinsonian medications, but 
for many the improvement was only marginal. There have been previous studies 
exploring how L-DOPA could potentially impact upon the transplanted neurons but 
these have not been systematic and have not taken into account L-DOPA pre- and post- 
transplantation (Blunt et al., 1991, Steece-Collier et al., 1995, Steece-Collier et al., 
2009).  
 
To date, there has been little agreement on whether L-DOPA could hasten or prevent 
nigral degeneration in PD patients. In an early study, Diamond and colleagues showed 
that life expectancy was increased in PD patients who had taken L-DOPA soon after PD 
symptoms appeared (1987). This idea was supported by autopsy of non-PD patients, 
who have been treated with L-DOPA for years (4 to 26 years) and displayed normal SN 
(Quinn et al., 1986, Rajput et al., 1997). A double-blind study reported a significant 
reduction in UPDRS scores of patients treated with L-DOPA for 40 weeks, when 
compared to placebo the group, suggesting that L-DOPA might slow down the 
progression of the disease. However, it has been argued that, although a washout period 
of 2 weeks was observed before assessing the patients “off medication”, the 
symptomatic relief from L-DOPA might still be present (Fahn et al., 2004). A more 
recent imaging trial, taking PET-scan measurements 2 years apart, of patients taking L-
DOPA or ropinirole showed a reduction in 18F-DOPA signal in the L-DOPA treated 
group (Whone et al., 2003). Similarly, the Parkinson Study Group reported a significant 
decrease of the DAT probe β-CIT binding in the striatum of patients treated with L-
DOPA for 4 years when compared the pramipexole treated group (2002). These 2 
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imaging studies used striatal DAT binding as an indirect measurement of the number of 
remaining DA neurons. Arguably, L-DOPA treatment could directly affect DAT level 
of expression and/or availability at the membrane without having any effect on 
dopaminergic cell survival. Moreover, due to the absence of placebo control, it is 
impossible to distinguish between a detrimental effect of L-DOPA and/or a protective 
effect of ropinirole and pramipexole. The effect that L-DOPA might have on the 
survival of the remaining dopaminergic cells is too delicate to address in patients 
because of the impossibility of directly evaluating neuronal survival. 
 
Many in vitro studies have tried to answer the question L-DOPA toxicity. Most of them 
have reported a toxic effect of DA and L-DOPA on human and rodent immortalized 
neuronal cells (Michel and Hefti, 1990, Tanaka et al., 1991, Mena et al., 1992, Basma et 
al., 1995, Pardo et al., 1995, Ziv et al., 1997). L-DOPA and DA are easily autoxidised 
and produce oxygen reactive species and free radicals causing apoptosis (Graham, 1978, 
Cohen, 1987, Michel and Hefti, 1990), which could explain the detrimental effect of L-
DOPA on neuronal cultures. These in vitro studies however have to be interpreted with 
caution, as they do not necessarily accurately reflect the environment of the neurons. 
For example, the concentration of L-DOPA used in culture is 100 to 1,000 times higher 
than the concentration measured in the cerebrospinal fluid of patients under L-DOPA 
treatment (Olanow et al., 1991, Tanaka et al., 1991, Basma et al., 1995, Pardo et al., 
1995, Ziv et al., 1997). Moreover, the lack of glial cells, which play a crucial role in 
defending the brain against quinones involved in L-DOPA-induced toxicity, has also 
raised concerns regarding the relevance of the neuronal cell culture model (Miyazaki et 
al., 2011). Indeed, the culture of foetal rat midbrain in the presence of astrocytes or 
simply glia-conditioned medium, can rescue DA neurons from L-DOPA toxicity (Mena 
et al., 1996, Mena et al., 1997).  
 
In vivo studies have suggested that L-DOPA is not toxic for the nigral DA neurons. 18 
months of L-DOPA treatment in mice had no effect on the survival of nigral neurons 
(Hefti et al., 1981). Similarly, L-DOPA treatment did not affect remaining cells in the 
SN of 6-OHDA-lesioned rat model of PD, and may even have had a trophic effect 
(Murer et al., 1998, Mytilineou et al., 2003). However, data regarding the effect of L-
DOPA upon the survival of foetal dopaminergic transplants are controversial. VM cells 
have been shown to be particularly vulnerable to dopamine L-DOPA in vitro (Blunt et 
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al., 1991, Pardo et al., 1995, Alexander et al., 1997). Nevertheless, other studies have 
reported both an absence of, or a beneficial effect of L-DOPA treatment on foetal 
neurons in cultures, depending on the presence of glial cells (Mytilineou et al., 1993, 
Mena et al., 1996, Mena et al., 1997). In vivo studies looking at the survival of VM 
transplant in rats also gave mixed messages. For instance, studies performed by Blunt 
and colleagues showed no significant effect of oral L-DOPA treatment (even at a very 
high dose: 200 mg/kg/day), on the survival and the function of VM transplant in 6-
OHDA lesioned rats (Blunt et al., 1990, Blunt et al., 1991, Blunt et al., 1992b). In 
contrast, Steece-Collier and co-workers, reported a morphological impairment of the 
foetal neurons when the rats received i.p. injections of L-DOPA following 
transplantation (Steece-Collier et al., 1990). Moreover, they have reported a reduction 
of behavioural improvement post-grafting in rats pre-treated with L-DOPA, although no 
cell loss has been observed (Steece-Collier et al., 2009). The question of the potential 
toxic effect of L-DOPA treatment on foetal dopaminergic transplant therefore remains 
unsolved.  
 
Direct neuronal toxicity is not the only way L-DOPA treatment could influence 
dopaminergic graft survival. Prolonged L-DOPA treatment has been shown to affect the 
blood-brain barrier, which could have knock on effects on the immune system. Micro 
vessels, present in the brain, express DA receptors (Choi et al., 2006) and it has been 
shown previously that chronic L-DOPA treatment is associated with alteration of 
microvasculature of the basal ganglia nuclei, predominantly in the striatum and output 
nuclei (GP and SNr), in the 6-OHDA-lesioned rat. Interestingly, the enhanced 
endothelial proliferation observed in these areas was associated with an increased 
permeability to bromodeoxyuridine and correlated with the severity of LID exhibited by 
the animals (Westin et al., 2006). Considering that good vascularisation of the transplant 
is necessary to ensure good graft survival, L-DOPA may in fact support the generation 
of the new vasculature and therefore enhance graft survival. The flip side of the coin is 
that the increased blood-brain barrier permeability associated with the 
neovascularisation could alter the “immune privileged” status of the brain and expose 
the graft to greater host immune challenges. This is further complicated by the fact that 
patients receive VM tissue collected from 5-8 embryos of unknown immunologic 
background. It is therefore reasonable to think that the combination of non-matching 
grafts with a permeable blood-brain barrier due to L-DOPA treatment could trigger 
	   78	  
immune response against the transplant and therefore affect how the graft matures and 
functions. 
 
4.1.1 Aims of the chapter 
The question of the impact that prolonged L-DOPA could have on the survival, 
implantation or function of foetal VM transplant has yet to be resolved. In order to 
generate a clinically relevant model, this experiment uses allograft and xenograft to 
assess the effect of L-DOPA on VM grafts of different level of immune compatibility. 
The different transplant groups were then subdivided in sub-groups receiving: no L-
DOPA, L-DOPA only prior to the transplant, only post transplant or both prior to and 
post-transplant (see details in 4.2. Experiment design). This chapter specifically aims to 
determine whether chronic L-DOPA treatment can affect the success of intrastriatal 
allogeneic and xenogeneic foetal transplantation of dopaminergic cells, depending on 
when it is administered, by assessing:   
1) Cell survival and graft function 
2) Motor function recovery 
3) AIMs severity 
4) Host immune response 
 
4.2 Experimental design 
All methods are detailed in the 2nd chapter. In this study, 140 female Sprague Dawley 
rats were unilaterally lesioned by injection of 6-OHDA in the right MFB and were 
assessed for motor deficits using assessment of amphetamine-induced rotation, 
lateralized stepping, vibrissae-elicited limb placement and cylinder tests before and after 
lesion. The 122 animals presenting most impairment (based on the amphetamine test) 
were kept for this experiment, while the 18 remaining rats were used for pilot studies on 
graft rejection (Chapter 5). Out of the 122, 2 had to be put down before the end of the 
experiment due to poor health (unrelated to the experiment: internal tumour and broken 
teeth); and 2 were excluded following histology due to the presence of brain tumour or 
pituitary gland tumour. The data presented here correspond to 118 rats for the behaviour 
experiments. TH cell counts are based on the original 118, further 
immunohistochemistry could only be carried out on 115 due to fungal contamination of 
3 samples. 
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The rats were distributed into 12 homogenous groups based on their performances on 
the 4 motor tests, in order to ensure that no group was statistically different from 
another using a one-way analysis of variance (Table 11, amphetamine test: p= 0.9564; 
Vibrissae test p=0.9999; Stepping test p=0.9978; cylinder test p=0.6114). The same 
tests were later to be used to assess motor recovery 12 weeks post-transplantation, with 
the exception of the cylinder test as the rats refused to explore the environment a 3rd 
time.  
 
Surgery 
Group 
Treatment 
Group 
Amphetamine 
Mean (±SEM) 
Vibrissae Test 
Mean (±SEM) 
Stepping Test  
Mean (±SEM) 
Cylinder Test  
Mean (±SEM) 
Sham 
SS 951.7 (±206.5) 1.5 (±0.2) 13.8 (±4.6) 17.0 (±4.8) 
SL 961.6 (±115.0) 1.5 (±0.5) 15.3 (±5.8) 14.4 (±4.3) 
LS 942.0 (±136.8) 1.4 (±0.4) 19.5 (±9.0) 14.3 (±5.1) 
LL 1117.0 (±103.2) 1.4 (±0.4) 13.8 (±3.6) 8.1 (±2.7) 
Allograft  
SS 925.9 (±180.1) 1.5 (±0.3) 15.0 (±2.8) 16.3 (±4.4) 
SL 943.3 (±70.0) 1.5 (±0.3) 14.3 (±4.8) 11.7 (±3.5) 
LS 997.5 (±118.2) 1.4 (±0.4) 13.4 (±3.2) 13.0 (±2.4) 
LL 834.4 (±58.9) 1.6 (±0.3) 17.7 (±3.4) 9.4 (±2.6) 
Xenograft 
SS 925.9 (±180.1) 1.4 (±0.3) 13.0 (±2.4) 21.0 (±7.2) 
SL 943.3 (±70.0) 1.5 (±0.2) 14.2 (±3.0) 15.3 (±2.8) 
LS 997.5 (±118.2) 1.8 (±0.3) 14.8 (±4.8) 15.5 (±3.8) 
LL 834.4 (±58.9) 1.5 (±0.3) 16.7 (±3.3) 19.2 (±4.3) 
 
Table 11: Group allocation. Animals were distributed evenly in 12 groups based on their 
performances on motor tests following 6-OHDA lesions. Animals were balanced based on 
results from amphetamine-induced ipsilateral rotations, contralateral deficit on the vibrissae-
elicited limb placing test (vibrissae test: expresses in percentage of left limb response), 
contralateral deficit on the lateralized stepping test (expresses in percentage of left steps taken 
while the animal were pulled to the right side) and contralateral deficit on the cylinder test 
(express in percentage of left touches). One-way ANOVA analysis of variance, p>0.05.  
 
The animals were administered L-DOPA (10 mg/kg) or saline for 8 weeks (daily for 4 
weeks then every other day for 4 weeks), corresponding to the first phase of the 
treatment (Phase I, Figure 22). The rats received intrastriatal transplant of 200 000 
foetal VM cells obtained from E14 Wistar rats (allograft) or E12 CD1 mice (xenograft) 
or had sham surgery (DNAse). The second phase of the treatment (Phase II) began on 
the first day following surgery and lasted for another 8 weeks (again, daily injections for 
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4 weeks and then every other day for an extra 4 weeks, Table 12). After the second 
phase of treatment there was a rest period of drug abstinence for 2 weeks to allow 
complete wash out of the drug prior to evaluation of motor function repeating the 
amphetamine-induced ipsilateral rotations, vibrissae-elicited limb placing and 
lateralized stepping. Finally, a last challenge with L-DOPA was performed a week 
before perfusion (Figure 22). Brains sections were stained for dopaminergic cells, 
immune cells and blood vessels markers. The statistical methods used to analyse the 
results are specified in the text. 
 
 
Figure 22: Time line of the experiment. 	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Group 
Number 
of 
animals 
Phase I 
(pre-graft) 
Graft 
Phase II 
(post-graft) 
Sham 
SS 6 Saline Sham Saline 
SL 8* Saline Sham L-DOPA 
LS 8 L-DOPA Sham Saline 
LL 8 L-DOPA Sham L-DOPA 
Allograft 
SS 10 Saline Rat VM (E14) Saline 
SL 11* Saline Rat VM (E14) L-DOPA 
LS 12* L-DOPA Rat VM (E14) Saline 
LL 12 L-DOPA Rat VM (E14) L-DOPA 
Xenograft 
SS 10 Saline Mouse VM (E12) Saline 
SL 10 Saline Mouse VM (E12) L-DOPA 
LS 11 L-DOPA Mouse VM (E12) Saline 
LL 12 L-DOPA Mouse VM (E12) L-DOPA 
 
Table 12: Treatment and transplantation received by the animals for each group. The group 
were named after the treatment they received in treatment phase 1 and 2: S = saline, L= L-
DOPA thus, SS group received saline in treatment phase 1 and 2, SL group received saline in 
treatment phase 1 and L-DOPA in treatment phase 2, LS received L-DOPA in Treatment phase 
1 and saline in treatment phase 2 and LL received L-DOPA in treatment phase 1 and 2.*loss of 
animal brain due to contamination. 
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4.3 Results 
4.3.1 Nigral lesion 
Retrospective analyse of the dopaminergic neurons of the SN demonstrated that all rats 
had lesions greater that 95%. No significant difference was found between the groups 
(F11,106= 1.009, p=0.4439), confirming the results obtained with the different motor tests 
(Table 13).  
 
Surgery 
Group 
Treatment 
Group 
TH+ cell survival on the lesioned SN 
(in % of intact side) Mean (±SEM) 
Sham 
SS 1.00 (±0.51) 
SL 0.91 (±0.45) 
LS 2.69 (±1.25) 
LL 0.85 (±0.36) 
Allograft  
SS 0.64 (±0.25) 
SL 1.23 (±0.99) 
LS 1.22 (±0.63) 
LL 1.50 (±0.75) 
Xenograft 
SS 0.98 (±0.37) 
SL 3.23 (±1.50) 
LS  1.23 (±0.37) 
LL 2.40 (±0.95) 
 
Table 13: TH+ survival in the SN. Percentage of dopaminergic cells remaining in the lesioned 
substantia nigra (in % of the non-lesioned side). One-way ANOVA analysis of variance, 
p>0.05.  
 
4.3.2 Survival and functionality of the graft 
Graft survival was estimated using TH immunohistochemistry as a marker of 
dopaminergic cells. As expected a significant difference was observed between the 
sham surgery group, which did not received any cell transplant, and the 2 grafted groups 
(F2, 106=37.103; p<0.0001). However, no difference was found between the different 
treatments groups (F3, 106=0.979; p=0.406), suggesting that chronic treatment with L-
DOPA pre and/or post graft did not affect the survival of dopaminergic neurons (Figure 
23).  
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Figure 23: Survival of intrastriatal VM graft. Dopaminergic cells were labelled by 
immunohistochemistry, using an antibody against TH. The total number of TH+ cells for each 
group is presented as mean ±SEM. Representative pictures of each transplant group are 
presented under the graph.  
 
The ability of the graft to release dopamine was assessed by recording the total of 
amphetamine-induced rotations performed by the rats 3 months post-transplantation. 
The animals receiving sham surgery did not show any reduction in the total rotations 
performed over 90 min. Conversely, both groups of animals transplanted with VM 
tissue had a significant reduction in rotational behaviour (F2,106=32.60; p<0.0001). 
There was no difference between the groups grafted with allogeneic (rat) or xenogeneic 
(mouse) tissue (F3,106=0.32; p=0.807), nor between the different treatments within each 
transplantation group (p>0.05) (Figure 24). Importantly, no amphetamine-induced 
dyskinesia was observed in any group. 
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Figure 24: Amphetamine-induced ipsilateral turns performed over 90min following 3months 
after transplantation, before (white) and after (black) transplantation. 
 
Linear regression analysis was used to see if a correlation existed between the number 
of TH+ surviving from the transplant and the reduction of cycling behaviour induced by 
amphetamine. No significant correlation was found (Figure 25). 
 	  
 
Figure 25: Correlation between the percentage of reduction in amphetamine-induced ipsilateral 
rotations and the number of dopaminergic cells present in the graft. No significant correlation 
has been found (linear regression). 
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4.3.3 Motor Function Recovery following Transplantation 
The impact of dopaminergic striatal graft on the improvement of the motor function was 
assessed by counting the number of lateralized steps and vibrissae-elicit limb placement 
performed on the contralateral side to the lesion (Figure 26, 27). The animals performed 
more steps while moved in the forehand direction compared to backhand direction. 
However, no motor recovery was observed in any of the group: the rats either showed 
no difference (vibrissae test F1,106=4.98; p=0.085, stepping test forehand F1,106=2.95; 
p=0.089) or a significant worsening after transplant (stepping test backhand F1,106=7.23; 
p=0.008).  	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Figure 26: Mean number of adjusting steps performed on the contralateral side (left) while 
moved sideway on the forehand (a) and backhand (b) direction, before (white) and after 
transplantation (black). Two-way ANOVA analysis showed no significant difference between 
the rats’ performance before and after transplantation, nor between the different treatments 
(p>0.05) 	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Figure 27: Mean number of vibrissae-elicited limb placement performed by the animals on the 
contralateral side of the lesion (left) expressed in percentage of response ± SEM, before (white) 
and after (black) transplantation. Two-way ANOVA analysis showed no significant difference 
between the rats’ performance before and after transplantation, nor between the different 
treatments (p>0.05). 	  
4.3.4 L-DOPA-induced motor dysfunction  
In order to evaluate the impact of L-DOPA treatment before and after transplantation, 
rats were scored using a stereotypy scale and AIMs scale (Scale B, see Chapter 3). As 
expected, all the control groups (SS), which received only saline during the two 
treatment phases never developed any AIMs, nor stereotypic or rotational behaviour. 
The SS AIMs results are not shown as all animals obtained a consistent null score.  
 
Rats that only received saline injections (SS) had a significantly lower stereotypy score 
when compared to L-DOPA treated animals (F3,106=23.97, Tukey post-hoc comparison, 
p<0.0001). In fact, their mean score was 1, reflecting basal activity rather than 
stereotypies, as this score is given to active but not stereotypic animals.  In the other 
treatment groups (SL, LS, LL), stereotypic scores gradually increased over the weeks of 
L-DOPA treatment, however, neither the treatment regime, nor the type of graft had an 
impact on L-DOPA-induced stereotypic behaviour in these 3 groups, as observed in the 
last L-DOPA challenge (Figure 28, Treatment: F3,106=23.97, p<0.0001, Tukey post-hoc 
comparison between SL, LS, LL p>0.05; Graft: F2,106=0.64, p=0.528).  
 
	   88	  
 
Figure 28: Stereotypic score obtained during the final L-DOPA challenge (week 12 post-
grafting). The SS group was injected with saline while the 3 other groups, which have received 
L-DOPA previously during at least 1 of the treatment phases, were injected with L-DOPA. Data 
presented as mean ± SEM, Univariate analyse of variance, Tukey post-hoc comparison, 
***p<0.0001. 
 
To evaluate the impact of the different L-DOPA regimes on the development and 
persistence of dyskinesia after transplantation, L-DOPA-induced AIMs were rated 
weekly. All L-DOPA treated groups (SL, LS, LL) progressively developed AIMs from 
the first day of L-DOPA treatment and rapidly increased to reach a ceiling after 2-
3weeks. Animals treated with L-DOPA during the first phase of the experiment only 
(LS) did not show any reduction in AIMs score, whether they had been grafted or not, 
when tested 12 weeks post transplant (Figure 29, b, e, h). The rats receiving chronic 
treatment with L-DOPA during the entire experiment (before and after grafting, LL, 
Figure 29, c, f, i) showed a decreasing trend in AIMs scores following VM 
transplantation, although this was only significant in the xenografted group p<0.05 from 
week14. Interestingly, the sham group with delayed L-DOPA treatment had a higher 
mean of AIMs scores than the corresponding treatment groups, which had received VM 
transplant (SL, Figure 29, a, F2,28=27.95; p<0.0001) (Dunnett 2-sided post-hoc, 
Allograft p=0.16; Xenograft p=0.49, Figure 29, b, c).  
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Figure 29: Means of AIMs scores rated before and after striatal transplantation (dotted line) of 
rat VM (left panel) mouse VM (central panel) or sham surgery (right panel). The different 
treatments for each phase (I and II) are indicated on each graph: a, b and c, received L-DOPA in 
phase I and saline in Phase II; d, e, f, received saline in phase I and L-DOPA in phase II; g, h, I 
were treated with L-DOPA all the way through. The arrows indicate the last L-DOPA challenge 
performed 12weeks post-transplantation. Data presented as mean ± SEM, *p<0.05. 
 
In order to better characterise the reduction in AIMs score observed in the xenogeneic 
group treated with L-DOPA in phase I and II, the score of each rat was plotted against 
the number on TH+ found in their striatum. Once again, no correlation was found 
between the number of TH+ surviving from the transplant and the decrease observed in 
the xenografted group that received L-DOPA all the way through this experiment 
(Figure 30). 
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Figure 30: Correlation between the percentage of reduction in amphetamine-induced ipsilateral 
rotations and the number of dopaminergic cells present in the graft. No significant correlation 
has been found (linear regression). 
 
The last L-DOPA challenge (12 weeks post-grafting) showed a reduction in rotational 
behaviour in grafted rats when compared to the sham surgery groups (Figure 31, 
Univariate analyse of the variance (F2,106=11.346, p<0.001, allogeneic graft: p<0.002, 
xenogeneic graft: p<0.0001). As expected, the rats that received saline instead of L-
DOPA during that challenge (SS) did not exhibit any L-DOPA-induced rotational 
behaviour (F3,106=8.493,  p<0.001, SS: p<0.01 when compare to the rats that received L-
DOPA (SL, LS, LL)). No significant difference was found between the 3 other 
treatment groups (SL, LS, LL). 
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Figure 31: Number of net rotations performed toward the left side during the 3h following 
saline (SS) or L-DOPA administration (SL, LS, LL), 12 weeks post-transplantation. Data 
presented as mean ±SEM. Univariate analyse of the variance, Bonferroni post-hoc test 
***p<0.0001 when compared to other treatment within the same graft group. 
 
4.3.5 Immune markers in the striatum 
The immune response against the graft was evaluated by immunohistochemistry using a 
leukocyte marker (CD45) and microglia marker (Ox42). The presence of the graft, 
whether it was an allogeneic graft or a xenogeneic graft, generally increased the number 
of microglia in the grafted area (Figure 32, F6,103=9.890, p<0.0001). However, an 
interaction was found between the type of graft that the rats received and the treatment 
they had been administered (F6,103=3.365, p=0.005). Bonferroni post-hoc comparison 
showed no significant difference between the 4 treatment groups, in the rats that 
received sham surgery or allograft. In contrast, the treatment’s regime had a significant 
impact on the number of Ox42+ cells in the xenograft group. Indeed, an increase in 
microglia was found in the group treated with L-DOPA in both treatment phases (LL) 
when compared to the other 3 treatment groups (SS and LS: p<0.0001, SL: p=0.020). 
Representative pictures of the microglia staining in each group are presented (Figure 
33). 
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Figure 32: Relative number of microglia counted in the grafted area (285.94x214.46 µm 
window). Data are presented as Mean±SEM. ***p<0.0001 relative to the corresponding SS 
group. 
 
Figure 33: Microglia immunochemistry staining (Ox42) of the grafted area. Scale bar: 100 µm. 
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The number of infiltrated leukocytes in the transplanted striatum was significantly 
higher in the xenogeneic graft group (Figure 34, F6,103=8.887, p=0.0001, Bonferroni 
post-hoc analysis p=0.001) but no difference was found between the sham and the 
allograft groups (p=0.827). No effect of treatment was found overall (p=0.149). To 
better understand the effect that the different L-DOPA regimes had on the xenograft 
group, data were analysed separately. As they did not have a normal distribution, a non-
parametric test was used. The mean number of leukocytes infiltrated in the 2 groups that 
received L-DOPA post-grafting was 3 to 6 times higher than in the saline group 
(Kruskal-Wallis test p=0.0052, Dunn’s multiple comparison test: SL p<0.05, LL p<0.01 
when compared to the SS group). 
 
 
 
Figure 34: Total number of leukocytes infiltrated in the striatum. 
 
In the group of rats that had never been expose to L-DOPA, very few CD45+ cells were 
observed (SS, Figure 35, a). In contrast, in the groups that had been treated with L-
DOPA, a consistent increase in infiltrated cells was found throughout the striatum. The 
most striking observation was the presence of agglomerated leukocytes along the blood 
vessels, close to the grafted area, which was only seen in some of the rats treated with 
L-DOPA post-grafting (SL and LL, Figure 35, b, d). Interestingly, in the same animals, 
the Ox42 staining revealed the presence of dense and aligned microglia, resembling 
gliosis (microglia scaring). 
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Figure 35: Leukocytes immunochemistry staining (CD45+) of the grafted area. Scale bar: 
100µm. 
 
There was a good correlation between the 2 immune markers studied, i.e. number of 
microglia and the number of leucocytes infiltrated in the striatum (Figure 36, p<0.001). 
 
 
Figure 36: Correlation between the total number of leukocytes and the relative number of 
microglia. 
 
To further investigate the leukocyte infiltration, the number and sub-type of 
lymphocytes involved in the immune response was evaluated using CD4+ and CD8+ 
markers. A complementary staining was performed on the group showing the most 
immune reaction, i.e. xenogeneic graft treated with L-DOPA during the 2 treatment 
phases (LL). The lymphocytic response was dominated by T helper cells (CD4+, Figure 
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37, Mann Whitney test, p=0.0351). (Note: the number of CD45+ has been added as a 
reference only, showing the total number of white blood cells infiltrated in the striatum, 
including lymphocytes. The number of CD4+ and CD8+ was obtained by double staining 
immunochemistry and therefore has been analysed as a non-parametric T-test, as the 
data did not follow a normal distribution).  
 
              
Figure 37: Lymphocytes population presents in the striatum of the xenograft rats treated with L-
DOPA in phase I and II.  Total number of CD4+ and CD8+ cells is presented as Mean ±SEM. 
*p<0.05 
 
To evaluate the effect of prolong exposure to L-DOPA on the blood vessels and 
angiogenesis, the sections were labelled immunohistochemically using a pan-vascular 
endothelium marker (RECA-1, Figure 38, 39). No significant difference was found 
between the contralateral (left) and ipsilateral (right) hemisphere to the graft 
(Multivariate analysis of the variance, F1,40=0.732, p=0.397). As no difference was 
found between groups receiving saline throughout and the group receiving L-DOPA 
throughout (F1,40=0.105, p=0.748), the other groups were not analysed as it reasonable 
to expect that L-DOPA treatment administered only during 1 of the 2 treatment phases 
would not have shown a different outcome. The xenograft group had a significantly 
reduced blood vessel surface area when compared to the allograft (F1,40=39.141, 
p<0.0001). 
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Figure 38: Relative surface of the blood vessel in the striatum. Mean ±SEM. 
 
 
Figure 39: Immunohistochemistry of the blood vessel in the striatum, ipsilateral side to the graft 
(RECA-1). Scale bar: 100 µm. 
 
4.4 Discussion 
Preclinical studies for foetal dopaminergic transplants in 6-OHDA rats have 
traditionally used VM tissue harvested from the same strain as the hosts, in order to 
avoid graft-induced immune response. Furthermore, most studies focused on 
transplantation only and overlooked the importance of using a chronic L-DOPA 
treatment, when trying to mimic the human condition. This type of model therefore 
suffers from major drawbacks as the use of syngeneic tissue does not trigger an immune 
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response, but post-mortem analysis performed on transplanted patients’ brains have 
demonstrated the presence of infiltrated immune cells (Kordower et al., 1997). To 
provide full consideration of these issues, the current study assessed the survival and 
function of allogeneic and xenogeneic VM grafts as well as host tolerance of the 
transplant, when being subject to different L-DOPA regimes. The original aim of this 
chapter was to evaluate how the timing of chronic L-DOPA treatment could affect the 
development of post-transplant dyskinesia. This question could not be addressed, as the 
animals did not develop spontaneous AIMs, or amphetamine-induced AIMs.  
 
4.4.1 Allogeneic versus xenogeneic graft 
Clinically, foetal VM transplants are allogeneic, human-to-human. However, because 
human transplants require multiple donor embryos, each with a different immunological 
background, the use of a xenogeneic graft constitutes a more realistic model.  
Additionally, it is generally held that the diversity of the human genome is much higher 
than that found between different rat strains or between rats and mice, again making the 
xenograft model more applicable (Sanchez-Mazas, 2007). Correspondingly, concordant 
xenograft are used in non-human primates to model human allogeneic transplantation 
(Sanchez-Mazas, 2007). The results of this study showed that VM allogeneic and 
xenogeneic transplant can survive equally well in the striatum of 6-OHDA-lesioned rats 
and produce some functional effects, enabling a reduction of drug-induced motor 
asymmetry. Nevertheless, the beneficial effect of the transplantation was limited and no 
improvement of motor functions has been observed. Transplant studies in 6-OHDA rats 
usually graft a higher number of cells (2-10 times more cells) (Dunnett et al., 1981, 
Nikkhah et al., 1994, Goren et al., 2005, Torres et al., 2007). Although it has been 
shown that transplantation of as little as 50 000 cells is enough to obtain reduction on 
the drug-induced rotation test, however, motor function recovery appears to require 
larger grafts (Bartlett et al., 2004). In the absence of correlation between the number of 
surviving dopaminergic cells and the reduction in amphetamine-induced cycling 
behaviour, it is reasonable to think that other factors might limit behavioural recovery. 
The location of the transplant was found to be more medial than expected, in the 
associative and limbic area of the striatum instead of the dorsolateral motor striatum as 
originally aimed for. Moreover, in light of previous work, the graft might have been too 
rostral to alleviate AIMs (Carlsson et al., 2006).  This location issue also explains the 
fact that, contrarily to what has been reported previously, the rats never developed post-
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transplant AIMs “off-drug” (neither during light-cycle or during dark-cycle), or 
following amphetamine injection (Carlsson et al., 2006, Lane et al., 2006, Lane et al., 
2009, Garcia et al., 2011). 
 
Over the past 25 years, several studies have demonstrated that intrastriatal VM 
transplants in 6-OHDA lesioned rats could reduce L-DOPA-induced motor dysfunction, 
including AIMs and rotational behaviour (Blunt et al., 1990, Gaudin et al., 1990, Blunt 
et al., 1992b, Olsson et al., 1995, Lee et al., 2000, Carlsson et al., 2006, Steece-Collier 
et al., 2009). The change is believed to occur through the normalisation of the glutamate 
decarboxylase (GAD67) and preproenkephalin (PPE) mRNA striatal level, as well as the 
normalisation of D2 DA receptor availability in the striatum (Blunt et al., 1992a, Rioux 
et al., 1993, Lee et al., 2000). Furthermore, the graft does not only reverse the 
modifications observed following lesion of the dopaminergic nigro-striatal pathway, but 
also normalizes L-DOPA-induced molecular changes, namely the up-regulation of 
prodynorphin and c-Fos expression (Ishida et al., 1996, Lee et al., 2000). Thus, Steece-
Collier and co-worker reported a decrease of 50-80% in AIMs scores when 
transplanting the same number of VM cells (200 000) (Steece-Collier et al., 2009). 
Interestingly, they have highlighted a decrease in AIMs score in L-DOPA naïve grafted 
rats compared to the sham group, when first exposed to the drug was 9 weeks post-
transplant. The results presented in this chapter corroborate the idea that foetal 
dopaminergic transplant could prevent the development of AIMs. Moreover, both 
allogeneic and xenogeneic grafts were able to significantly decrease the development of 
dyskinesia, with drug treatment initiated as soon as 24h post-surgery. Taken together, 
these findings provide some support for the conceptual premise that dopaminergic 
transplant should be seen, not only as a “last chance therapy” to reduce PD symptoms 
and dyskinesia, but also as a potential preventive treatment for dyskinesia. Indeed, it is 
reasonable to think that VM transplantation could be more beneficial for early-stage and 
L-DOPA naïve patients, as the cells would be grafted in an environment of modest 
depletion, still containing some remaining endogenous dopaminergic neurons able to 
regulate the system. It is however important to acknowledge that the inclusion of L-
DOPA naïve patients in transplantation clinical trials raises important ethical issues. 
Patients who can cope without L-DOPA treatment are usually at a very early stage of 
the disease and, although there is a strong rational in believing that VM transplant will 
improve their condition and provide them with better future perspectives, the outcome 
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remains uncertain and the risks associated with brain surgery seem too high to justify 
the gamble. 
 
4.4.2 L-DOPA-induced modifications in brain immune responses 
The data collected in this chapter provide the first evidence that L-DOPA treatment 
post-graft increases the host immune response around mouse VM xenotransplant in 
immunosuppressed rats. This observation raises important questions regarding the 
mechanisms underlying this enhanced immune response. 3 main hypotheses can be 
formulated: 1) L-DOPA interferes with the action of cycloA immunosuppressive 
treatment, 2) L-DOPA acts on immune cells proliferation and/or activation, 3) L-DOPA 
treatment induced blood-brain barrier impairment.  
 
4.4.2.1 L-DOPA & immunosuppression  
CycloA was originally extracted from the fungus Tolypocladium inflatum. In the 1970s 
Borel and colleagues published a series of articles demonstrating the anti-lymphocytic 
properties of the cycloA peptide (Borel et al., 1976b, Borel et al., 1977, Borel, 1980, 
Wiesinger and Borel, 1980). It is still currently the preferred immunosuppressive 
treatment for most organ transplant, as well as for cell therapy clinical trials (Aliabadi et 
al., 2012). Although the full mechanism underlying cycloA actions remains unclear, it is 
known to reduce lymphocytic activity by inhibiting the production of cytokine, such as 
interleukine-2 (IL-2) and interferon-gamma (INF-γ). As cycloA, L-DOPA can also act 
on lymphocytes, but has an opposite effect promoting lymphocytic proliferation (this 
will be discussed in more detail in the following paragraph 4.5.2.2 L-DOPA & Immune 
cells). However, it has been shown that the effect of L-DOPA on lymphocytes is not 
mediated by an increase of IL-2 production, or by an alteration of IL-2 receptors, thus 
disproving a direct interaction between the two drugs at a lymphocytic level. Another 
possible way of interaction would be at the blood-brain barrier level. Indeed, cycloA 
can enter the brain through the ATP-Binding Cassette sub-family B member 1 
(ABCB1) transporter, which can also be used by L-DOPA. It can therefore be 
hypothesised that L-DOPA might compromise the transport of cycloA through the 
brain. Because there is also a possibility that the reverse happens, and that cycloA 
interferes with L-DOPA access through the brain, the first experiment of the following 
chapter (Chapter 5) will investigate whether or not immunosuppression modifies L-
DOPA-induced AIMs. 
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4.4.2.2 L-DOPA & immune cells 
Another possible way by which chronic L-DOPA post-graft could have contributed to 
the increase of host leukocytic and glial response is by direct action on immune cells. 
There is a growing body of evidence showing that DA can play a role in the regulation 
of the immune system. Immune cells, such as lymphocytes, are known to express DA 
receptors (D1-D5), (Santambrogio et al., 1993, Ricci and Amenta, 1994, Ricci et al., 
1998, Amenta et al., 1999, Ricci et al., 1999, McKenna et al., 2002). In 1996, Josefsson 
and colleagues did an in vitro study demonstrating that murine lymphocytes can 
actively produce L-DOPA and DA. They hypothesised that DA was released in an 
auto/paracrine manner and intervened as a regulator of lymphocyte activity through 
induction of apoptosis (Josefsson et al., 1996). Similar results have been recognized by 
others scientists, who showed that human CD4+ T lymphocytes and B lymphocytes also 
express DA and noradrenaline receptors and that in vitro exposure to these two 
catecholamines down-regulate proliferation and differentiation of the lymphocytes 
(Bergquist et al., 1994, Cook-Mills et al., 1995, Bergquist et al., 1998). In contrast, in 
vivo studies demonstrated that continuous infusion of L-DOPA, for 5 days, increased 
the number of lymphocytes present in the spleen of mice (Carr et al., 2003b, Carr et al., 
2003a). This effect was abolished by co-administration of L-DOPA with the peripheral 
DOPA-decarboxylase inhibitor benserazide (Carr et al., 2003a). Similarly, intravenous 
injections of D1 or D2 DA receptor agonists led to an increase in splenic lymphocytes 
(Tsao et al., 1997). Taken together, the data suggests that L-DOPA is taken up by spleen 
cells, converted into DA, which acts on DA receptors and stimulates lymphocytic 
proliferation in nearby cells. Considering that L-DOPA is always co-administered with 
a peripheral DOPA-decarboxylase inhibitor in the treatment of PD, the increase host 
immune response induced by L-DOPA treatment post-graft is unlikely to be due to 
lymphocytic proliferation at the spleen level. However, L-DOPA might act on T and B 
cells already infiltrated in the brain. Moreover, the increase of microglia surrounding 
the xenograft observed in this chapter indicates that L-DOPA might have an effect on 
these immune cells. Microglia are important actors in brain immunity and constitute the 
main antigen presenting cells of the central nervous system. Although very little is 
known about possible effect of L-DOPA on glial cells, it has been shown that microglial 
cells express DA receptors and that DA could play a role in their migration (Farber et 
al., 2005, Chang and Liu, 2000). In the 6-OHDA-lesioned rat model, it has been shown 
that chronic L-DOPA treatment (in absence of graft) does not increase immune-
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reactivity of astro- and microglia (Maeda et al., 2008). These results corroborate with 
the data obtained in this chapter that no difference has been found in the sham and 
allogeneic group, suggesting that L-DOPA had no effect on glial cells in a non-
immunologically challenged environment. Based on these results, and considering the 
fact that microglia cells express dopaminergic receptors, one can speculate that L-
DOPA might have a direct role on glial proliferation, in an immunologically 
challenging situation, for example a xenogeneic graft. However, further work is needed 
to assess this hypothesis.  
 
4.4.2.3 L-DOPA & blood-brain barrier 
Finally, L-DOPA treatment post-grafting might increase the immune response by 
compromising blood-brain barrier functions. The access to the brain is normally 
restricted by the tight microvascular endothelial cells, which form a wall of blood 
vessels and regulates cells, molecules and ions access to the brain. Other cells, such as 
astrocytes, pericytes and perivascular neurons, are also involved in the regulation of the 
selective diffusion toward the central nervous system. Although the brain is not exempt 
from the immune system, the number of leukocytes, in a non-diseased brain, is usually 
extremely low (Sallusto et al., 2012). This contributes towards a higher level of immune 
tolerance of intracerebral transplants. Indeed, early studies have shown that mice 
tumorigenic or skin cells survived in rat brains, whilst it was quickly rejected in the 
periphery (Murphy and Sturm, 1923, Medawar, 1948). These observations later led to 
the concept of the brain being an “immunologically privileged” site (Billingham and 
Boswell, 1953). Westin and colleagues reported that chronic L-DOPA treatment in 6-
OHDA-lesioned rats increased blood-brain barrier permeability by promoting 
angiogenesis in the basal ganglia (Westin et al., 2006). This dose dependant effect is 
mediated by D1 DA receptor stimulation and correlates with the severity of AIMs 
(Lindgren et al., 2009, Ohlin et al., 2011). Furthermore, chronic L-DOPA treatment has 
been shown to increase cerebral blood flow in the striatum, with greater effect in 
dyskinetic animals (Ohlin et al., 2012). Enhanced blood flow and blood vessel 
permeability, in the striatum of L-DOPA treated animals, are likely to facilitate the 
access of the brain to peripheral immune cells, such as leukocytes. Blood-brain barrier 
permeability might, therefore, have played a role in the increased number of CD45+ 
cells observed around the xenograft in L-DOPA treated animals. Interestingly, the 
angiogenesis observed in dyskinetic rats by Ohlin and co-worker was linked to an 
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increase in vascular endothelial growth factor (VEGF) released by astrocytes (Ohlin et 
al., 2011). It has been suggested that VEGF could induce proliferation and migration of 
microglia cells, which suggests an indirect effect of L-DOPA on microglia (Forstreuter 
et al., 2002). However, since no significant effect of L-DOPA has been found in the 
sham or the allogeneic group, this VEGF-mediated L-DOPA action on microglial cells 
is unlikely to be the primary mechanism involved in the L-DOPA-induced microglia 
proliferation phenomenon. Further work is required to establish the role played by, L-
DOPA-induced blood-brain barrier modifications, on the increased host immune 
response observed in the xenogeneic transplanted group.  Moreover, the question of the 
impact that this increased immune response could have on the outcome of cell therapy 
for PD still has to be determined. 
 
4.5 Conclusion 
The main finding of this chapter is that chronic L-DOPA treatment post VM transplant, 
in the context of xenogeneic transplant, increases glial and lymphocytic responses. 
However, this combined action on the innate and adaptive immune system did not affect 
graft survival or function. The next chapter will look at the development of a controlled 
method to trigger graft rejection, in order to provide the tools necessary to further 
characterise the relationship existing between chronic L-DOPA treatment and immune 
response, and it potential impact on the development of dyskinesias following 
transplantation. 
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Chapter 5: Establishment a model of multi-
donor graft rejection 
 
Summary 
Cell therapy for PD requires the use of ventral mesencephalon obtained from several 
donors pooled together to provide enough to form a transplant capable of alleviating 
motor impairments. Given that these tissues may come from disparate genetic 
backgrounds, which will have varied immunogenic backgrounds, it is unclear how this 
could affect the success of cell therapy. I have hypothesized that the incompatibility 
between the patient immune system and one or more of the donors could either 
contribute towards global rejection of the transplant, or the inflammatory response 
around it. Despite the fact that patients receive multi-donor grafts, most experiments 
only ever explore single donor grafts. Therefore, to address the issue of multi donor 
grafts, I have aimed to develop a better model of heteroimmunogenic double grafts, 
using combinations of syngeneic, allogeneic and xenogeneic donors.  
 
Declaration 
The first half of this chapter is a series of pilot experiments, performed on small groups 
of rats, to gather information regarding the time course of rejection. Altogether, they 
informed the design of the final experiment of double donor grafts. 
 	    
	   104	  
5.1 Introduction  
As discussed previously in chapter 4, patients entering clinical trials for cell transplant 
would have been under L-DOPA treatment for years, and most of them have developed 
LID. They receive foetal mesencephalic tissue grafts, pooled from up to 8 donors of 
unknown immunologic background and remain under L-DOPA medication for months 
before the graft hopefully matures and provides some alleviation of the motor 
symptoms (Lindvall et al., 1990). In most of the trials, patients were immunosuppressed 
for 6-24months (Winkler et al., 2005). The immunosuppression typically administered 
in VM transplantation procedures is cyclosporine A, (CycloA), a potent 
immunosuppressant, widely used in organ transplants to prevent rejection. It is 
administered alone or in combination with other drugs, such as azathioprine and/or 
prednisolone, but as with most issues in clinical trials of transplantation there is little 
consistency between studies and the duration of immunotherapy is similarly variable 
(some studies even decide not to give immunosuppressive treatment) (Winkler et al., 
2005). Post-mortem studies have shown that grafts are able to survive years after the 
withdrawal of immunosuppression but also reported the presence of immune cells 
around the host-graft border (Kordower et al., 1997). Interestingly, an apparent 
relationship may exist between the withdrawal of immunosuppression and the 
development, or worsening, of the graft-induced abnormal movements observed in 
some of the transplanted patients, suggesting a link between immune response and GIDs 
(Piccini et al., 2005). Taken together, these observations suggest that the host immune 
response could be a key player in failure of transplantation in many patients. 
  
Chapter 4 demonstrated that prolonged L-DOPA treatment following non-
immunologically compatible transplants increases the striatal immune response, despite 
immunosuppression, suggesting an interaction between the immune response and L-
DOPA treatment. Moreover, regarding the multi-donors situation, questions can be 
raised as to how the rejection of part of the graft might affect the survival and function 
of the rest of the transplant. Preclinical studies have been carried out to address part of 
these questions but not in a patient relevant scenario. In order to investigate the role of 
L-DOPA in multi donor grafts, a model of mixed transplants presenting with different 
levels of immune compatibility is required. However, the design of such a model 
required intermediate experiments to define the following key parameters: 
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1) Does cycloA interfere with the action of L-DOPA or the development of 
AIMs? 
2) Can slow and controlled rejection of allogeneic or xenogeneic tissue be 
engineered in a rat model and what is the time course of rejection? 
3) In a double graft scenario, does the rejection of the “less compatible 
graft” affect the survival of the “more compatible” tissue 
 
In addressing point 1, it has been shown that although L-DOPA uses the large amino 
acid transporter in order to cross the blood-brain barrier; it can also be a substrate at the 
ABCB1 transporter. Similarly, the dopamine agonist bromocriptine can interact with the 
ABCB1 transporter, also known as P-glycoprotein (Vautier et al., 2006, 2008). This 
efflux protein is used by cyclosporine to cross the blood-brain barrier and enter the 
brain (Tsuji et al., 1993, Sakata et al., 1994, Vautier et al., 2008). Competition at this 
transporter could lead to either the reduced level of L-DOPA or cycloA in the brain, 
causing either less immunosuppression or less effect of the L-DOPA. 
 
It is necessary to address the second point in order to develop a well-characterised 
model of graft rejection; the research to date has produced a number of inconsistent and 
contradictory results regarding the survival of brain allo- and xenografts. Sprague 
Dawley rats have been used extensively for both VM transplant and dyskinesia studies 
and are therefore a logical choice as host for these experiments. In an allograft 
paradigm, Wistar rats VM transplants are well-tolerated and survive for a long period of 
time in Sprague Dawley rats without immunosuppression (as demonstrated in chapter 4) 
despite a lack of histological compatibility (Wistar rats express histocompatibility 
haplotype Ag-B2, while Sprague-Dawley rats express the Ag-B6 haplotype (Low et al., 
1983)). Nevertheless, these compatible grafts can be rejected in a temporally controlled 
manner by peripheral stimulation of the immune system. For instance, orthotopic skin 
grafts, using the same donor strain as for the VM allograft induces a brutal rejection of 
the intra-striatal graft within 2 weeks of the challenge (Lane et al., 2008). A milder 
peripheral challenge can be achieved by the systemic injection of spleen cells, rich in 
immune cells (e.g. lymphocytes, macrophages and dendritic cells) (Soderstrom et al., 
2008). It may be argued that human genetic diversity is such that, an allograft paradigm 
is insufficiently aggressive, therefore a more appropriate animal model would be a 
mouse to rat xenograft (Sanchez-Mazas, 2007). This idea has been confirmed in primate 
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in whom concordant xenografts are used to model human allotransplantation (Michler et 
al., 1996).  
  
Most xenogeneic intra-cerebral neural transplants will be vigorously rejected in the 
complete absence of immunosuppressive treatment at the time of transplantation and 
even the later withdrawal of immunosuppression can also precipitate some form of 
rejection. The time course is highly variable and depends of a number of parameters, 
such as the host and donor species concordance (e.g. transplantation of mouse to rat is 
“concordant” whereas the transplantation of hamster or rabbit to rats is “discordant”), 
graft location, type of tissue and preparation (e.g. solid graft are rejected faster than the 
cells suspension) (Low et al., 1983, Brundin et al., 1985, Inoue et al., 1985, Mason et 
al., 1986, Finsen et al., 1990, Pakzaban and Isacson, 1994). With regard to immune 
compatibility between donor and host, mouse-to-rat transplant are considered as “easy” 
concordant graft, creating gradual rejection involving mainly T cell-dependent 
mechanisms (Dymecki and Freed, 1990, 1990, Murphy et al., 1996). Indeed some early 
studies have reported the long-term survival of mouse intra-cerebral neural transplant 
into rat, in the absence of immunosuppressive treatment (Daniloff et al., 1984, 1985a, 
1985b, Brundin et al., 1985). Similarly, allogeneic graft survival highly depends on the 
host and donor immune compatibility. Some studies have therefore reported long term 
survival of neural rat allograft (over 6 months), when others found a strong immune 
response, leading to acute graft rejection (Low et al., 1983, Mason et al., 1986, 
Lawrence et al., 1990, Sloan et al., 1990, Isono et al., 1993).  
 
This chapter sets out to define the experimental parameters of the allogeneic and 
xenogeneic rejection process, and the time course to set the scene for addressing the 
question of multi-donors grafts. Ultimately, grafts would be transplanted in a single 
pooled graft suspension made up from the tissue of multiple donors. However 
experimentally this is challenging, as there is no marker available to discriminate 
between the different types of tissue in the post-mortem analysis. Therefore, a more 
straightforward initial approach is to examine separate grafts implanted into the same 
striatum. 
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5.1.1 Aims of the chapter 
The main aim of this chapter was to develop a reliable and well-characterised model of 
rejection of VM co-transplant of different level of compatibility (syngeneic, allogeneic 
and xenogeneic). To this end, 4 experiments have been carried out: 
• Assessing possible interactions of cycloA treatment with the development 
of L-DOPA-induced dyskinesia. 
• Creating a model of allogeneic graft rejection 
• Establishing the time course of xenogeneic graft rejection 
• Defining the impact that the rejection of the “less compatible” graft could 
have on the survival a “more compatible” one, when transplanted 
simultaneously. 
  
5.2 Experimental design 
Each of the following 4 experiments was performed separately on different groups of 
rats.  
 
5.2.1 Effect of prolonged cyclosporine treatment on AIMs and rotational bias 
16 female Sprague Dawley received unilateral 6-OHDA lesions and were selected to be 
included in the experiment based on the results of the amphetamine-induced rotation 
test. One group was treated daily with L-DOPA and cycloA (n=8), the other group with 
L-DOPA only (n=8). AIMs were scored twice a week, for 4 weeks (L-DOPA 6mg/kg) 
and then once a week, for 2 weeks (L-DOPA 12mg/kg, Figure 40). The rotational 
behaviour of the rats was recorded concomitantly. In addition, to evaluate any effect of 
cycloA on the behavioural response to the dopamine D2 agonist bromocriptine (another 
substrate for the ABC transporter), the rats were injected with bromocriptine (2mg/kg) 
and AIMs and rotations were recorded 10 days after the last L-DOPA injection. 
 
	  
Figure 40: Time line of the experiment 
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5.2.2 Model of allogeneic graft rejection 
18 female Sprague Dawley rats received unilateral 6-OHDA lesions and were 
subsequently assessed by amphetamine test. All rats received grafts of 400 000 cells 
E14 Wistar VM into the lesioned striatum. Spleen cells, obtained from male Wistar rats 
were then injected i.p. either: at day 1 and 14 (n=6), at day 14 and 21 (n=6) or at day 21 
(n=4) following the VM graft. An additional group, which was used as a control cohort 
did not receive the spleen cell injections (n=3) (Figure 41). The animals were perfused 
at 60 days post transplantation and immunohistochemical analyses were performed 
using markers for dopaminergic cells (TH) and leukocytes (CD45). 
 
	  	  
Figure 41: Time line of the experiment 
 
5.2.3 Model of xenogeneic graft rejection 
3 groups (each, n=4) of female Sprague Dawley rats received unilateral 6-OHDA 
lesions and were subsequently assessed by amphetamine test. All animals were grafted 
with VM tissues obtained from E12 CD1 mice (1 VM per transplant). Each group 
received cycloA for 4, 5 or 6 weeks. All rats were perfused 6 weeks post-transplantation 
(having either continuous treatment or 1 or 2 weeks of cycloA withdrawal) (Figure 42) 
and immunohistochemical analyses were performed using markers for dopaminergic 
cells (TH) and leukocytes (CD45). 
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Figure 42: Time line of the experiment 
 
Since no effect of cycloA treatment was seen on dopaminergic cell survival in the graft 
was found, a second experiment was performed using another 16 unilaterally lesioned 
Sprague Dawley. Two groups of 8 rats were grafted with CD1 mouse E12 VM and 
treated with cycloA for 2 weeks to allow closure of the blood-brain barrier, and then all 
animals were withdrawn from cycloA treatment for the rest of the experiment (Figure 
43). According to a study published by Brundin and co-worker, minor leakage are 
observed 8 days after transplantation and the blood-brain barrier became completely 
impermeable to Evan’s blue, a dye used to track blood-brain barrier leakage, after 12 
days (Brundin et al., 1989). The rats were perfused 3 weeks (n=8) or 10 weeks (n=8) 
after the withdrawal from cycloA and immunohistochemical analyses were performed 
using markers for dopaminergic cells (TH) and leukocytes (CD45). 
 
	  
Figure 43: Time line of the experiment 
 
5.2.4 Model of multi-donors graft  
60 female Sprague-Dawley rats were unilaterally lesioned and a cohort of 56 rats was 
selected based on the number of spontaneous ipsilateral rotations that they performed 
over 10min (<10 full turns). And split into 8 groups. All the animals received 2 striatal 
grafts of VM tissue (200 000 cells/transplant): Syngeneic=E14 Sprague-Dawley rats, 
Allogeneic=E14 Wistar rats, Xenogeneic=E12 CD1 mice (Table 14) (Note: the 
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syngeneic-syngeneic group originally included 6 rats but 1 animal was removed from 
the study due to a blockage in the syringe during transplantation). All the animals were 
perfused 3 months after transplantation and immunohistochemical analyses were 
performed using markers for dopaminergic cells (TH) and leukocytes (CD45+). 
 
n= Graft 1 (rostral) Graft 2 (caudal) CycloA Note 
5 Syngeneic Syngeneic - - 
6 Syngeneic Allogeneic - - 
8 Syngeneic Allogeneic - 
Spleen cell injections 
(day 7 and 14) 
6 Syngeneic Xenogeneic Up to the end - 
8 Syngeneic Xenogeneic First 4 weeks - 
6 Allogeneic Xenogeneic Up to the end - 
8 Allogeneic Xenogeneic First 4 weeks - 
8 Allogeneic Xenogeneic - - 
Table 14: Summary of the different experimental groups. 
 
5.3 Results 
5.3.1 Effect of prolonged cyclosporine treatment on AIMs and rotational bias 
As described in Chapter 3, AIMs and rotations increased with L-DOPA dose (two-way 
ANOVA: AIMs: F9,126=9.46, p<0.0001; rotations: F9,126=16.38, p<0.0001). However, 
chronic cycloA treatment neither interfered with the development of AIMs, nor the 
rotational behaviour induced by L-DOPA treatment, (regardless of the dose of L-DOPA 
used 6mg/kg or 12mg/kg; Figure 44-45; two-way ANOVA, effect of cycloA on AIMs: 
F1,126=0.03, p=0.8755 and rotations: F1,126=0.01, p=0.9207). 
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Figure 44: The effect of chronic injection of cycloA on the development of L-DOPA-induced 
AIMs, mean ±SEM. 
 
 
Figure 45: The effect of chronic injection of cycloA on the development of L-DOPA-induced 
contralateral rotations, mean ±SEM. 
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Similarly, no difference was found between cycloA treated and non-treated animals in 
the severity of dyskinesia or extent of rotational behaviour following the administration 
of bromocriptine (Figure 46, two-tiled T-test: AIMs: p=0.6208; rotations: p=0.4631). 
 
 
Figure 46: Effect of chronic injection of cycloA on the development of Bromocriptine-induced 
AIMs (left) and contralateral rotations (right), mean ±SEM. 
 
5.3.2 Model of allogeneic graft rejection 
Peripheral injections of Wistar spleen cells into Sprague Dawley rats led to decreased 
survival of the allogeneic transplanted dopaminergic (Figure 47, Univariate analyse of 
the variance, F3,16=5.855, p=0.0093). However, this reduction was only significant in 
the group that received 2 early injections of spleen cells (day 1 and 14) when compared 
to the non-injected control and the group receiving a single injection (day 21) (Dunnett 
post-hoc test: p<0.05, p<0.001 respectively). 
 
	  
Figure 47: The effect of allogeneic spleen cell injections on the survival of dopaminergic 
neurons, (mean ±SEM, **p<0.01).  
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The rats that either did not receive spleen cells, or received late injection(s) showed a 
significant decreased in rotational behaviour (percentage of reduction relative to the 
number of amphetamine-induced rotations performed before transplant: no injection: 
212.2% reduction, 1 injection: 107.3% reduction and 2 late injections: 101.2% 
reduction). In contrast, the early injections group showed an increase in the number of 
amphetamine-induced ipsilateral turns (24.5% increase). The difference in the 
percentage of change in rotations was significant in the 2 groups, which received 2 
spleen injections when compared to the no injected control group (Univariate analysis 
of the variance, F3,16=11.70, p=0.0005, Dunnett post-hoc test, late injections group: 
p<0.05, early injections group: p<0.001, Figure 48). 
 
 
Figure 48: Effect of allogeneic spleen cell injections on amphetamine-induced ipsilateral 
rotations. Data presented as percentage change (mean ±SEM) in full ipsilateral rotations 
between the test pre-graft and 4weeks post-transplant, ***p<0.001.  
 
No significant difference was observed in the number of infiltrated white blood cells 
(CD45+) in the grafted striatum between the different groups (Figure 49, Univariate 
analysis of the variance, F3,16=1.6990, p=0.2181). However, it is interesting that the 2 
groups receiving 1 or 2 late spleen cell injections showed a trend towards an increased 
CD45+ response when compared not only to naïve animal, but also when compared to 
the group injected early after transplantation. 
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Figure 49: Effect of allogeneic spleen cell peripheral injections on striatal leukocytic response. 
Data shown as mean ±SEM of the total of CD45+ present in the striatum.  
 
5.3.3 Model of xenogeneic graft rejection 
Only 62% (5 out 8) and 50% (4 out of 8) of the transplanted animals still had TH 
positive cells present in the grafted striatum, 3 weeks and 10 weeks after the withdrawal 
of cycloA respectively. Despite a trend for decreased dopaminergic cell survival 3 and 
10 weeks after the withdrawal of cycloA, no significant difference was found in the 
survival of xenogeneic dopaminergic cells when compared to the control group, which 
remained under cycloA treatment (mean=4227) (Figure 50, Univariate analysis of the 
variance, F4,27=2.787, p=0.0505).  
 
 
Figure 50: Effect of cycloA withdrawal following VM xenogeneic transplant (experiment 1: a 
and experiment 2: b) on dopaminergic cells survival, presented as mean ±SEM.  
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No significant difference was observed in the amphetamine-induced rotation test, 
between the animals experiencing none, 1 or 2 weeks of cycloA withdrawal (Univariate 
analysis of the variance, F2,11=0.9513, p=0.4219, data not shown). Although xenogeneic 
grafts significantly decreased the total number of ipsilateral rotations performed after 
amphetamine administration (p<0.05), the withdrawal of cycloA abolished this 
improvement after 7 weeks (Repeated measure ANOVA, F8,71=4.646, p=0.0002, Tukey 
post-hoc test p<0.05 at week 7 and 8 of cycloA withdrawal, when compared to prior 
cycloA withdrawal, Figure 51).  
 
 
Figure 51: Effect of 3 (top) and 10 (bottom) weeks of cycloA withdrawal following VM 
xenogeneic transplant on rotational behaviour induced by amphetamine, presented as mean 
±SEM. 
 
Despite a trend for increased numbers of infiltrated CD45+ cells in the striatum of rats 
following 2 and 3 weeks of cycloA withdrawal when compare to the control group kept 
under immunosuppression (mean=1911 cells), no significant difference was detected 
(Figure 52, Univariate analysis of the variance, F4,26=1.889, p=0.1481).    
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Figure 52: Effect of cycloA withdrawal following VM xenogeneic transplant (experiment 1: a 
and experiment 2: b) on leukocytes infiltration in the grafted striatum, presented as mean 
±SEM.  
 
 
5.3.4 Model of multi-donors graft  
The statistical analysis was first performed using multivariate analysis of the variance to 
compare all the groups together. The data are presented in subgroups. Each graph thus, 
represents a single group of rats (8 groups in total), and each bar on a graph represents 
the data for one of the double grafts: the rostral striatal graft (left bar on the graph) and 
the caudal striatal graft (right bar on the graph). Syngeneic grafts are represented in 
white bars, allogeneic in grey bars and xenogeneic in black bars. 
 
5.3.4.1 Dopaminergic cells survival 
Critically, there was no interaction between the two types of graft, suggesting that the 
grafts did not adversely affect each other (Multivariate analysis of the variance, 
F1,47=0.0001, p=0.992) meaning that the presence of the rostral graft did not affect the 
survival of the caudal graft, and vice versa. 
 
When the rats received 2 syngeneic grafts, no difference was observed in the number of 
dopaminergic cells that survived, whether the graft was placed in the rostral or caudal 
part of the striatum, confirming that the position of the graft does not play a role in 
survival of the dopaminergic cells (Figure 53, t(8)=0.2021, p=0.8449). 
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Figure 53: Double syngeneic grafts, number of TH+ cells present in the rostral striatal graft (left 
bar) and caudal striatal graft (right bar). Data shown as mean ±SEM. 
 
No difference was found between the number of dopaminergic cells that survived from 
the allografts, despite immune peripheral challenge with spleen cells (Figure 54, 
t(12)=1.165, p=0.2668).  
 
 
Figure 54:  Syngeneic-Allogeneic double grafts, with (right graph) or without (left graph) 
immune challenge (spleen injection).  Number of TH+ cells present in the rostral striatal graft 
(left bar) and caudal striatal graft (right bar). Data shown as mean ±SEM. 
 
Similarly, no significant difference was found between the survival of TH+ cells in the 
xenografts, whether or not the rats were kept under cycloA for 4 weeks or the entire 
experiment (Figure 55, t(12)=0.3535, p=0.7298).  
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Figure 55:  Syngeneic-Xenogeneic double grafts, with continuous (left graph) or brief (right 
graph) immunosuppressive treatment (cycloA).  Number of TH+ cells present in the rostral 
striatal graft (left bar) and caudal striatal graft (right bar). Data shown as mean ±SEM. 
 
No significant difference was observed in term of TH+ survival in the xenogeneic grafts, 
despite the different immunosuppressive regime, (Figure 56, Univariate analyse of the 
variance: F2,21=1.576, p=0.2326). 
 
  
Figure 56: Allogeneic-Xenogeneic double grafts, with continuous (left graph), brief (middle 
graph) or no (left graph) immunosuppressive treatment (cycloA).  Number of TH+ cells present 
in the rostral striatal graft (left bar) and caudal striatal graft (right bar). Data shown as mean 
±SEM. 
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5.3.4.2 Leukocytic response 
No interaction was found between the number of CD45+ cells infiltrated around the 
rostral graft and the caudal graft, suggesting that the immune response against a “less 
compatible” graft does not impact on the leukocytic response against the “more 
compatible” graft, transplanted at the same time (Multivariate analysis of the variance, 
F1,47=0.346, p=0.559). 
 
In the double syngeneic graft group, no difference was observed in the number of 
infiltrated leukocytes found around the rostral graft and the caudal graft, confirming that 
the position of the graft does not influence the level of immune response (Figure 57, 
t(8)=1.035, p=0.3307). 
 
 
Figure 57: Double syngeneic grafts, number of CD45+ cells present around in the rostral striatal 
graft (left bar) and caudal striatal graft (right bar). Data shown as mean ±SEM. 
 
No difference was found between the number leukocytes present around the allografts, 
whether or not the rats have been immunologically challenged by peripheral challenge 
with spleen cells (Figure 58, t(12)=1.707, p=0.1136). 
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Figure 58:  Syngeneic-Allogeneic double grafts, with (right graph) or without (left graph) 
immune challenge (spleen injection).  Number of CD45+ cells present around the rostral striatal 
graft (left bar) and caudal striatal graft (right bar). Data shown as mean ±SEM. 
 
No significant difference was found between the number of infiltrated leukocytes 
around the xenograft, whether or not the rats were maintained under cycloA for 4 weeks 
or the entire experiment (Figure 59, t(12)=1.747, p=0.1062).  
 
 
Figure 59: Syngeneic-Xenogeneic double grafts, with continuous (left graph) or brief (right 
graph) immunosuppressive treatment (cycloA).  Number of CD45+ cells present around in the 
rostral striatal graft (left bar) and caudal striatal graft (right bar). Data shown as mean ±SEM. 
 
No significant difference was observed in the number of CD45+ cells between the 
different xenografts, despite the different immunosuppressive regimes, (Figure 60, 
Univariate analyse of the variance: F2,21=0.6596, p=0.5285) 
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Figure 60:  Allogeneic-Xenogeneic double grafts, with continuous (left graph), brief (middle 
graph) or no (left graph) immunosuppressive treatment (cycloA).  Number of CD45+ cells 
present around in the rostral striatal graft (left bar) and caudal striatal graft (right bar). Data 
shown as mean ±SEM. 
 
5.4 Discussion  
The fact that current animal models of VM transplant fail at evoking spontaneous graft-
induced motor side effects could highlight incapacity at reproducing clinically 
important factors. A better rat model would create a multi-donors scenario with partial 
rejection and maintain the animals under L-DOPA prior and post-graft. Nevertheless, 
some important parameters needed to be refined in order to develop this model. 
 
5.4.1 Effect of prolonged cyclosporine treatment on AIMs and rotational bias 
Despite the fact that the commonly administered anti-parkinsonian drug L-DOPA and 
the immunosuppressant cycloA can both act on the ABCB1 efflux protein, no effect of 
their co-administration was found on LID or rotational behaviour. Similarly, cycloA did 
not affect AIMs or rotations induced by bromocriptine, which can also a substrate for 
ABCB1 transporter. In early clinical studies, bromocriptine was reported to induce 
dyskinesias, in late stage patients who previously suffered from LIDs (Calne et al., 
1974, Teychenne et al., 1975, Godwin-Austen and Smith, 1977). Interestingly, Godwin-
Austen and Smith reported the case of 2 patients (out of 18), who did not exhibit 
abnormal movements under L-DOPA treatment but developed dyskinesias when 
changing from L-DOPA to bromocriptine (dyskinesias disappeared when the patients 
were back on L-DOPA treatment). The dyskinesias involved dystonic movements of the 
limbs, which were troublesome and distressing in one of the patients (Godwin-Austen 
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and Smith, 1977). Bromocriptine does not induce AIMs in rat PD models, when 
administered de novo (Henry et al., 1999, Lundblad et al., 2002). However, as shown in 
the first experiment of this chapter, AIMs can be observed in rats that were previously 
chronically injected with L-DOPA. Although AIMs and rotations are crude measures, 
behaviour read-out could be a useful indicator of the effect of possible modifications of 
L-DOPA or bromocriptine action induced by co-treatment with cycloA and is clinically 
more relevant than simply looking at in vitro binding measures. Nevertheless, it is not 
sufficient to confirm whether or not cycloA can modify the entrance of these 
dopaminergic drugs into the brain. To my knowledge, no report of reduction of 
treatment efficacy in PD patients receiving cycloA has emerged, so it is unlikely that 
cycloA could heavily modify L-DOPA access into the brain. It is, however, important to 
confirm experimentally that the effect of anti-parkinsonian medications will not be 
compromised by the chronic cycloA treatment. 
 
5.4.2 Model of allogeneic graft rejection 
Allogeneic VM transplantation produced good grafts, comparable to syngeneic grafts, 
with a good survival of dopaminergic neurons in the absence of a peripheral trigger 
(Duan et al., 1995a, 1997a, 1997b, Lane et al., 2008, Soderstrom et al., 2008). 
Accordingly, in the previous chapter (Chapter 4), no significant difference was found 
between the syngeneic and allogeneic grafts. In contrast, a peripheral challenge of the 
immune system by spleen cell injections could compromise the survival of the allograft, 
normally well tolerated by the host, especially when administered early after 
transplantation (as showed in experiment 2). Again, this observation correlates with 
previous works, which demonstrated that intravenous, intraperitoneal or subcutaneous 
injections of spleen cells, either obtained from the donor itself or animals belonging to 
the same strain as the donor, could increase the host immune response toward 
allogeneic intraventricular neural graft (Freed et al., 1988, Soderstrom et al., 2008). In a 
previous study, Söderström and colleagues used subcutaneous injection of spleen cells 
to induce rejection of VM graft obtained from Lewis rats and transplanted into Sprague 
Dawley rats. The authors found it was an insignificant trend for reduced TH+ cell 
number in the rats injected at 10 and 18 weeks post-transplant with 1 000 000 spleen 
cells. Simultaneously, they reported a significant increase in MHC II expression around 
the graft. However, this result requires further clarification as an anti-mouse secondary 
antibody was used to detect the anti-MHC II primary antibody, which could just as well 
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bind infiltrating host antibodies (although an increase in infiltrated host antibodies 
would still indicate a sign of an enhanced immune response) (Soderstrom et al., 2008). 
In this chapter, I showed that the injection of spleen cells at day 14 and 21 post-graft 
increases the level of CD45+ cells infiltrated around the graft, highlighting an increase in 
the host immune response against the transplant. Interestingly, in the late 80s, Freed and 
Poltorak demonstrated that neural graft rejection induced by spleen cell injections 
depends, not only on the combination of rat strains, but also on which strain plays host. 
For instance, intraventricular transplants of embryonic cortex of F344 rats are not 
rejected when transplanted into Brown-Norway rats, despite spleen cell injections 
(Poltorak and Freed, 1991). In contrast, Brown-Norway rat tissue transplanted in the 
lateral ventricle of F344 rats will undergo severe rejection following spleen injections 
(Freed et al., 1988). Alternatively, some studies used more drastic ways to trigger the 
host immune system, by transplanting a mix of spleen cells and VM cells directly into 
the brain or by later performing orthotropic skin grafts using the same donor strain. 
These techniques induced rapid and violent rejection of the neural transplant and would 
not be appropriate as a model of human neuronal allograft, which is unlikely to induce a 
similarly extremely severe immune response (Carder et al., 1988, Duan et al., 1995b, 
1997b, 1997a, Lane et al., 2008). Taken altogether, the data highlighted the importance 
of defining the time course of allograft rejection in pilot studies, before using a new 
model as it can be influenced by various factors, such as: the host and donor strains, the 
type of peripheral immune trigger (e.g. spleen cells injections, skin graft), the time 
between VM transplant and the immune challenge. 
 
5.4.3 Model of xenogeneic graft rejection 
Previous studies have proven that VM xenografts can restore motor functions in the 
lesioned rat model of PD, assuming that they are not rejected by the host brain 
(Bjorklund et al., 1982, Brundin et al., 1985, 1986, Dymecki and Freed, 1990). The 
literature differs greatly on the survival rate of xenogeneic grafts in absence of 
immunosuppression (Low et al., 1983, Brundin et al., 1985, Inoue et al., 1985, Mason et 
al., 1986, Finsen et al., 1990, Dymecki and Freed, 1990, 1990, Pakzaban and Isacson, 
1994, Larsson et al., 1999). In the current experiment, the rats were kept under cycloA 
for at least 2 weeks post-transplantation in order to provide time for the closure of the 
blood-brain barrier following the invasive surgery. A slow rejection process was seen 
after 2 weeks following cycloA withdrawal, eventually leading to the abrogation of the 
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reduction observed in rotational behaviour induced by amphetamine (after 10 weeks). 
Interestingly, although it was not significant, the number of leukocytes infiltrated into 
the grafted striatum was higher 3 weeks after cycloA withdrawal than after 10 weeks 
where more of the graft has already been rejected, suggesting the end of the rejection 
process. The results of experiment 3 suggest that graft rejection could occur, even after 
closure of the blood-brain barrier, although confirmation of blood-brain barrier closure 
remains to be confirmed. This result corroborate with previous studies, which showed 
that cycloA cessation still results in rejection of some of the graft, even if the rats have 
been treated for more 42 days (Brundin et al., 1989).  
 
5.4.4 Model of multi-donors graft rejection 
Finally, the survival of syngeneic, allogeneic and xenogeneic grafts was assessed in the 
paradigm of multi-donors transplant. Although the pilot studies (experiments 2 and 3) 
showed a significant reduction of TH+ cells when rejection was induced (by spleen cells 
injections for the allograft or by withdrawal of cycloA for the xenograft) these results 
could not be reproduced in the double graft experiment. Indeed, despite a decreasing 
trend in graft survival, the degree of variability between the rats was very high and the 
results were not significant. Although it seems that the survival of syngeneic graft was 
not altered by the presence of allogeneic or xenogeneic transplant, neither was the 
survival of the allograft in the presence of a xenograft nearby. These results must 
therefore be taken with great caution and further experiments are required before any 
results could be confirmed. The general survival of the syngeneic and allogeneic 
transplant was extremely low comparing to what has been observed in the other 
experiments carried out for this thesis, as well as in the literature (Duan et al., 1995a, 
Lane et al., 2006, Torres et al., 2007, Soderstrom et al., 2008). Moreover, the mice 
embryos used for the generation of the 3 allogeneic-xenogeneic groups were much 
smaller than expected. The embryos measured 6-7mm (crown to rump length), which is 
the expected size of a E11 embryos (Butler and Juurlink, 1987). This might explain the 
increased number of xenogeneic dopaminergic cells observed in the 3 allogeneic-
xenogeneic groups. Indeed, it has been shown that E12 rat VM transplant survive much 
better than the E14 (Torres et al., 2007). Thus, it is not surprising that mouse E11, 
which are equivalent to the rat E12 VM transplant, survives better than the mouse E12 
(equivalent to the rat E14) (Butler and Juurlink, 1987). The question of the survival of 
heteroimmunogenic grafts has been partially addressed by Schwarz and colleagues, in 
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Sprague Dawley rats before, using Wistar rats and C57BL/6 mice foetal VM and 
striatum tissue, grafted either as separated deposits or pooled together. In this study, the 
authors reported a decrease in the graft volume when rat and mouse VM tissues were 
pooled together. However, they did not find any significant difference between pooled 
and non-pooled mixt grafts in term of TH+ cells survival (Schwarz et al., 1996). There is 
still a crucial need for a model of pooled mixed grafts with different level of immune 
compatibility with the host to better model the clinical paradigm of multi-donors 
transplants. Indeed, the potential immunogenic disparity of the donor embryos used in 
the clinical trials might have played an important role in the heterogeneity of the benefit 
derived by different patients from the transplant. In clinical practice, testing and 
selecting the foetal donors based on their immunogenic profile is impossible, it is 
therefore important to establish whether or not rejection of one of the donor cells might 
compromise the graft as a whole. To address this concern, it is important to create a 
model of multiple-graft enabling the analysis of each component of the graft separately. 
This could be challenging, as there is currently no good marker allowing the 
discrimination between mouse and rat tissues.  
 
5.5 Conclusion 
Establishing a reliable model of rejection, whether it is an allogeneic or xenogeneic 
model, is a complex task. The information available in the literature is quite limited in 
scope regarding the time course of rejection of allograft and xenograft in the rat. This 
could be due to the fact that most preclinical studies for transplantation do not publish 
results of rejection as it is seen as a failure of the experiment. The difficulty in 
interpreting results also derives from the fact that every study specifically investigating 
the host tolerance of the graft have used different protocols, not only to induce rejection, 
but also to quantify the level of rejection or the time course of rejection (e.g. number of 
TH+ cells, graft volume, changes in amphetamine or apomorphine-induced rotational 
bias). This chapter emphasizes the importance of better characterizing the multi-donors 
model in Sprague Dawley rats before further investigating the impact of L-DOPA 
treatment on double grafts.  
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Chapter 6: General Discussion 	    
	   127	  
The future of cell therapy for PD faces numerous challenges. The aim of this PhD was 
to identify some critical factors that influence the functional outcome of 
neurotransplantation, and based on these findings, develop an improved 6-OHDA 
unilaterally lesioned/transplant rat model. Since dyskinesias represent the major side 
effect of both L-DOPA and cell transplant therapies, the first step was to assess and 
compare the reliability of the available dyskinesia evaluation techniques. This was to 
ensure the use of a comprehensive and adequate methodology throughout my PhD. The 
second part of this thesis was arranged to determine the effect of chronic L-DOPA 
treatment, administered at different times, pre and/or post-transplantation, had on the 
survival and function of foetal VM graft of different level of immune compatibility. 
Originally, this part was also intended to investigate how L-DOPA treatment and non-
compatible grafts interacted and affected the severity of dyskinesia post-transplantation. 
However, since no spontaneous or amphetamine-induced dyskinesia have been 
observed, and given that, interesting results were obtained on the effect of L-DOPA on 
the immune response, the focus of this work focused toward assessing the impact of 
these factors on brain immunity. Indeed, L-DOPA treatment, when administered post-
grafting had a clear impact on the host’s immune response around the xenogeneic 
transplant. Therefore, the last set of experiments were arranged to create 2 separate 
models of allogeneic and xenogeneic controlled rejection, before attempting to develop 
a multi-donor model. All of these studies fill a critical niche: the lack of a model, which 
accurately represents all aspects of patients undergoing transplantation for PD. 
 
6.1 L-DOPA-induced modifications of immunity 
Due to the risks associated with cell therapy, patients eligible for foetal VM transplants 
are at a late stage of the disease, meaning that they have been treated with L-DOPA for 
several years and have consequently developed dyskinesias. The severity of late stage 
symptoms of PD dictates that their anti-parkinsonian medication cannot be halted or 
reduced until, hopefully, the graft matures and provides some functional improvement. 
However, most of the pre-clinical studies looking at graft survival and motor function 
recovery failed to take this into account, using either untreated animals or animals 
treated only prior to transplantation (Brundin et al., 1986, Nikkhah et al., 1994, Goren et 
al., 2005, Carlsson et al., 2006, Maries et al., 2006, Torres et al., 2007, Lane et al., 2009, 
Garcia et al., 2011). The work carried out in chapter 4 demonstrated that L-DOPA 
treatment post-transplant has an effect on the host immune response towards the 
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dopaminergic xenotransplant. Although the mechanisms involved remain to be 
determined, it is unlikely that the main effect relies on L-DOPA altering cycloA access 
to the brain, via the ABCB1 transporter.  The fact that chronic cycloA administration 
did not affect the development of AIMs, as observed in chapter 5, only suggests that the 
immunosuppressive drug treatment does not modify L-DOPA action, but cannot 
exclude the possibility of a reversed effect. Considering that lymphocytes are formed in 
the bone marrow and are released in the blood stream (directly: B lymphocytes, or after 
maturation in the thymus: T lymphocytes), the effect of cycloA on lymphocytic 
proliferation is likely to take place principally in the periphery. Consequently, even if L-
DOPA treatment was to compromise the access of cycloA into the brain, this may not 
have any impact on the overall immunosuppression. Nevertheless, the mechanisms 
underlying L-DOPA enhancement of the immune response needs to be fully addressed 
before removing the interaction between L-DOPA and cycloA out of the equation. Also, 
more needs to be done to investigate the effect that L-DOPA can have on the immune 
system of PD patients, which might be already altered by the disease. 
 
Several studies have described changes in dopamine receptor expression on peripheral 
immune cells in PD patients, when compared to age matched healthy individuals. 
Indeed, an increased density of D1-like and D2-like receptors has been found on 
peripheral blood lymphocytes in L-DOPA-naive patients, although DA transporter 
immunoreactivity was unchanged (in 10 patients out of 11 assessed) (Barbanti et al., 
1999, Buttarelli et al., 2009). The density of some immune cells also seems to be 
altered. For instance, the percentage of natural killer lymphocytes present in the blood 
stream has been reported to be higher in PD patients (Niwa et al., 2012). In contrast, the 
proportion of T helper and B lymphocytes appeared to be reduced, with a greater 
decrease in T-helper cells (Baba et al., 2005, Bas et al., 2001, Niwa et al., 2012). In 
clinical study results it is hard to distinguish between modifications in immunity, 
associated with disease progression and neuroinflammation, or changes induced by 
pharmacologic treatments. Bas and colleagues published one of the rare studies directly 
comparing untreated and L-DOPA treated PD patients. The authors have found no 
difference between the two groups, which both showed comparable reduction of T and 
B lymphocytes when compared to the healthy controls group (Bas et al., 2001). In 
contradiction, Stevens and co-worker compared PD patients before and 3 months after 
the initiation of L-DOPA treatment and showed a 15% decrease in total of B cells with 
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L-DOPA (Stevens et al., 2012). Other scientists have also reported important 
modifications on T-cell proteome in patients undergoing long-term treatment with L-
DOPA (Alberio et al., 2012). Taken together, these studies suggest that the 
modifications of the peripheral immune system observed in PD patients might be a 
manifestation of the disease, which may be further altered by dopaminergic stimulation. 
It has been suggested that α-syn may be one of the primary causes of the immune 
abnormalities observed in PD, inducing lymphocyte apoptosis (Kim et al., 2004). The 
question of the extent of the alteration of the immune system in PD patients, depending 
on: the disease stage, the dose and duration of L-DOPA treatment, is important and 
needs to be addressed. Furthermore, its potential impact on the outcome of neuronal 
transplantation for PD will also have to be determined. 
 
6.2 L-DOPA enhancement of the immune response: friend or foe? 
Although chronic L-DOPA treatment post-xenogeneic transplant enhanced the host 
immune response observed around the graft, the treatment did not affect the survival of 
the transplant or the rats’ performances during the amphetamine test (chapter 4). This 
suggests that the increased immune response might not be detrimental to the graft. 
Moreover, the results in chapter 4 also demonstrated that the lymphocytic response 
observed was mainly composed of CD4+ lymphocytes helper T cells (Th). This 
observation corroborates the study performed by Boukhris and co-workers 
demonstrating that L-DOPA treatment reduced the proliferation and generation of 
cytotoxic T cells (CD8+ cells) in mice injected with sheep blood cells (Boukhris et al., 
1987). By limiting the proliferation of cytotoxic CD8+ lymphocytes, L-DOPA could 
promote graft survival. Moreover, CD4+ helper T lymphocytes, which are the main 
actors in the lymphocytic response under L-DOPA treatment, can have various 
phenotypes and could either promote or reduce inflammation. Th1 CD4+ phenotypes 
release pro-inflammatory cytokines, including INF-γ, interleukin (IL)-2 and 6 and tumor 
necrosis factor (TNF), whilst in contrary, Th2-type lymphocytes produce IL-4, 5, 10, 13 
and are associated with an anti-inflammatory response (Zhu and Paul, 2008). A shift in 
the balance of the helper lymphocytes population toward Th2 phenotype could have a 
beneficial effect on the survival of the graft. In 2003, Carr and colleagues demonstrated 
that repeated L-DOPA treatment in mice reduces the quantity of INF-γ produced by 
splenic lymphocytes, despite a global increase in lymphocytic cells, suggesting a 
specific inhibition of the Th1 subtype of CD4+ lymphocytes helper T cells (Carr et al., 
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2003b). Interestingly, it has been shown that DA stimulation of inactivated lymphocytes 
tends to polarize the differentiation toward a Th2 phenotypes, while D1 DA receptor 
antagonist SCH-23390 inhibits Th2 differentiation, increasing INF-γ production and 
reducing IL-4 concentration (Nakano et al., 2009, Mori et al., 2013). These studies 
suggest that DA could play a role in the determination between pro or anti-
inflammatory phenotypes of lymphocytes. Finally, L-DOPA might reduce inflammation 
via other mechanisms, such as astrocytes stimulation as it has been suggested that 
astrocytic D2 DA receptors stimulation could decrease neuroinflammation in mice 
treated with MPTP (Shao et al., 2013). Taken altogether, the data suggests that L-DOPA 
supports an anti-inflammatory response. However, great caution has to be taken in the 
interpretation of these studies, as most of them have not been performed in animal 
models for PD and might not reflect the effect that L-DOPA could have in a PD 
paradigm.  
 
While immune activation within the brain is commonly viewed as a detrimental process 
in cell therapy, there has been evidence that, dependant on the form of the immune 
response, immune-reactive cells can support neural survival. For instance, the 
infiltration of cells as an adaptive response from the periphery can, in some conditions, 
be beneficial and support the graft through the release of neurotropic factors, such as 
brain-derived neurotrophic factor (BDNF) or insulin-like growth factor 1 (IGF-1) 
(Batchelor et al., 1999, Aberg et al., 2003). This phenomenon has been well studied in 
the modulation of hippocampal neurogenesis. For instance, microglia can acquire an 
alternative phenotype (M2), which is neuroprotective and plays a central role in 
regenerative processes. M2-type microglia produces anti-inflammatory cytokines, such 
as IL-10 or neural growth factor (NGF), and BDNF (Colton, 2009). It has been shown 
that anti-inflammatory cytokines such as IL-4 or INF-γ, released by CD4+ lymphocytes 
can push microglia toward an M2 phenotype (Butovsky et al., 2006).  In agreement, Ziv 
and colleagues suggested that T lymphocytes could shift microglia towards M2 
phenotype and contribute to neurogenesis in learning processes (Ziv et al., 2006). Since 
L-DOPA treatment seems to increase lymphocytes, in particular Th2 type T helper 
lymphocytes, and considering that these lymphocytes could promote M2 phenotype in 
microglia, it can be hypothesised that L-DOPA may support neuronal survival and 
proliferation. Importantly, the morphology of CD45+ infiltrated cells was different in 
chapter 4 and chapter 5. Indeed, in chapter 4, all CD45+ cells were spherical. In 
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contrast, in chapter 5, when rejection was voluntarily induced, either by withdrawal of 
cycloA in xenografted rats or peripheral spleen cells injection in the allograft model, 
round shaped cells CD45+ were found, as well as “microglia-like shape” cells (Figure 
61). Considering their morphology, these cells are likely to be dendritic cells. This 
striking difference suggests that the type of immune response might differ between the 
leukocytic infiltration observed in L-DOPA treated and immunosuppressed rats, 
compared to the xenogeneic rejection processes. Therefore, it would be interesting to 
further study these 2 types of immune responses and establish whether or not L-DOPA-
induced immune response can be beneficial and support neuronal survival.  
  
 
Figure 61: Difference in leukocytes (CD45+) shape between L-DOPA-induced immune response 
following xenograft (chapter 4, left) and xenograft rejection in untreated rats (chapter 5, right).  
 
The withdrawal of immunosuppression in 6 of the transplanted patients, 2.5 years after 
the last surgery, did not seem to compromise graft survival. Indeed, no difference was 
found between the UPDRS motor scores collected before and after withdrawal of 
immunosuppressive treatment. Moreover, the 18F-DOPA uptake increased in the grafted 
putamen. However, all of these patients experienced a worsening of dyskinesias off-
medication as compared to when they were receiving immunosuppression, suggesting 
that the immune response could play a role in the development of graft-induced 
dyskinesias (Piccini et al., 2005). It has been shown that immune cells, such as 
lymphocytes and dendritic cells contain L-DOPA and can release DA (Cosentino et al., 
2007, Nakano et al., 2009). It can therefore be hypothesised that the presence of 
immune cells surrounding the dopaminergic graft could result in aberrant regulation of 
DA and might play a role in the development of GIDs. Moreover, gliosis was observed 
in some of the rats treated with L-DOPA post-xenograft (chapter 4) and it has been 
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shown that this phenomenon is associated with a 60% decrease in striatal DA following 
L-DOPA administration in rats. Indeed, Wang and colleagues, who used basic fibroblast 
growth factor infusion to induce gliosis in rats, reported an increased activity of MAO-
A and MAO-B resulting in an increase in DA catabolism (Wang et al., 1994). In a 
transplantation scenario, this increased degradation of DA is likely to limit or even 
compromise functional recovery. It can therefore be hypothesized that, even if the 
enhanced immune response induced by L-DOPA treatment post-graft does not alter 
dopaminergic cells survival, it might compromise functional recovery and could to play 
a role in the development of post-graft motor side effects.  
 
6.3 Animal models of transplantation 
Over the last 30 years, different clinical trials using foetal transplants for PD reported 
inconsistent benefits and adverse effects that were not predicted in the preclinical 
studies. Not only could they not be predicted, but, to date, no reliable animal model of 
spontaneous graft-induced dyskinesia has been developed. Part of the issue could be 
that a multitude of factors that could alter the clinical outcome of cell therapy for PD 
has not been considered in preclinical studies. Recently, it has been suggested that the 
severity of LIDs pre-transplantation, as well as the inclusion of 5-HT neurons in the 
graft could increase the risk of developing GIDs (Lane et al., 2009, Steece-Collier et al., 
2009, Politis et al., 2010, Politis et al., 2011). Clinical trials are therefore taking this into 
account, now recruiting patients at earlier stages of the disease and presenting lower 
incidence of LIDs. Moreover, the VM dissections will be performed with a greater 
emphasis on minimising contamination with 5-HT cells. However, until now, other 
factors, such as L-DOPA treatment post-graft and non-immunologically fully 
compatible transplant, have not been considered with the same degree of rigour. The 
work presented here combined 3 factors for the first time, L-DOPA pre-graft, L-DOPA 
post-graft and immune incompatible of the donor tissue with the host. The data 
collected showed that the association of a non-immunologically compatible VM 
transplant with chronic L-DOPA treatment post-grafting has an effect on the host 
immune response. There was no suggestion of graft rejection resulting from this 
process, but larger grafts with greater functional effects need to be considered in the 
future and this potentially could reveal some effects of L-DOPA administration on the 
graft function. Moreover, the number of dopaminergic cells present in the graft is 
usually used as a measure of graft survival and behaviour tests as a way to evaluate 
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graft function. Although they provide useful information and are clinically relevant, 
these methods are fairly crude. The assessment of finer parameters, such as: 
measurement of dopaminergic fibres outgrowth, or evaluation of DA release from the 
graft, could provide a better insight of the effect that this newly discovered L-DOPA-
induced immune response phenomenon could have on the efficacy of VM transplant. 
 
The increased inflammation observed in rats treated with L-DOPA post transplant was 
limited to the animals receiving xenograft. Because the position of the graft was to 
medial, the experiment carried out in chapter 4 was inconclusive regarding the effect 
that this enhanced immune response could have on the development of amphetamine-
induced post-graft dyskinesias. More work is required to unveil the mechanisms 
underlying the L-DOPA-induced enhancement of host immune response in 
incompatible grafts and determine the impact that this effect could have on the 
development of GIDs. The question of the impact that an increased inflammation could 
have on the development of GID has been addressed before, by Lane and colleagues; 
who showed that the induction of severe striatal inflammation using IL-2 inflammatory 
cytokine infusion did not worsen amphetamine-induced post-allograft dyskinesias. In a 
second experiment, the authors used a delayed orthotopic skin graft to induce complete 
rejection of the VM intra-striatal allograft, which abolished amphetamine-induced 
dyskinesias (Lane et al., 2008). These results suggest that severe striatal inflammation 
or graft rejection does not promote post-graft dyskinesia. However, this thesis provided 
the first evidence that immune response induced by L-DOPA differs from the one 
observed during graft rejection. Moreover, the immune response induced by L-DOPA 
treatment post-grafting seems to be biased toward Th2 lymphocyte types, which do not 
produce IL-2 and have anti-inflammatory effect. In light of this result, it is now 
reasonable to think that the IL-2 model would not be appropriate to assess the link 
between L-DOPA-induced immune response and dyskinesia post-graft. A further issue 
that has never has never been taken into account is the fact that patients received tissue 
collected from multi-donors. In chapter 5, I aimed to develop a model of multi-donor 
transplantation using the 6-OHDA-lesioned rat model to study how the rejection of a 
part of the graft could affect the other components of the transplant. Although the 
rejection of the less compatible graft did not seem to affect the second part of the co-
transplant, it is important to bear in mind that patients are transplanted with a pool of the 
different embryos collected and that this question should be addressed in similar 
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conditions. A better model of transplant should therefore combine a mixed-pooled 
transplant, using tissues presenting different level of immune compatibility with the 
host, and chronic L-DOPA treatment pre and post-graft. Such a model could provide 
valuable data regarding the VM transplant and might help to improve the outcome of 
cell therapy. The question must be asked, would it be enough to accurately mimic the 
patient situation and create a reliable model, not only able to reproduce GIDs, but also 
able to predict side effects of new therapies?  
 
The field of transplantation is moving toward the use of stem cells as a more 
sustainable, controlled and ethical source of dopaminergic precursors. As such, there are 
questions that need to be addressed as we transition from foetal cells to stem cells. 
Although the “multi-donor factor” will become obsolete and need to be taken out of the 
equation, the questions of incompatible allograft and continuous L-DOPA treatment 
remain valid. Since the 6-OHDA-lesion model failed to predict the side effect of foetal 
transplant, its validity in assessing the outcome of stem cell transplant is questionable. 
Although the genetic animal models of PD do not reproduce the extensive dopaminergic 
cell loss observed in the patients, they present the advantage of being progressive and 
are associated with protein inclusion. Moreover, they might better reproduce the 
alterations observed in the immune system of PD patients. Indeed, there is evidence that 
the 2 main genes involved in PD, α-syn and LRRK2 could play a role in the regulation 
of immune cells (Kim et al., 2004, Gardet et al., 2010, Kubo et al., 2010, Hakimi et al., 
2011, Thevenet et al., 2011). They might therefore become a useful tool in the attempt 
to unveil the mechanisms underlying L-DOPA modifications of the immune system.  
 
6.4 Conclusion 
This PhD work highlighted the importance of using a model, which accurately 
reproduces most aspects of the patient’s situation. This promises to be a herculean task, 
as we know so little about certain aspects of PD. For instance, the modifications of the 
immunity, whether they are caused by the disease or by pharmacological treatment, are 
poorly understood and understudied. So are the alterations of the blood-brain barrier 
induced by L-DOPA and their implications, not only for cell therapy, but more broadly 
for the development of any new treatment for PD.   
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Appendix I 
 
6-OHDA
6-hydroxydopamine hydrobromide 
salt
Sigma
Acetic acid Fisher
Amantadine Adamantanamine hydrochloride Sigma
Amphetamine D-Amphetamine Sigma
Benserazide benserazide hydrochloride Sigma
Bromocriptine Bromocriptine mesylate Sigma
Cyclosporine A ciclosporin (250 mg/5ml) Sandoz Sandimmun
DAB
3,3!-Diaminobenzidine 
tetrahydrochloride hydrate
Sigma
DMEM
Dubelcco's minimum Eagle 
medium
Gibco
DNAse
Deoxyribonuclease I from bovine 
pancreas
Sigma
DPX
distyrene plasticizer and xylene 
mounting medium
Fisher
Ethanol Sigma
Euthatal Pentobarbital sodium (200mg/ml) Merial Animal Health Ltd.
Glucose-Saline
0.18% sodium chloride 4% 
glucose (Aquapharm, UK)
Aquapharm
HBSS Hanks’ balanced salt solution Gibco
Hydrogen peroxide Solution (30%) VWR
Isofluorane IVAK
L-DOPA
L-3,4-Dihydroxyphenylalanine 
methyl ester hydrochloride 
Sigma
Metacam Meloxicam 5mg/kg Bohinger Hingelheim
Methanol Fisher
Nylon Mesh 100"m Nylon Mesh Fisherbrand
Paraformaldehyde Fisher
PFA Paraformaldehyde 96% Fisher
R(-)-Raclopride(+)-tartrate D2 DAR antagonist Sigma
R(+)-SCH-23390 hydrochloride D1 DAR antagonist Sigma
Saline 0.9% sodium chloride Aquapharm
Serum (goat) Gibco
Serum (horse) Gibco
Sodium azide Fisher
Sodium pentabarbitone Euthatal, Merial Animal Health Harlow
Sucrose Fisher
Triton Triton-X 100 Sigma
Trizma base Sigma
Trypan blue solution (0.4%) Sigma
trypsin Trypsine EDTQ 0.05% Gibco
Trypsin inhibitor Sigma
Vectastain Elite ABC Vector
Vicryl 4-0 suture
Coated VICRYL® (polyglactin 
910) Sutures, ETHICON
VWR
Xylene Fisher
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An  expert  is  a  person  who  has  made  all  the  mistakes  that  can  be  made   
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